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Summary 
 
 
Cold-adapted (ca) live attenuated influenza vaccines (LAIVs) have been introduced as alternatives 
to existing inactivated influenza vaccines.  The influenza A components of the FDA-approved ca 
LAIVs (Flumist®; Medimmune) have common internal genes derived from the donor strain 
A/Ann Arbor/6/60 ca and surface genes derived from current wild-type (wt) epidemic strains.  The 
aim of this thesis was to investigate determinants of immunogenicity for reassortants of A/Ann 
Arbor/6/60 ca, using a range of immunological assays, including recently developed MHC 
tetramer techniques.   
 
From the study, the extent of viral replication in the respiratory tract of mice, the primary site of 
inoculation, was a key factor in determining ca vaccine immunogenicity.  Replication was shown 
to be influenced by both viral surface Ags and the host MHC.  The H3 ca reassortants CR6, CR18, 
CR29 and CR6-35* exhibited greater replication efficiency (as determined by their PFU:HAU 
ratios) than the H1 ca reassortants CR35 and CR6-35.  The H3 ca reassortant CR6 caused a 3.79% 
loss in body weight but no losses were observed for the H1 ca reassortant CR35 and the ca H2N2 
donor strain A/Ann Arbor/6/60 ca.  Higher HI responses were detected after 3 weeks in groups 
infected with the H3 ca reassortant CR6 (GMT 80) than with the H1 reassortant CR35 (GMT 10) 
and the H2 ca donor strain A/Ann Arbor/6/60 ca (GMT 13). 
 
Recently developed techniques were used to evaluate specific T-cell response to ca LAIVs.  
Fluorescent-labelled tetramer is the key reagent for use in tetramer-based flow cytometry assays.  
The NP366-374 peptide of influenza A viruses comprises an immunodominant epitope that is highly 
conserved between subtypes.  Tetramers developed for A/PR/8/34 (H1N1) were able to detect NP-
specific cytotoxic T lymphocytes (CTLs) induced by A/Ann Arbor /6/60 ca (H2N2).  An attempt 
to prepare the A/Ann Arbor/6/60 ca-specific-NP-tetramer is described.  H-2Db monomers were 
 XVI 
successfully refolded with the peptide, but only 20% were able to form tetramers through biotin-
streptavidin linkage, resulting in a poor capacity to stain.  By contrast, an IFN-γ ICC assay 
developed in parallel demonstrated that peptide NP366-374 was able to restimulate A/Ann 
Arbor/6/60 NP ca-specific CTLs and secrete IFN-γ when tested in vitro.   
 
Specific-B and T cell responses induced in the lungs in response to infection by ca reassortants 
exhibited great variability that was determined by the growth characteristics of different viruses.  
Type I (CTL) responses were induced by low yielding ca reassortants, such as CR35 (H1N1).  
Viruses with enhanced growth characteristics, such as CR6 (H3N2), produced higher Type II (HA-
specific Ab) responses.  In addition, host factors, such as MHC type, were found to play an 
important role in responses to the same viruses.  Susceptible mouse strains, such as C57BL/6, 
showed higher CTL but lower serum Ab responses than more resistant strains, such as BALB/c.   
 
Throughout this PhD project, a fine balance between the humoral and CMI, local and systemic 
immune responses induced by ca LAIVs was demonstrated.  The need to assess local immune 
responses, in addition to serum antibody levels, for the evaluation of vaccine efficacy was an 
important conclusion of the thesis.  Further studies of regulation between the humoral and CMI 
responses to ca LAIVs and of cytokines secreted by TC and TH cells, such as IL-2, IL-4, IL-6, IL-
12 and INF-γ, would allow the selection of better candidate vaccine strains. 
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Chapter 1:  Literature Review 
  
  2
1.1 INFLUENZA VIRUSES 
 
Influenza viruses can infect a wide range of animals from birds to humans.  Subsequent respiratory 
disease in humans is common and often requires medical attention which imparts a huge economic 
burden to society.  In a typical season, influenzal disease affects 5-40% of the population 
(Stamboulian et al 2000).  Common symptoms of infection are fever, sore throat, muscle pain, 
severe headache, coughing, weakness and general discomfort.  Pneumonia is a significant 
complication of influenza virus infections and a frequent cause of death in the elderly, the very 
young and patients with underlying cardiopulmonary conditions.  
 
Because of their capacity to undergo changes, influenza viruses are able to emerge or re-merge as 
antigenically new viruses with the potential to spread rapidly through susceptible populations as the 
cause of epidemics or pandemics.  The three most important influenza pandemics of the 20th 
century occurred in 1918/19, 1957 and 1968. The 1918/19 Spanish pandemic was responsible for 
more than 40 million deaths throughout the world and occurred in three waves.  Twenty-five 
million people died during the first wave of 25 weeks.  By comparison, the same number of deaths 
for the current HIV/AIDS epidemic was only reached after 25 years (Wright et al 2007).  Although 
the 1957 Asian and the 1968 Hong Kong pandemics resulted in far fewer deaths (about 1 million 
for each), their impact was still substantial (Nicholson et al 2003; Luke and Subbarao 2006).  Since 
1997, a new pandemic threat has appeared from avian influenza viruses, which directly infect 
humans and have been responsible for limited human-to-human transmission (Lin et al 2000).  
Current plans to prepare for the next pandemic include the use of vaccination and antiviral drugs to 
minimize or mitigate its impact.  Their use in prevention and prophylaxis will be discussed later in 
this chapter. 
 
 
 
  
  3
1.1.1 Nomenclature  
Influenza viruses belong to the family Orthomyxoviridae and possess negative-sense, single-
stranded, segmented RNA genomes.  There are five different genera or types within the family:  
influenza A, B, and C viruses, thogotoviruses (isolated from ticks) and isaviruses (isolated from 
salmon).  Reassortment between different genera does not appear possible, due to differences in the 
mechanisms of replication and the extent of evolutionary divergence between genes with similar 
functions.  However, reassortment of individual genes can take place within the same genera 
(Wright et al 2007).  Classical breakage and reunion does not appear to occur between influenza 
genomes from the same genera, despite suggestions of such a mechanism to explain the origin of 
the pandemic viruses of 1918-19 (Gibbs 2006).  
 
Of the five genera, only type A influenza viruses can be further classified into subtypes, based on 
their two surface glycoproteins, the haemagglutinin (HA) and the neuraminidase (NA).  There are 
now 16 different HA subtypes and 9 different NA subtypes of influenza A viruses (Wright et al 
2007), which form the basis of the current system of nomenclature for describing individual 
influenza A viruses (Figure 1.1).  
 
1.1.2 Virion and genome structure 
The eight segments of influenza A and B viruses code for 11 known viral proteins (Figure 1.2B); 
influenza C viruses have seven segmented RNAs that code for 9 proteins.  Each segment contains 
non-protein coding-regions at the 5’- and 3’ terminals and a coding region within.  Viral proteins 
have been categorised as structural and non-structural, according to their presence in complete 
virions.  Structural proteins determine the host range, tissue tropism, and efficiency of transmission, 
antigenicity and, to a large extent, the pathogenicity of influenza viruses.  Non-structural proteins 
are present only in infected cells and are not components of assembled viruses.  However, they 
encode virulence factors that assist the virus to evade host defences (Yewdell and Garcia-Sastre 
2002; Baigent and McCauley 2003). 
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Figure 1.1 The nomenclature system for influenza A virus 
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A: Electron micrograph image showing the position of the eight RNP segments (Noda et al 2006) 
B: Schematic diagram of virus particle that shows the viral proteins (Digard et al 2007)  
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Figure 1.3  Genome structure of influenza A/ Puerto Rico/8/34 (A/PR8) virus and the functions of viral proteins (Wright et al 2007) 
* Non-structure proteins showed in blue letters 
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1.1.2.1  Viral structural proteins 
The virion outer layer and its proteins: HA, NA, HEF and M2 
Influenza viruses possess an outer envelope consisting of a lipid bilayer membrane derived from  
the host cell during the budding process that results in release of progeny virus.  There are several 
different proteins embedded within the viral membrane, which vary between different types of 
influenza viruses.  For influenza A and B viruses, the HA and NA surface glycoproteins are present 
at an approximate ratio of 4:1.  Only a single surface glycoprotein, haemagglutinin-esterase-fusion 
(HEF) protein, is present in influenza C viruses.   
 
HA and NA differ in their three-dimensional structure and function.  For influenza A viruses, the 
HA is a trimeric, rod-shape glycoprotein which is expressed in large quantities on the surface of 
infected cells (approximately 106 per cell) and in mature virions (approximately 103 per virion) 
(Bennink et al 1986).  The major function of HA is to act as a receptor-binding protein.  HA also 
plays an important role in viral host restriction and pathogenesis.  By contrast, the NA glycoprotein 
consists of a homotetrameric head domain, a stalk, a trans-membrane region and a short tail (Figure 
1.2B).  NA is recognised as a receptor-destroying enzyme, which is responsible for the release of 
newly budded virus from infected cells.  Both HA and NA are subtype-specific antigens.   
 
Other tetrameric proteins present within the viral envelope are M2 for influenza A, NB and BM2 
for influenza B and CM2 for influenza C viruses, all of which act as proton-selective 
transmembrane ion channels that are activated at acidic pH and are responsible for uncoating after 
virus entry into the cell (Pinto et al 1992).  
 
The internal virion proteins: M1 and NEP/NS2 
Beneath the viral envelope, is a layer of M1 matrix proteins - the most abundant structural protein.  
M1 proteins are present in all three influenza virus genera and are type-specific antigens.  They 
form a bridge between membrane proteins and the inner core components.  M1 proteins are non-
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glycosylated and play a vital role in virus assembly.  A recent study of virion structure using 
cryoelectrotomography demonstrated that some influenza A virions had substantial gaps in their 
matrix layer, while others appeared to lack a matrix layer entirely (Harris et al 2007).  These 
findings indicate that M1 is not exclusively responsible for virion packaging and budding.  In 
addition, M1 is a critical determinant of virion pleomorphology in determining whether the progeny 
are spherical or filamentous (Roberts et al 1998; Burleigh et al 2005).  For influenza A viruses, the 
gene that codes for the M1 protein produces a spliced mRNA which encodes the M2 protein 
(Figure 1.3).   
 
The NEP/NS2 (nuclear export protein / non-structural protein 2) is also present in influenza virions 
(Richardson and Akkina 1991).  Both are associated with the M1 protein.  NEP is responsible for 
exporting assembled viral core components from the nucleus to the cytoplasm of infected cells.  
 
The virion core and its associated NP & polymerase proteins 
The core of the influenza virion is the RNP, which comprises viral RNA complexed with 
nucleoprotein (NP) and polymerase proteins.  Viral NPs and RNA are present in segmented form as 
double-helices, to which a copy of the segment-specific polymerase complex is attached (Lamb 
1989).  Recently, the internal arrangement of vRNP’s has been visualised by electron microscopy 
(Figure 1.2A).  However, an earlier study showed that both the supernatant of influenza-infected 
chicken embryo chicken cells and allantoic fluid containing non-virion NP account for 50% of total 
extracellular NP (Prokudina and Semenova 1991).   
 
Viral NP possesses a highly compact monooligomer helical structure (Ortega et al 2000; Ye et al 
2006).  The oligomerization of NP is mediated by a tail loop structure, which is a potential target 
for antiviral compounds.  The shape of NP resembles a crescent with a head and a body domain 
(Figure 1.2B).  The viral RNA-binding groove is found between head and body domains, whereas 
the viral polymerase-binding site is located within the body domain.  The RNA-NP interaction is 
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mediated by the positive charge carried by NP and the negative charge carried by RNA.  Viral 
RNA is wrapped around the outside of the NP with one NP monomer consisting of approximately 
24 RNA nucleotides (Ortega et al 2000).  Uncoated viral RNAs have not been detected in infected 
cells and are always associated with NP.  Besides being a type-specific antigen, NP is also a major 
source of immunodominant epitopes which are recognised by the host immune system.  
 
Each individual RNP segment carries its own polymerase complex (Figure 1.2B).  The viral 
polymerase is a heterotrimeric complex consisting of polymerase basic 1 (PB1), polymerase basic 2 
(PB2) and polymerase acid (PA) subunits.  The genomes encoding these three subunits are the 
largest RNA segments in the influenza virion (Figure 1.3).  These subunits assemble in the nucleus 
to form a functional complex in which PB1 interacts with PA and PB2 at its C- and N- terminal 
regions with no direct contact between the PB2 and PA subunits.  The influenza RNA-dependent 
RNA polymerase subunits are responsible for transcription and replication of the viral RNA 
genome within the nucleus of infected cells.  Their roles in the virus life cycle, transmission and 
pathogenesis will be discussed in later sections.  
 
1.1.2.2  Viral non-structural proteins  
NS1 
All three types influenza virus have been found to express a 230-amino acid (aa), dimeric non-
structural protein, the so-called non-structural protein 1 (NS1) within the nucleus of infected cells.  
This protein has its RNA-binding-domain located within the N-terminal half and an effector-
domain.  The NS1 protein has been demonstrated to be a highly versatile viral protein because of its 
multiple roles in virus replication.  The NS gene is the smallest of all viral RNA gene segments and 
not only encodes NS1 but also gives rise to a spliced mRNA that encodes NS2.  
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PB1-F2 
PB1-F2 is the 11th viral protein and has been identified only in influenza A viruses.  It consists of an 
87-aa polypeptide that is only present in infected cells.  The PB1-F2 is encoded by an alternate 
open reading frame (ORF) near the 5’ terminus of the influenza A PB1 gene (Figure 1.3).  PB1-F2 
appears an accessory protein, since it is not present in all influenza A viruses.  However, it has been 
shown to be present in 64 of the 75 influenza A isolates whose PB1 sequences are registered in 
GeneBank, most of which are human isolates, and has not been identified in influenza B or C 
viruses.  Recent studies indicate that PB1-F2 accelerates cell apoptosis through its interaction with 
mitochondria (Yewdell and Garcia-Sastre 2002).  Both NS1 and PB1-F2 appear to play influential, 
but not essential, roles in viral replication and are important contributing factors to viral 
pathogenesis.  Their detailed functions in virus-host interaction will be discussed later.  
 
1.1.3 Viral replication 
Although significant advances have been made in recent years, mechanisms of influenza virus 
replication have not been completely determined.  Replication is tightly regulated by both cellular 
and viral factors; and can be divided into four phases: (1) adsorption and entry; (2) fusion and 
uncoating; (3) viral RNA transcription and replication; (4) assembly/packaging and budding 
(Figure 1.4).  One cycle of influenza virus replication takes about 4 to 6 hr to complete (Zambon 
1999).  Atypical events can also occur which result in the production of deficient viral progeny.  
 
Phase 1: Adsorption and entry 
The influenza virion enters the cell with the aid of its surface glycoprotein HA (receptor-binding 
molecule) and initiates infection.  Attachment requires the precursor glycoprotein HA0, consisting 
of HA1 and HA2 subunits covalently linked by a disulphide bond that must be cleaved 
enzymatically.  Cleavage makes the receptor-binding site at HA1 subunit accessible to the cell.  
Uncleaved HA is able to bind to the receptor, but not causing fuse.  Infection is then initiated by the 
specific binding between HA1 and sialic acid cell receptors on epithelial cell surfaces.    
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Figure 1.4  
 
Influenza virus replication 
cycle (Wright et al 2007) 
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& 
   
  11 
Multiple low-affinity interactions between HAs and their receptors induce endocytosis which 
facilitates virus entry into cell.  Subsequently, the virus particle or virion is internalised within the 
endosome and transported to the cytoplasm. 
 
Phase 2: Fusion and uncoating 
The low-pH environment of the endosome induces the joining of viral and endosomal membranes.  
Under acidic conditions, the cleaved HA0 molecule undergoes a conformational change exposing 
the fusion peptide at the N terminus of the HA2 subunit.  This allows the fusion peptide to interact 
with the endosomal membrane forming a fusion pore.  At the same time, viral membrane ion-
channel M2 proteins allow proton entry to the viral core from the endosome, resulting in the 
dissociation of vRNPs from M1 protein.  The free vRNPs are then released from the interior of 
virion to the cytoplasm through the fusion pore.  
 
Phase 3: Transcription and replication 
Unlike other RNA viruses, the initiation of influenza viral (v)RNA synthesis entirely relies on the 
primers provided by cellular RNA polymerase II (Pol II).  As a result, vRNA synthesis occurs only 
within the nucleus.  This negative-sense vRNA serves as a template for both messenger (m)RNA 
transcription and complementary (c)RNA replication.  The series of reactions, from vRNA → 
mRNA, vRNA → cRNA → progeny vRNA, are catalysed by a viral polymerase complex (Ps).  
 
Once vRNPs enter the nucleus, the incoming vRNAs are transcribed into mRNAs by a primer-
dependent mechanism.  First, the PB1 subunit from the polymerase complex binds to the 5’ end of 
each vRNA segment.  This step results in attachment of the PB2 subunit to a cap structure on host 
pre-mRNAs attached to host Pol II.  Then, PB1 acts as an endonuclease and cleaves host pre-
mRNAs 10 to 13 nucleotides downstream of the cap structure, with the remainder acting as a 
primer for viral mRNA transcription.  Newly synthesised mRNA is then exported to the cytoplasm 
where viral proteins are translated.  Of the viral proteins, the NP and P travel back to nucleus, to 
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initiate the switch from vRNA synthesis of primer-dependent mRNA transcription to primer-
independent cRNA replication.  Then, newly synthesised negative-sense vRNAs, NP and P form 
vRNP complexes within the nucleus.  Finally, the newly assembled vRNPs are exported to 
cytoplasm.  The movement of vRNPs in and out the nucleus is complicated by processes that 
involve several viral proteins (NP, P, NEP, M1) and cellular factors, which are beyond the scope of 
this discussion. 
 
Phase 4: Packaging and budding  
Following export from the nucleus, viral mRNAs are translated into proteins at the endoplasmic 
reticulum (ER) in the cytoplasm.  Viral internal proteins then travel back to the nucleus after post-
translational processing.  They then interact with segmented RNAs, resulting in vRNP assembly 
and subsequent export to the apical plasma membrane.  Meanwhile, viral membrane proteins are 
processed through the ER, where they are folded, glycosylated, and assembled into trimers (HA) or 
tetramers (NA and M2).  Finally, after passage through Golgi apparatus, they are inserted into the 
apical plasma membrane where the virus budding takes place prior to release (Figure 1.4).  These 
actions are controlled by a signal network by mechanisms that are not fully understood.   
 
However, recent studies on the viral genome have revealed the existence of packaging-signal 
sequences at each viral RNA segment.  One study has demonstrated that the introduction of 
synonymous mutations within the highly conserved packaging-signal region in the PA gene 
resulted in more than 90% of progeny virions being assembled without the PA segment (Marsh et 
al 2007).  Similar observations were made for the HA segment.  These findings provide the basis 
for the current selective packaging hypothesis which suggests that influenza virus packaging is a 
segment-specific process mediated by specific RNA-RNA or protein-RNA interactions (Marsh et al 
2007).  Based on this hypothesis, influenza viruses are able to package the correct RNA segments 
into each virion to produce infectious particles. 
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Before infectious virions can be produced, budding involving the release of viral components in the 
vicinity of the apical plasma membrane must occur.  The budding process starts after the cellular 
lipid bilayer becomes curved outwards following accumulation of the M1 protein.  It ends with the 
viral envelope separating from the cell membrane (Figure 1.4).  Until this point, virions remain 
attached to the cell surface or to themselves because of the binding of HA to the sialic acid 
receptor.  The final release of influenza virions requires the enzymatic activity of NA (for Type A 
and B viruses) and HEF (for Type C viruses), which removes sialic acid receptors from the cell 
surface and mucus.  
 
Defective interfering particles (DIPs) 
The tendency to generate and propagate defective interfering particles (DIPs) is an innate feature of 
influenza, and many other viruses.  DIPs are virus-like particles (VLPs) that are formed during both 
in vivo and in vitro replication.  DIPs arise most readily under conditions of high multiplicity of 
infection (MOI), where many virus particles infect a single cell (Chambers and Webster 1987; 
Kirkwood and Bangham 1994).   
 
Influenza A DIP genomes usually have a single, large deletion in their polymerase genes (PA, PB1 
and PB2) but unchanged 3’ and 5’ termini (Chambers and Webster 1987; Mann et al 2006).  The 
smaller sizes of DIP RNAs may provide a replicative advantage over the full-length RNAs due to 
their higher copying efficiency.  When a certain ratio of DIP and infectious virus is reached, 
interference takes place, giving rise to progeny yields containing alternatively high and low 
amounts of infectious virus (Kirkwood and Bangham 1994).  These changes can be measured from 
infectivity and haemagglutinin ratios during successive passaging of undiluted virus.  However, 
this phenomenon does not occur if a diluted inoculum is used. 
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1.1.4 Viral genomic and antigenic evolution 
Human influenza viruses have evolved continuously because of changes to the host-parasite 
relationship that are caused by viral genetic, cellular, environmental and social factors (Smirnov et 
al 2000; Fauci 2006).  After infection, influenza viruses face pressure from the host for antigenic 
change due to innate and adaptive immune responses.  Further changes may also arise from 
increases in the use of antivirals and vaccines.  
 
Influenza A viruses existed for a long time in other species before becoming established in humans.  
A mathematical model, based on the origin and evolution of HA genes, suggests that influenza A, 
B and C viruses first appeared about 2, 4 and 8 thousand years ago, respectively (Suzuki and Nei 
2002), but were not established in human populations until only a few centuries ago.  Influenza B 
and C viruses have evolved at significantly slower rates than influenza A viruses.  Influenza B 
viruses do not infect animals and produce less severe respiratory disease than influenza A viruses; 
they only infect humans and are the cause of localised infections.  Influenza C viruses are an 
infrequent cause of localised cold-like upper respiratory infections in humans.  Influenza A viruses, 
on the other hand, have the capacity to evolve rapidly and produce a range of disease syndromes 
throughout the entire respiratory tract.   
 
1.1.4.1  Genomic evolution of human influenza A virus 
Origin of human influenza A viruses 
Based on phylogenetic analysis of host-restricted genes, such as NP, PB2, M and NS from avian 
and human viruses, all mammalian influenza A viruses are thought to have originated from an 
avian influenza virus pool (Webster et al 1992 & 2007).  All known HA and NA subtypes are 
continuously maintained in avian species, especially ducks and shorebirds (Figure 1.5).  
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Figure 1.5 DNA maximum-likelihood trees of influenza A viruses (Fouchier et al 2005) 
 
This dendogram was generated by comparing the nucleotide sequences of HA and NA 
sequences.  The scale bars represent approximately 10% nucleotide changes between 
close relatives.  The red arms indicate current circulating subtypes; green arms indicate 
potential pandemic subtypes. 
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Genomic evolution of human influenza A viruses 
Only recent highly pathogenic avian influenza (HPAI) H5N1 viruses cause disease in wild aquatic 
birds.  Many mutations in avian influenza viruses do not result in amino acid changes (Webster 
2007).  In contrast, aa substitutions have been detected frequently in all eight virus gene segments 
from mammalian or terrestrial bird isolates, including poultry (Scholtissek 1994, Widjaja et al 
2004).  These observations indicate that optimal adaptation of influenza A viruses in these species 
has not yet occurred (Lin et al 2000; Arora 2002; Choi et al 2004).  Furthermore, the current 
Influenza Genome Sequencing Project has revealed diversity in the human influenza A genome.     
Multiple point mutations, deletions and segment exchanges have been detected in both surface and 
internal gene segments (Ghedin et al 2005).  These mutational events have been reported 
previously in separate studies (Brown et al 1998; Barr et al 2003; Lindstrom et al 2004). 
 
Among the eight gene segments, viral surface genes have evolved faster than internal genes due to 
the greater selective pressure they experience, resulting in a greater number of aa substitutions 
(Lindstrom et al 2004; Smith et al 2004).  For example, 43% of all changes to the human H3 HA 
gene have resulted in aa changes, compared with only 10 and 4% for the PB2 and M1 genes 
(Webster et al 1992).  However, the HA gene is subject to functional and structural constraints and 
aa substitutions occur mainly at HA antigenic sites (Gojobori et al 1994).  These changes are linked 
to variations in viral antigenicity, which allow the virus to evade host immune responses. 
 
1.1.4.2  Antigenic evolution in human influenza A viruses 
Viral antigenicity is the primary criterion for vaccine strain selection and a main driving force in 
influenza A virus evolution (Ferguson et al 2003).  As with the phylogenetic tree that has been used 
to measure genetic differences between strains, antigenic mapping had been developed to estimate 
the extent of immunogenic differences between strains (the so-called antigenic distance; Smith et al 
1999).  Mapping allows antigenic distances to be directly correlated with haemagglutination 
inhibition (HI) titres.  One unit distance in the map corresponds to a twofold dilution of antiserum 
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in HI assays, two units to a fourfold dilution and three units to an eightfold dilution.  When the 
antigenic distance between vaccine strains and epidemic strains is greater than two units, the 
influenza vaccine strains should be updated in order to achieve the maximum protection (Smith et 
al 2004).  In a study where antigenic maps and phylogenetic trees of human influenza A H3N2 
isolates from 1968 to 2003 were compared, it was demonstrated that antigenic changes occurred at 
irregular intervals, whereas genetic changes occurred continuously (Smith et al 2004).  These 
findings confirm that not all of the nucleotide changes lead to aa substitutions and to consequent 
changes in antigenicity. 
 
In summary, influenza A viruses are antigenically variable pathogens with great potential to evade 
host immune responses owing to their rapid mutation rates and broad host range.  Human influenza 
A viruses have developed two strategies for varying their antigenicity in order to escape host 
immune defences, which are referred to as antigenic drift and antigenic shift.   
 
Antigenic shift and influenza pandemics 
Pandemic influenza occurs when a new influenza A virus variant emerges against which the entire 
human population has no pre-existing immunity.  Three well-documented influenza pandemics 
have occurred in humans over the past century.  The most significant of these occurred in 1918/19 
(the so-called Spanish pandemic) which was caused by an H1N1 virus of avian origin that became 
adapted to humans through a series of point mutations (Taubenberger et al 2005).  Based on recent 
phylogenetic analysis of the HA1 and M genes, the 1918 virus belongs to a clade, which is more 
closely related to avian strains than other human strains (Reid et al 1999 & 2002).  In 1957, H2N2 
influenza viruses entered human populations and were responsible for the Asian pandemic.  The 
1968 Hong Kong pandemic was caused by an H3N2 subtype; the H3 antigen had not been 
experienced by humans previously, but the N2 was derived from the Asian viruses.   
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Unlike the 1918/19 pandemic virus, both the 1957 and 1968 viruses arose through genetic 
reassortment between contemporary human and avian influenza A viruses.  The 1957 H2N2 virus 
acquired PB1, HA and NA genes from an avian influenza A virus whereas, for the 1968 H3N2 
virus, only the PB1 and HA genes were of avian origin (Wright and Webster 2001).  Regardless of 
their different evolutionary paths, all three previous pandemic strains acquired an HA gene of an 
avian influenza virus that allowed them to infect humans unimpeded by any immunity from past 
infections.   
 
Avian influenza H5N1 virus and the potential pandemic threat  
Pandemic influenza A viruses of avian origin, especially H5N1 viruses, are of particular concern 
and have crossed the species barrier several times since 1997 (Hampson 2006; Thomas and 
Noppenberger 2007; Peiris et al 2007).  Avian influenza H5N1 human infections caused more than 
360 infections and 193 deaths worldwide by mid-2008 (WHO 2008).  This situation could become 
dramatically worse if the infectivity of avian viruses for humans were increased by reassortment 
between the genes of human and avian viruses (Audsley and Tannock 2004).  Such reassortment 
events, together with mutations at HA receptor binding site and/or in PB2 host-restriction gene, 
could lead to efficient replication in and transmission between human populations (Wright et al 
2007).  Fortunately, this has not yet taken place to date.  
 
Co-infection of humans or an intermediate host with an avian strain and an existing human strain 
could produce new viruses of unknown pathogenicity, for which the entire population would be 
susceptible.  The pig has been suggested as the host for co-infection (the mixing vessel) in the 
origin of new shift variants of influenza A viruses (Brown et al 1998; Xue et al 2007).  However, 
during recent avian H5N1 outbreaks in humans, chickens appear to have played the key role in 
transmitting the viruses between wild birds (ducks) and humans (Gambaryan et al 2006).    
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Antigenic drift and seasonal influenza epidemics  
In years subsequent to a pandemic, changes to the epidemic strains occur from immunological 
selection pressures caused, in part, by the high error rate of viral RNA replication.  Circulating 
human influenza viruses do not appear to accumulate avian influenza virus genes during inter-
pandemic periods (Shu et al 1996), but tend to change in adapting to humans.  Mutations within the 
antigenic sites of HA and NA accumulate, resulting in changes to the antigenicity of both influenza 
A and B viruses (antigenic drift).  Drifted strains may partially or completely evade neutralisation 
by antibodies induced by earlier infections.  Variant viruses circulate in the general population, 
causing annual influenza epidemics of variable severity.  Since 1977, two influenza A virus 
subtypes (H1N1 and H3N2) have co-circulated with influenza B viruses.  Seasonal influenza 
viruses are responsible for 250,000-500,000 deaths throughout the world each year, mostly in older 
individuals (> 65 years), compared with pandemic influenza viruses which mainly targets young 
adults (aged 15 ~ 35 years) (WHO 2008). 
 
 
1.2 HOST IMMUNE RESPONSES TO INFLUENZA A INFECTIONS 
 
The course of a primary respiratory infection with Type A influenza virus is determined by the viral 
growth and spread and the development of immune responses (Doherty et al 1996 & 1997; Gerhard 
W et al 1997).  Such immune responses (innate and adaptive immunity) are multifactorial and 
include the components for detecting infection and initiating defence reactions that lead to viral 
clearance.  Innate and adaptive immunity are closely related, yet very different (Table 1.1).  Innate 
immunity mediates antiviral effects at the earliest stages of primary infection and occurs before the 
optimum development of adaptive responses.  Moreover, innate immunity provides regulatory 
signals for driving the appropriate cascades of adaptive subset responses that are required for viral 
clearance.   
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1.2.1 Host innate immune responses to influenza A virus infections 
 
 
1.2.1.1  The respiratory tract as a physical barrier for the prevention of influenza infections 
The respiratory tract can be considered as two parts of a single organ (1) the upper respiratory tract 
(URT) consisting of the nasal cavity and the pharynx; and (2) the lower respiratory tract (LRT) 
consisting of the trachea, bronchi, bronchioli, respiratory bronchioli and pulmonary alveoli 
(Tamura et al 2004).  The surface of the entire tract is covered by a mucosal layer that contains 
epithelial and mucus-secreting goblet cells.  This layer is primarily concerned with respiration 
(Iwasaki 2007). 
 
Influenza viruses need to overcome host non-specific protective mechanisms present throughout 
the respiratory tract before they can infect respiratory epithelial cells.  The respiratory mucin layer, 
ciliary action, and protease inhibitors are responsible for prevention of cell entry and virus 
uncoating (Wright et al 2007).  In addition, local secretory macromolecules present in the fluid 
lining of the tract provide immediate inhibition of early viral growth and spread.   
 
These mediators include: surfactant proteins A (SP-A) and D (SP-D), mannose-binding lectins, 
defensins, pentraxin-3 (PTX3), complement, entry blocker peptide and natural immunoglobulins, 
consisting of mainly IgM (Baumgarth et al 1999; Hartshorn et al 2003; van Eijk et al 2003; Gomi et 
al 2004; Hawgood et al 2004; Brown 2006; Jones et al 2007;  Reading et al 2007).  All of these 
mediators can inhibit infection by either neutralising or aggregating the viruses, or by binding to 
them and so enhancing the potential for viral phagocytosis. 
 
1.2.1.2  The respiratory mucosal immune system   
The respiratory tract mucosa is not only the primary site for influenza infections but also the site for 
the induction of protective immune responses.  These responses are initiated at regional draining 
lymphoid structures, the mucosal-associated lymphoid tissue (MALT) located beneath the mucosal 
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layer.  MALT from the URT is termed the nasopharyngeal-associated lymphoid tissues (NALT) in 
mice and Waldeyer’s Ring (consisting of palatine and lingual tonsils, adenoid and paired tubal 
tonsils) in humans.  In both mice and humans LRT, MALT consists of the inducible bronchus-
associated lymphoid tissue (iBALT; Mayron-Quiroz et al 2004).  Lymph from MALT drains to the 
secondary lymphoid organs, for instance, lymph from upper and lower respiratory MALT drains to 
cervical lymph nodes (LNs) and bronchial/ mediastinal LNs respectively.   
 
NALT and iBALT play different roles in local responses against influenza infections.  Earlier 
studies demonstrated that both NALT and cervical LNs are involved in the generation of local 
responses against influenza infections within the URT but are not essential for the induction of 
protection against viral challenge and viral clearance.  However, the cervical LNs are essential in 
the induction of local immune tolerance against non-pathogenic antigens (Fokkens and Scheeren 
2000; Wiley et al 2005).  By contrast, iBALT functions as an inducible secondary lymphoid tissue, 
and generates protective immune responses throughout the entire course of an influenza infection 
(Nicod 1999; Mayron-Quiroz et al 2004).  Detailed descriptions of their role in the induction of 
adaptive responses against influenza viruses were given in Section 1.2.2.  
 
 1.2.1.3 Mechanisms for signalling infections and initiating innate immune responses 
Toll-like receptors (TLRs) are a family of trans-membrane proteins expressed by host cells that 
recognise pathogen-associated molecular patterns present early in infection, which trigger specific 
cellular responses (Seitz 2003).  Eleven different TLRs have been described for humans, 12 for 
mice, with some (i.e.TLR2, 4, 6) being located on cell surfaces and others (TLR3, 7, 8, 9) on the 
ER (Boehme and Compton, 2004).  Therefore, TLRs are capable of detecting pathogens that evade 
extracellular defences within the cell.  Several complex signal transduction pathways can be 
activated after TLRs bind to their ligand.  These pathways are mainly involved in the regulation of 
the host genes and are especially important in the production of inflammatory cytokines (Seitz 
2003).
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Table 1.1  Comparison of innate and adaptive immune responses to viral infections 
 
 
Innate Adaptive 
Reaction kinetics Faster (non-specialised system; 
earliest times of primary 
infections)  
Slower (specialised system: re-arranging gene 
segments to form antigen receptors; requirements for 
activation and expansion of a small pre-existing 
subset of antigen-specific cells) 
 
Receptor diversity Low (conserved receptors, 
broadly expressed, recognising 
non-protein viral products) 
 
High (recognising viral protein products) 
Pre-existing cell subset 
size 
 
Large Small 
Cell types Non-immune cells and 
innate immune cells: monocytes, 
monocytic cells (macrophages), 
DC, NK, PMN, neutrophil 
 
T – and B – lymphocytes 
DC: dendritic cells 
NK: natural killer cells 
PMN: polymorphonuclear leukocytes 
 
 
                              
Figure 1.6 Circulation of dendritic cells (DC) from lung to lymphoid organs and recirculation of activated lymphocytes      
(Nicod 1999). 
   
LN: lymph node 
   BALT: bronchus-associated lymphoid tissue 
   GALT: gastrointestinal-associated lymphoid tissue 
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TLR3 and -7 have been identified as major receptors for influenza viruses.  They are both located 
within endosomal compartments where viral RNA is degraded.  TLR3 is found constitutively 
expressed in human alveolar and bronchial epithelial cells, the primary targets for influenza virus 
infection.  TLR3 is able to bind to viral replicative intermediate dsRNA and has a role in detecting 
events in influenza virus replication (Guillot et al 2005).  By contrast, TLR7 is found in 
professional antigen-presenting cells (APCs), DCs and B cells and can identify influenza viral 
ssRNA prior to viral replication (Diebold et al 2004).  Binding between TLR and viral RNA 
induces the interferon (IFN) pathway and other inflammatory cytokines that are involved in 
limiting viral replication and initiating innate immune responses (Lund et al 2004).   
 
1.2.1.4  The effectors of innate immune response to influenza infection 
Effector cells 
There are two types of cells involved in innate responses, non-immune and innate immune cells.  
During influenza infections, non-immune cells, such as epithelial cells, are not only the main 
targets of virus infection but also the first line of host defence against infection.   
 
• Airway epithelial cells 
Following infection, epithelial cells undergo necrotic death (Gruta et al 2007).  Cell necrosis 
triggers immune responses and the production of a number of chemokines, cytokines (i.e. IFNs, 
TNFs) and growth factors (i.e. GM-CSF).  In response, epithelial cells up-regulate the expression of 
cell surface molecules, such as intercellular adhesion molecule-1 (ICAM-1) and the major 
histocompatibility complex (MHC).  Through a complex signalling network, epithelial cells recruit 
and sustain innate immune cells at the site of infection.  Moreover, they also have the capacity to 
directly present viral antigens to lymphocytes by MHC molecules (Nguyen et al 1998; Nicod 
1999).  Lastly, epithelial cells can facilitate the transport of specific secretory IgA (sIgA) within the 
airways following adaptive responses.  The secretory process is initiated by poly Ig receptors 
(pIgR) which are expressed on the basolateral surfaces of the overlying epithelial cells (Tamura and 
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Kurata 2004).  Beside non-immune cells, innate immune cells are involved in early responses to 
influenza infections.  They are monocytes, alveolar macrophages (AMs), DCs, NK cells and 
neutrophils.   
 
• Alveolar macrophages (AMs) 
AMs comprise 85% of the cells in bronchoalveolar lavages (BAL) and are normally the only 
phagocytic cells present within the LRT (Nicod 1999).  When a large amount of progeny virus is 
released from infected respiratory epithelial cells, AMs can also be infected.  Within 24-48 hr after 
infection, infected AMs undergo apoptosis, which induces inflammatory cytokine and chemokine 
production in the LRT (Gruta et al 2007).  The amount of cytokines produced by AMs has been 
shown to be proportional to the extent of virus shedding (Tamura and Kurata 2004).  These 
cytokines are also responsible for fever and NK cell activation.   
 
• Dendritic cells (DCs)  
Over the past 35 years, DCs have been studied intensively because of their unique ability to prime 
naïve T cells (Banchereau and Steinman 1998; Reischl 2000).  They also have a central role in 
initiating and modulating protective T-cell responses during respiratory infections (Dupuis and 
McDonald 1997; Andersson and Ahmed 2002).  Respiratory DCs migrate continuously throughout 
the DC network (Figure 1.6).  In the URT, DCs are present both within and beneath the epithelial 
layer but, in the LRT, they are also present in the lamina propria and alveolar lumen (Iwasaki 
2007).   
 
Many studies have indicated that DCs from different organs or parts of a single organ have 
different functions.  For example, URT DCs have a rapid turnover time (< 72 hr), with 85% of the 
cells being renewed every 24-36 hr (Lambrecht et al 1996; Iwasaki 2007).  During the early phase 
of pulmonary infections, URT DCs demonstrate an accelerated rate of migration towards the 
regional LNs.  They occur in bronchial LNs as early as 6 hr (peak at 24-28hr) after encounter with 
   
  25 
antigens in the airways mucosa (Hamilton-Easton and Eichelberger 1995).  By contrast, DCs in the 
LRT have a much slower basal turnover rate and a weaker T-cell priming ability, possibly because 
of the inhibition of regulatory signals from AMs (Lambrecht et al 1996; Iwasaki 2007).  At the 
commencement of a respiratory infection, such a lung antigen-tolerant microenvironment would 
help to prevent the development of immunopathology.   
 
DCs reside in tissues as immature APCs but are highly efficient at facilitating antigen uptake.  In 
the case of influenza infections, the maturation of airway DCs is initiated via TLR3, which can 
recognize viral dsRNA.  During the process of maturation, the expression of co-stimulatory 
molecules and the MHC on the cell membranes of DCs increases but the capacity for antigen 
uptake is reduced (Reischl 2000).  Following arrival in lymphoid tissues and under the influence of 
tumor necrosis factor (TNF-α) and GM-CSF, mature DCs are able to present antigen to and prime 
naïve T cells in an efficient manner (See Section 1.2.1.5 for more details on influenza viral antigen 
presentation).   
 
However, the accelerated migration of respiratory DCs to the regional LNs occurs only during the 
early phase of respiratory infections.  Studies with influenza infections have shown that activated 
respiratory DCs can continually accumulate at secondary LNs, such as cervical and 
bronchial/mediastinal LNs, and reach their peak by 18 hr post-infection.  Then migration of DCs 
from infected airways and lungs to their draining LNs ceases by 48 hr, despite sustained virus 
replication in the lungs (which occurs up to 5-6 days).  These observations indicate that such a 
transitional refractory state exhibited by respiratory DCs may lead to a diminished host adaptive 
response to a second stimulus with the same antigen (Legge and Braciale 2003).    
 
• Natural killer (NK) cells 
NK cells are large granular lymphocytes with increased lytic activity, and appear in the lungs 48 hr 
after influenza infections.  They are IFN-γ producers and can lyse infected cells by a perforin-
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dependent pore-forming mechanism (Brown 2006).  However, their role in virus clearance is less 
important than T cells and neutralizing antibody (Ab), both of which appear later.  
 
• Neutrophils  
Neutrophils are also called PMN because of their multilobed nuclear appearance.  Neutrophils are 
the most abundant immune cells in the body and constitute 60% of the circulating leukocytes 
(Fokkens and Scheeren 2000).  However, they represent less than 2% of the cells in BAL (Nicod 
1999).  Activated neutrophils kill microorganisms or infected cells by a range of mechanisms, 
which include phagocytosis, the release of oxygen radicals and the production of cytotoxic peptides 
or proteins (Fokken and Scheeren 2000).  In addition, toxic agents that are released from 
neutrophils can also cause tissue oxidative damage and inflammation. 
 
There is only a brief transient increase in neutrophils in the lungs during mild influenza infections, 
and extravasation of neutrophils into the alveolar space is mediated by ICAM-1 receptors located 
on the alveolar epithelial cells.  However, when cells in the alveoli are unable to restrain an 
infection, a massive influx of neutrophils with accompanying tissue damage can occur, which was 
frequently observed in post-mortem lung samples taken during both the 1918 pandemic and the 
more recent avian H5N1 outbreaks. 
 
Chemokines and cytokines 
Following influenza infection, epithelial cells and AMs die by necrosis/apoptosis which triggers the 
production of a range chemokines and cytokines.  Levels of chemokines and cytokines in human 
nasal lavage fluids peak at day 2-3 post-infection (Table 1.2; Fritz et al 1999).  These chemokines 
and cytokines play a major role in the control of infections.  They are also involved in the induction 
of influenza-like symptoms (i.e. the sudden onset of malaise and fever, followed by upper and 
lower respiratory symptoms, myalgia and headache).    
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• Chemokines 
Chemokines are small proteins which are released from a range of cells.  At least 50 proteins have 
been identified within the human chemokine superfamily.  They can be separated into two major 
groups, according to whether they have regulatory and inflammatory functions.  Regulatory 
chemokines are constitutively produced at homing sites by specialised cells.  By contrast, 
inflammatory chemokines of the CC and CXC subfamilies are found only where pathology is 
present and are responsible for modulating the recruitment of leukocytes to infected tissues 
(Kaufmann et al 2001).  CC chemokines preferentially act on mononuclear cells, but most CXC 
chemokines favour neutrophils (Table 1.2; Fritz et al 1996; Lazarus et al 2003; Singh et al 2004).  
Recruitment and activation of leukocytes by chemokines also relies on the expression of specific 
chemokine receptors (CCR or CXCR) on the target cells (Kaufmann et al 2001; Debes et al 2004). 
 
Induction of the chemokines (i.e. MCP-1, MIP-1α/β, IP-10 and RANTES), which attract 
mononuclear leukocytes, occurs within 2 days of an influenza infection.  However, no significant 
production of neutrophil-attracting chemokines (IL-8 and GRO-α) occurs at the same time (Fritz et 
al 1999; Kaufmann et al 2001; Wareing et al 2004).  These observations provide confirmation that 
infiltration of mainly monocytes and lymphocytes to infected tissues occurs during the early stages 
of influenza infections.   
 
An earlier study with live and killed influenza viruses demonstrated that the secretion of 
inflammatory chemokines was related to the nature and extent of viral replication  
 (Kaufmann et al 2001).  For example, viral RNA replication was necessary for the maximal MIP-
1α production.  By contrast, the intact HA proteins, which are responsible for virus adsorption, 
endocytosis and fusion, were found to be sufficient for initiating the maximal MCP-1 production.  
Therefore, gradual chemokine release which depends on specific events in virus replication is 
necessary for an efficient antiviral response. 
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Table 1.2  Links between influenza infection and chemokine/cytokine-mediated immunopathogenesis (La Gruta et al 2007) 
 
 
 
Chemokine 
/cytokine * 
Full name Function  Produced by  
MIP-1   macrophage  Monocyte, T cell chemoattractant Monocytes/macrophages, 
(CCL4) inflammatory protein ; activates neutrophils neutrophils, T cells, 
  1β   dendritic cells  
       
MIG  monokine induced Monocyte, T-cell chemoattractant Respiratory epithelium, 
(CXCL9) by IFN-γ  monocytes/macrophages 
    
IP-10  interferon-inducible Monocyte, T-cell chemoattractant Monocytes/macrophages, 
(CXCL10) protein of 10kD  T cells, 
   respiratory epithelium 
       
RANTES  regulated up after  Monocyte, T cell, DC chemoattractant. T cells, 
(CCL5) activation, normal T Activates T cells  respiratory epithelium 
 cells expressed and   
 secreted   
       
IL-8  interleukin 8 Neutrophil, T-cell chemoatrractant. Respiratory epithelium, 
(CXCL8)  Activates neutrophils  monocytes/macrophages, 
   neutrophils 
    
IFN-   interferon γ Inhibits viral replication. T cells, NK cells 
   Stimulates CTL-mediated killing.   
   Increases MHC I expression.   
   Activates macrophages and neutrophils.   
  Promotes T-cell proliferation  
       
TNF-  tumor necrosis  Direct antiviral effects. T cells 
  factor α Neutrophil chemoattractant. monocytes/macrophages, 
   Stimulates macrophage  dendritic cells, neutrophils 
  phagocytosis and production of IL-1.  
   Increases vascular permeability  
       
IL-1 interleukin 1 Increases expression of adhesion  Monocytes/macrophages, 
                            factors on endothelium dendritic cells 
   Increases vascular permeability  
   Stimulates IL-6 production   
       
IL-6 interleukin 6 Pro-inflammatory cytokine. Respiratory epithelium, 
   Activates T cells. T cells, dendritic cells, 
     monocytes/macrophages 
      
 
 
 
*  Cytokines and chemokines listed here are induced by highly pathogenic influenza viruses in human and animal models.  
They are associated with extreme pathological damages (La Gruta et al 2007).  
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•  Cytokines  
Soon after intranasal influenza virus infections of humans or animals (i.e. mice and pigs), levels of 
proinflammatory cytokines, such as IFNs (especially type I IFN-α/β), TNF-α and interleukin-6 (IL-
6), increase in nasal lavage fluids (Fritz et al 1999; Kaiser et al 2001; van Reeth et al 2002).  Of 
these, IL-6 appears first and has proven to be one of the most reliable indicators of infections.  IL-6 
is a pro-inflammatory pleiotropic cytokine.  It can induce terminal B cell differentiation and is also 
involved in activating type II immunity, leading to antibody production (Figure 1.8).  TNF-α is a 
well-known mediator of local inflammatory reactions in the lungs (Table 1.2) and is responsible for 
gross lung lesions, weight loss and mortality (van Reeth et al 2002).   
 
 The IFN response is an important component of innate immunity because it is responsible for early 
anti-viral activity.  IFNs were discovered in 1957 from studies on influenza virus-infected chicken 
cells (Isaacs and Lindenmann 1957).  There are two types of IFN (I and II; Samuel 2001).  Type II 
IFNs (i.e. IFN-γ) are secreted by NK cells and T cells (Table 1.2).  Compared with type II IFN 
(IFN-γ), which is induced as a component of both innate and adaptive responses, type I IFNs (IFN-
α/β) are only part of the innate response.  In a study of human experimental influenza infections, 
high IFN-α/β titres were detected by day 1 after the commencement of virus shedding (Firtz et al 
1999).  Type I IFNs were secreted by infected host epithelial cells, macrophages, DCs and 
monocytes in the response to the presence of viral RNAs (Kadowaki and Liu 2002).   
 
All type I IFNs have a common cell surface receptor.  Binding between IFN-α/β and their receptors 
can result in the transcriptional stimulation of about 400 host genes (Garcia-Sastre 2001).  Of them, 
those encoding the dsRNA-activated protein kinase (PKR), the 2’5’-oligoadenylate synthetase (2-
5A synthetase) and the Mx proteins are known to interfere with viral replication and induce 
antiviral activity in nearby uninfected cells.  In addition to their antiviral activities, both type I and 
II IFNs are involved in regulating cell growth, differentiation, apoptosis and modulating antigen-
presentation by elevation of MHC expression on the surface of APCs (Samuel 2001).  Besides IFN- 
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α/β, other inflammatory cytokines which are produced primarily by macrophages at the 
commencement of viral infections also play a role in the coordination of innate and adaptive 
immune responses (Fig 1.9; Murtaugh and Foss 2002).  Their detailed functions are beyond the 
scope of this thesis and will not be discussed further. 
 
1.2.1.5  Presentation of influenza viral peptide antigens to lymphocytes 
Pulmonary antigen-presenting cells (APCs)  
As mentioned above, APCs are part of the innate immune system and are also essential for the 
initiation of the adaptive responses to viral infections.  APCs serve as a bridge linking innate and 
adaptive responses by (1) regulating T lymphocytes by the secretion of cytokines and chemokines, 
and (2) presenting peptides from viral antigens to T lymphocytes (Kadowai and Liu 2002).  Non-
immune cells which can be infected by influenza viruses have the capacity for antigen presentation 
and include both airway epithelial cells (Section 1.2.1.4) and M cells. 
 
• Membranous (M) cells of mucosal-associated lymphoid tissues (MALT) 
M cells are present in the epithelium between epithelial, columnar and mucous goblet cells, and 
above the MALT.  After infection of human adenoid tissues with influenza A viruses, it has been 
shown by transmission electron microscopy that virions are endocytosed by M cells and then 
transported to surrounding macrophages, dendritic cells and lymphoid cells.  This whole process 
occurs 30-90 min after infection (Fujimura et al 2003).  Similar findings had also been 
demonstrated in studies in mice using a range of different mucosal pathogens, including Group A 
streptococci, reoviruses, poliovirus and HIV (Sminia and Kraal 1999; Park et al 2003).  These 
findings suggest that M cells of the MALT are responsible for antigen presentation to the 
underlying lymphoid tissues during mucosal infections.  They also suggest that the respiratory 
MALT, together with cervical and bronchial/mediastinal LNs, are the sites where antigen 
presentation takes place and where naïve T cells are primed.   
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APCs, AMs, DCs and B cells can present antigen to T lymphocytes more efficiently than non-
immune cells, such as airways epithelial and M cells.  These cells and especially DCs and B cells, 
the so-called professional APCs, can express MHCs and co-stimulators on cell surface which are 
required for initiating T cell proliferation (Hare et al 2003; Reinders et al 2003). 
 
• Lung dendritic cells (DCs) 
DCs are the most potent APCs and are present in most tissues.  They capture antigens in situ and 
migrate to lymphoid organs where they activate naïve T cells (Cella et al 1996).  After isolation 
from enzyme-digested murine lungs and BAL, mature DCs were shown to possess a lower buoyant 
density and to be loosely adherent, nonphagocytic and heterogeneous (Pollard and Lipscomb 1990).  
These DCs express costimulatory molecules including CD80, CD86, CD40L, CD2, CD54, and 
CD11a, which play important roles in lung DC-initiated T cell proliferation (Masten et al 1997).  
An earlier study showed that the numbers of MHC Class II-bearing lung DCs in mice were 
increased after treatment with INF-γ (Suda et al 1996).  
 
Airway DCs are responsible for the uptake and processing of antigens and the consequent 
presentation of antigenic peptides to T lymphocytes.  Beside their ability to capture virus directly, 
DCs also have the capacity to acquire antigens derived from necrotic or apoptotic cells, a process 
called cross-priming or cross-presentation.  Cross-priming can generate virus-specific CD4 as well 
as CD8 cytotoxic T lymphocyte (CTL) responses (Abbas and Lichtman 2003), and is especially 
important for antigen presentation in the LRT.  In contrast to URT DCs, those within the lung 
parenchyma do not readily engulf particulate antigens, including virus particles (Nicod 1999).  By 
cross-priming, lung DCs can present antigenic peptides which are processed by lung interstitial 
macrophages or AMs to T cells (Gong et al 1994).  Cross-priming is regulated by AMs.   
 
When there is only a small number of mature DCs in lungs following infection, AMs tend to 
enhance the function of DCs, in part by releasing antigenic peptides; their ability to present antigen 
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to lung parenchyma DCs is only modestly increased following INF-γ stimulation.  When more than 
50% of lung DCs became mature, AMs start inhibiting DC function; probably by releasing soluble 
inhibitors (see Section 1.2.1.3).  This change, from stimulation to inhibition, could prevent 
excessive immune responses and tissue damage in the lungs. 
• B cells 
B lymphocytes use their membrane Ig (mIg) as antigen receptors (so-called BCR) to bind and 
internalise soluble protein antigens and then to present processed peptides to T helper (TH) cells.  
Because of their high affinity for antigens, B cells can effectively capture protein antigens that are 
present at very low concentrations in the extracellular fluid.  The antigen-presenting function of B 
cells is essential for TH-dependent Ab production, such as anti-HA and NA Abs, to influenza 
viruses (Abbas and Lichtman 2003).   
 
Mechanisms of antigen presentation 
• The Major Histocompatibility Complex (MHC) 
MHCs were recognised initially as self-recognition proteins in graft rejection, but are now known 
to be integral parts of all immune response systems (Danchin et al 2004).  The MHC region is a 
very large (2-4 Mb) multigene cluster within the cell genome and is among the most polymorphic 
genes of vertebrates (Parham and Ohta 1996).  More than 881 different MHC class I alleles have 
been identified in humans (Marsh et al 2002).  Due to the extreme polymorphism within the peptide 
binding region, individuals with different MHC molecules respond to different antigenic peptides 
derived from the same pathogen.  MHC variation is found at both the population (allelism) and 
individual (many loci) levels.  Some studies have suggested that populations with limited MHC 
diversity are more susceptible to viral infections (Evans et al 1996; Borghans et al 2004).   
 
There are at least four sets of genes encoded within the MHC: (1) Class I MHC genes that are 
responsible for self-recognition.  The classical Class I molecules are called H-2K, H-2D and H-2L 
in mice and HLA-A, HLA-B and HLA-C in humans.  Class I MHC molecules present short 
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peptides (usually 8-10 aa) to CD8+ T cells (Figure 1.7A), which can be induced to become CTLs 
that identify and destroy infected cells.  (2) Immune response (Ir) genes encoding the Class II 
MHC molecules that determine the strength of an immune response.  MHC Class II molecules 
present peptides derived from exogenous antigens to the MHC Class-II-restricted TH cells.  (3) Tla 
and Qa genes that encode cell surface proteins structurally similar to Class I MHC molecules 
(hence, often called non-classical Class I molecules) whose function is relatively unknown.  (4) 
Genes that encode many components of the complement system, which is part of the innate 
immune system.  
 
Class I molecules consist of two polypeptide chains, one of which is highly polymorphic (the α 
chain, containing a single peptide-binding cleft) and the other an invariant polypeptide, β-2 
microglobulin (β2m).  Class I molecules are constitutively present on the surfaces of nearly all 
nucleated cells.  By contrast, Class II molecules consist of two polymorphic chains and are found 
mostly on the surfaces of APCs (DCs, B lymphocytes and macrophages).  However, the stable 
expression of MHC molecules on cell surfaces requires a bound antigenic peptide that stabilizes the 
MHC molecules (Figure 1.7).  Many studies have also demonstrated that the cytokines secreted 
during innate and adaptive immune responses (i.e. IFNs and TNF) can enhance MHC expression by 
stimulating the transcription rate of Class I and II genes.  The MHC molecule and antigenic peptide 
form the ligand for T cell receptors (TCRs).  Binding of TCR to its ligand initiates adaptive 
immune responses.   
 
• T cell receptors (TCRs)  
The broad peptide-binding specificity of MHC molecules from a single host does not allow 
differentiation between foreign and self peptides (Barinaga 1992; Matsumura et al 1992; Parham 
1992).  The detection of foreign peptides is largely dependent on antigen receptors on the surface of 
T lymphocytes (TCRs).  TCRs can only respond to antigens that have been processed and presented 
by APCs via MHC molecules (the phenomenon of MHC-restriction; Rudolph et al 2006; Figure 
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1.7B).  Different T cell clones express different TCRs which recognize different antigenic peptides 
derived from the same pathogen (i.e. they are clonally distributed).  Each TCR is a heterodimer that 
is comprised of a variable αβ complex (responsible for the antigen binding) and an invariant 
complex, CD3 (responsible for signaling) (Davis et al 1997).   
 
Unlike BCRs, which can recognize conformational determinants of protein antigens, TCRs only 
recognize linear peptide antigens.  Accordingly during influenza infections, neutralizing Abs (i.e 
anti-HA and NA) are capable of distinguishing different subtypes whereas CTLs (NP or PA 
peptide-specific) are not (Ada 1994).  However, an earlier study demonstrated that TCRs, 
especially those specific for NP, were mainly responsible for the CTL cross-subtype responses to 
influenza A viruses (Townsend and Skehel 1984).  The reasons for this are: (1) viral internal 
proteins, such as NP, are relatively conserved proteins; (2) inherent properties of the αβ TCRs 
allow a degree of flexibility in peptide binding (Parham 1992; Mason 1998).   
 
Apart from the cross-reactivity, TCRs have sufficient specificity to discriminate between many 
different antigenic peptides.  In vitro studies had shown that TCRs can recognize multiple peptide 
ligands, but only those with the highest TCR affinity could fully activate T cells at low peptide 
concentrations (Demotz et al 1990).  Because only limited amounts of antigenic peptides are 
present on the surfaces of host animals, cross-reactivity from T cells is restricted and the fine 
specificity of CTL recognition is only maintained to a limited extent (Burrows et al 2000). 
 
• Use of MHC tetramers in the measurement of T cell responses  
Altman et al (1996) first described the application of MHC tetramers in the measurement and 
analysis of Ag-specific T cell responses.  CTLs, which were first described in 1968 (Brunner et al 
1968), can now be directly phenotyped and enumerated without the need for a functional assay.  
Tetramer-based methodologies have further applications in studies of autoimmune disorders, 
transplantation, cancer and vaccination (Doherty 1998 & 2002; Klenerman et al 2002).  They have 
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Figure 1.7 Diagram of the MHC Class I assembly and the peptide presentation (A, Petersen et al 2003).  MHC Class I α chain and β2m assemble with a peptide in a multimeric complex with calreticulin, 
ERp57, tapasin, and the TAP heterodimer in the ER.  Once the peptide is bound, the complete MHC Class I molecule is released from ER and proceeds through the Golgi apparatus by 
vesicular transport.  The MHC Class I complex reaches the cell surface where the peptide can be presented to CTL.  After arrival at cell surface, certain virus proteins can undergo 
endocytosis. The cartoon shows interaction of TCR and CD8 co-receptor with the peptide-MHC I complex (B, Partham 1989).  
APC 
CTL 
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been particularly useful for studies of virus-specific CTL responses to a range of viral infections, 
including influenza, HIV, viral hepatitis, Epstein-Barr virus, cytomegalovirus, human 
papillomavirus and herpes simplex virus infections (Ogg et al 1998; Kuroda et al 1998; Skinner et 
al 2000; Burrows et al 2000; Keiholz et al 2002).  
 
The key reagent for the staining of Ag-specific T-cells is the MHC tetramer, which forms the TCR 
ligand.  Fluorescent tetramers are comprised of four identical MHC molecules, each presenting an 
antigenic peptide (Figure 1.8a).  Details of their preparation are given in Materials and Methods 
(Section 2.11).  Briefly, complexes of soluble MHC α chain, β2m and the peptide of interest are 
first assembled as monomers and then biotinylated at the terminus of α chain.  The addition of 
fluorochrome-labelled streptavidin (containing four biotin-binding sites) leads to the formation of a 
final product, consisting of tetrameric peptide-MHC complexes or tetramers (Pittet et al 2001, 
Vollers and Stern 2007).   
 
Before use, the newly generated tetramers need to be tested for the specificity and their optimal 
concentrations are determined.  These pre-test procedures are critical for reducing non-specific 
background signals and for enhancing the specific fluorescent signals that can be measured by flow 
cytometry.  In a two colour system, such as one using anti-CD8 and MHC I tetramers for cell 
staining (Figure 1.8b), cells which stain positively with both CD8 and MHC I tetramers correspond 
to an antigen-specific CTL population (Figure 1.8c).  When additional cell surface molecules are 
stained, further analysis of T cell subsets can be achieved in a single assay (multi-colour flow 
cytometry; see Section 1.2.2.2). 
 
The affinity of MHCs for their TCR ligands is greatly enhanced by the use of four MHC-peptide 
complexes (tetramers), compared with a single monomer complex for the detection of low-
frequency T cell populations.  The lower limit for detection by tetramers is approximately 0.01% of 
the total cells screened by flow cytometry (Dunbar et al 1998).  Any smaller specific cell  
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Figure 1.8 MHC tetramer staining for visualising antigen-specific T cells (McMicheal and O’Callaghan 1998; Beckman 
Coulter Website 2003).   
(a) Schematic representation of a human MHC class I tetramer.The monomer is shown in the pink box; 
(b) Complexes are bound to a distinct set of T cell receptors (TCRs) on a subset of human CD8+ T cells; 
(c) The cellular response against one specific peptide or epitope can be detected by flow cytometry.  
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population cannot be distinguished from background non-specific staining (Pittet et al 2001; 
Keiholz et al 2002; Vollers and Stern 2007).  Class I MHC tetramer staining is now commonly 
used to stain antigen-specific CD8+ T cells directly in peripheral blood samples (Vollers and Sterm 
2007).  By contrast, Class II MHC tetramers are less commonly used because of low TCR-tetramer 
avidity and the low frequency of specific CD4+ T cells (Klenerman et al 2002; Lucas et al 2004). 
    
Tetramer-based assays are now amenable to standardization and can be used in the combination 
with well-established functional assays, such as the cytokine enzyme-linked immunospot 
(ELISPOT) and the intracellular cytokine cytometry (ICC) assays, (especially the latter) which are 
more time consuming and require in vitro stimulation with specific antigens (Murali-Krishna et al 
1998; Riberdy et al 2001; Keilholz et al 2002).   
 
• Immunodominant epitopes of influenza A viruses  
When an individual is immunised or infected with a live virus (i.e. an influenza virus), the majority 
of the responding T cells recognise very few processed linear amino acid sequences from viral 
proteins (Thomas et al 1995; Abbas and Lichtman 2003).  These linear sequences are termed the 
immunodominant epitopes.   
 
Factors that contribute to immunodominance are: (1) IFN-γ production, (2) their MHC binding 
affinity, (3) the available TCR repertoire, (4) the epitope abundance and (5) the capacity of the 
target cells to process antigens, such as the cleavage patterns of whole proteins into small peptides 
that can bind to MHC (Boon et al 2002; Chen et al 2004; La Gruta et al 2006; Kedzierska et al 
2004 & 2006; Jenkins et al 2006; Thomas et al 2007).  The underlying mechanisms that govern 
these factors are largely unknown and are under intensive study (Sette and Sundaram 2006).   
 
In contrast to natural infections, no obvious patterns of immunodominance have been observed 
following immunisation with inactivated virus by the parenteral route (Thomas et al 1995).  In an 
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earlier study in mice, an even distribution among nine antigenic epitopes of HA1 was observed 
following injection with inactivated influenza viruses, whereas only two epitopes were identified 
following intranasal (i.n) immunisation with live attenuated influenza viruses (Thomas et al 1995).   
 
Immunodominant epitopes are the main determinants of cellular immune responses.  Most Class I 
MHC binding epitopes consist of 8-11 residues; Class II binding epitopes consist of 10-30 residues 
(Brown et al 1993).  Pathways of assembly for MHC molecules ensure that Class II molecules 
preferentially display peptides that are derived from extracellular proteins and are taken up by 
vesicles in APCs.  Class I molecules present peptides from cytosolic proteins.  Consequently, CD4+ 
T cells (i.e. TH cells) mainly respond to epitopes derived from extracellular proteins, such as the 
influenza surface glycoproteins HA and NA.  CD8+ T cells (i.e. CTLs) respond mainly to epitopes 
from the cytosol, which include the influenza virus internal proteins NP, PA, PB, M and NS 
(Bennink et al 1987; Thomas et al 1995; Chen et al 2003).   
 
However, there were several earlier reports that CTL-epitopes derived from influenza HA were not 
responsible for the cross-subtype responses (Bennink et al 1986; Spencer and Braciale 2000).  
More recently, a dominant TH-epitope from the influenza A NP protein has been identified, in 
addition to the HA peptide (Table 1.3; Crowe et al 2006).  However, downstream antibody 
responses to NP, alone, are not protective whereas antibodies to HA and NA are (Wright et al 
2007).   
 
Identification of influenza T cell epitopes, and especially conserved epitopes shared by different 
viral strains (drift viruses) or sub-types (shift viruses), is crucial for an understanding of host 
homosubtype and heterosubtype immunity to influenza infections (see also Section 1.2.2.3).  
However, until the recent application of MHC tetramer technology, screening for T cell epitopes 
was difficult for studies with humans, although possible with inbred mice (Crowe et al 2006; Wang 
et al 2007).   
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Most studies on T cell responses to influenza viruses have been conducted with A/PR8 (H1N1) 
and/or A/HK×31 (H3N2) in C57BL/6 mice.  The A/HK×31 reassortant has the same six internal 
genes as A/PR8.  Following primary infection with A/HK×31, a total of 16 Class I and 12 Class II 
epitopes have been identified (Crowe et al 2006).  Within them, NP366-374, PA224-233 and PB1703-711 
are Class I immunodominant epitopes; whereas HA211-225 and NP311-325 are Class II immuno-
dominat epitopes.  A similar pattern of CTL immunodominance had been observed after secondary 
i.n infection with A/HK×31 following primary intraperitoneal infection with A/PR8 (Table 1.3; 
Doherty 2007).  No epitopes were identified from NA protein of A/HK×31 in C57BL/6 (H-2d) 
mice, but multiple epitopes derived from NA were found during a parallel screen in BALB/c (H-2d) 
mice (Crowe et al 2006).  
 
Identification of influenza T cell epitopes in humans is far more difficult than for inbred mice, due 
to the highly polymorphic nature of the HLA.  At least 615 Class I isoforms are present among the 
human homologues HLA-A, -B, -C; and they can be grouped into 9 different supertypes with 
overlapping peptide binding specificities (Block et al 2003; Boon et al 2002).  A peptide that binds 
to one allele within a supertype has a high probability of binding to other allelic members of the 
same supertype.   
 
Using search tools involving bioinformatics, Wang et al (2007) predicted that 167 HLA-I peptides 
were derived from A/PR8, 13 of which were confirmed as CTL targets by INF-γ ELISPOT assays 
(Table 2.3).  These 13 CTL-epitopes are highly conserved among human influenza A viruses and 
are also present in recent isolates of avian influenza viruses (Wang et al 2007).  These findings 
confirmed the earlier view that critical epitopes should be included in vaccines that are capable of 
stimulating broad protective responses to drift and shift influenza viruses (Ben-Yedidia et al 1999; 
Thomas et al 2006).   
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Table 1.3  Influenza virus A/PR8/34 (H1N1) – derived immunodominant epitopes at C57BL/6 mouse lung and 
human peripheral blood mononuclear cells (PBMCs) after in vivo and ex vivo infection. 
 
Host MHC Class I restricted cytotoxic T lymphocyte 
(CTL) epitopes 
MHC Class II restricted T helper 
(TH) epitopes 
 
Inbred mice C57BL/6 
 
 
D
b
 – restricted NP366-374, PA224-233 and PB1-F262-70  
K
b
 – restricted PB1703-711, M1128-135 and NS2114-121 
 
 
Ab – restricted HA211-225 & NP311-325 
 
HLA-A1 – restricted PB1591-599 and NP44-52 
HLA-A2 – restricted PB1166-174 and M158-66 
HLA-A26 – restricted PB141-49 
HLA-B7 – restricted PB1540-548 
HLA-B8 – restricted NP225-233 and PA601-609 
HLA-B27 – restricted PB1349-357 and NP383-391 
HLA-B39 – restricted M1173-181 
HLA-B58 – restricted NP199-207 
Humans 
HLA-B62 – restricted PB1566-574 and PB1347-355 
Not been reported to date 
 
 
 
 
 
 
Figure 1.9 Host responses to proliferating pathogens (Murtaugh and Foss 2002).  The response is characterised by an 
immediate non-specific innate response and a prolonged antigen-specific adapted response (type I or/and II 
immunity).  During innate immune responses against infection, cytokines produced by macrophages or DCs play a 
central role in regulating the downstream adaptive immune responses. 
 
  APC: antigen-presenting cell 
  TH cell: helper T cell 
  TC cell: cytotoxic T cell 
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1.2.2 Host adaptive immune responses to influenza A viruses infections 
 
Following the presentation of antigenic peptides derived from influenza A viruses to T cells via 
APCs, specific adaptive immune responses (humoral and cell-mediated; local and systemic) can 
be initiated (Figure 1.9).  Specific neutralizing antibodies and CTLs generated by adaptive 
responses contribute to viral clearance, recovery from the disease and complete or partial 
protection against re-infection.   
 
Current understanding of immune responses (especially CMI responses) has largely come from 
the studies using inbred mice, which have also been used extensively for the studies of viral 
adaptation and virulence.  However, such models do not always provide an indication of the 
situation in primed and outbred human populations (Eichelberger et al 2006).  For instance, 
most mouse strains used in the laboratory lack biologically active Mx gene products (Staeheli et 
al 1988), which inhibit primary transcription of the viral PB2 polymerase and interfere with the 
viral replication (Section 1.2.1.4).  Consequently, Mx1-/- mice are more susceptible than Mx1+/+ 
mice or humans to influenza and show prolonged viral replication in the LRT (Doherty 2006; 
Salomon et al 2007).  Overall, mouse studies are relevant to immunopathology in humans 
caused by influenza virus infections and the full recovery requires both innate and adaptive 
responses. 
 
Although mice are not natural hosts for influenza infections, most mouse strains can be infected 
experimentally.  Several earlier studies demonstrated that many egg-adapted human influenza 
viruses were capable of replicating asymptomatically in the respiratory tract of mice to high titre 
(Tannock et al 1984, 1995).  Pathogenic lesions can be observed when the egg-grown viruses 
are multiply passaged in mice, implying that selection occurs within the viral population (Ward 
1997; Sealy et al 2003).  The great advantages of mouse models for influenza studies are their 
relatively low cost, their defined genetic status, and the large number of reagents available.  
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Many of the problems of extrapolation to human infections can now be overcome by the use of 
genetically modified (humanised) strains of mice (Thomas et al 2006).   
 
1.2.2.1  Host humoral and cellular immune responses to natural influenza infection 
Humoral immunity   
Humoral immunity is mediated by antibodies (Abs) secreted by B cells.  Innate and adaptive 
humoral immunities coexist in both humans and mice (Baumgarth et al 1999).  Innate humoral 
immunity is mediated by B1 cells and their secretory products consist of natural Igs, mainly 
IgM (Kopf et al 2002).  Adaptive humoral immunity is initiated by follicular B (B2) cells, and 
they secrete antigen-specific IgM, IgA, and IgG in response to infections (Bice et al 1993; 
Baumgarth et al 1999).  Specific Abs and memory B cells are critical effectors against re-
infection (Bachmann and Kopf 1999).   
 
• Antibody secreting cells (ASCs)  
Mature B-lymphocytes have membrane-associated IgM and IgD on their cell surfaces as BCRs 
for antigen recognition (see Section 1.2.1.5).  After encounter with influenza viruses, mature B 
cells undergo activation and differentiate into influenza-specific ASCs.  During the process of 
differentiation, two changes occur: (1) IgM is spliced to express a secreted form; (2) the heavy 
chain of immunoglobulin undergoes class switching to isotypes other than IgM and IgD.  
Compared with mature B cells, antigen-specific ASCs have reduced amounts of membrane-
associated IgM or IgD but high rates of IgG secretion (Abbas and Lichtman 2003).  Like most 
infections of immune competent individuals, influenza viruses initiate humoral immune 
responses consisting of an early increase of antigen-specific IgM followed by isotype switching 
and the production of anti-influenza IgG, IgA and IgE (Baumgarth et al 1999).   
 
An earlier study demonstrated that ASCs appeared 3 days after the exposure of mice to an 
aerosolised preparation of human influenza A virus (WSN) grown in Madin-Darby bovine 
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kidney cells, which were mainly found in major airways and in consolidated lung parenchyma 
(Owens et al 1981).  WSN-specific ASCs then appeared in the MLN and spleen after a delay of 
4 days.  Virus-specific IgA-secreting ASCs were the most abundant and comprised 40% of total 
ASCs found in the lungs.  Accumulation occurred in the lamina propria of the major airways 
and close to the natural site of infection.  By contrast, IgG-secreting ASCs were least frequently 
present in the airways and appeared mostly (85%) within consolidated lung lesions (Owens et al 
1981).  In the same study, IgM-secreting ASCs declined rapidly by 30 days post-infection (p.i.). 
 
• Anti-influenza antibodies 
Of the three antibody isotypes (IgM, IgA and IgG) induced in response to influenza infections, 
the short-lived IgM response has been shown to be insufficient to provide full protection 
(Bachman and Kopf 1999).  By contrast, active sIgA (Section 1.2.1.4), the predominant isotype 
in human mucosal secretions, is able to provide full protection against re-infection (Czerkinsky 
et al 1987; Nicod 1999).  The reasons for this are: (1) sIgA persists for up to 12 months after 
primary infections; (2) heterotypic immunity to drift viruses following natural infection is 
largely caused by local sIgA and not by serum Abs or CTLs (Liew et al 1984; Sealy et al 2003).  
Nevertheless, local IgG, together with the CTLs, are important in viral clearance from the lower 
lungs during primary infection.  In all, both, IgA and IgG play important roles in the control of 
influenza infection in URT and LRT, respectively (Renegar et al 2003; Tamura and Kurata 
2004).   
 
Antibodies control influenza infections by impairing viral infectivity (virus neutralization) and 
viral release (yield reduction).   Virus neutralization activity is mediated by HA-specific Abs, 
whereas yield reduction is induced by M2- and NA-specific Abs (Gerhard 2001; Mozdzanowska 
et al 2003).  Neutralizing Abs are of central importance for the development for protective 
immunity against all cytolytic pathogens, including influenza viruses.  For influenza A viruses 
there are five major antigenic sites, which surround the receptor-binding pocket on the surface 
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of the influenza A virus HA1 subunit.  Antibodies to one or more of these regions are capable of 
neutralizing viral infectivity by blocking the entrance to the target cells (Thomas et al 1995).  
The neutralizing activity of influenza virus-specific Abs can be enhanced by serum components, 
Fc-receptor expressing cells (such as macrophages) and lectins from the innate immune system 
(Mozdzanowska et al 2006). 
 
• Influenza-specific T cell-dependent (TD) antibody responses 
Virus-specific antibody production by B cells takes place by both T cell-independent (TI) and -
dependent (TD) pathways.  For influenza viruses, the TD Ab response is more effective than the 
TI response and protection against infection is mainly mediated by TD neutralizing Abs 
(Mozdzanowska et al 2005).  Within the influenza-specific TD Ab response, two types of 
interaction between CD4+ T cells and B cells are responsible for the production of specific Abs.  
During the early-phase of influenza infections, a local neutralizing IgA response is generated, in 
the absence of B-T cell signalling, via the MHC II peptide/TCR or CD40/CD40L pathways.  
These non-specific or bystander CD4+ T cells provide help only to viral-specific ASCs in the 
production of neutralizing IgA Abs against the viral surface HA glycoprotein (Sangster et al 
2003).  Unlike the IgA response, IgM and IgG responses require specific CD4+ help through 
TCR or CD40L pathways and hence occur later than the IgA response.  As a consequence of 
these two different types of B-T interaction, most IgAs are capable of neutralizing HAs.  By 
contrast, IgG2a Abs contain substantial non-neutralizing components that recognise NA, NP and 
M2 (Kilbourne 2006).   
 
Cellular immunity 
The CMI response to influenza infections is mediated by antigen-specific CD4+ and CD8+ T 
cells and cells of the innate immune system [e.g. DCs, NK cells and macrophages (Section 
1.2.1.3)].  Both effector CD4+ and CD8+ T cells produce a spectrum of cytokines that are 
involved in cell recruitment and activation.  Overall, during viral infection of the respiratory 
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tract, CD4+ T cells act mainly as helpers and CD8+ T cells as killers (Doherty et al 1997).  
Specific CD4+ and CD8+ T cell responses can only be induced if an MHC molecule presents an 
appropriate antigenic peptide to T cells (MHC-restriction).  Peptides of suitable length and 
capacity to bind to MHC receptors are the main determinants of adaptive cellular immune 
responses.  By contrast, humoral antibody responses are determined by the 3-dimensional 
structure of the presenting antigen.   
 
Other factors, such as the antigenic load or dose and the local presence of cytokines and 
accessory molecules, are also important in the development of viral immunity (Doherty et al 
1997; Hozler et al 2003).  For example, primary responses to replicating viruses are qualitatively 
different to those of purified non-replicating antigens prepared from the same virus (i.e. subunit 
influenza vaccines).  Qualitative differences have also been observed between the responses to 
high-yielding virulent influenza strains and low-yielding attenuated strains (Mak et al 1982; 
Baumgarth and Kelso 1996; Wareing et al 2003 and 2005).   
 
• CD4
+
 T helper ( TH) cell responses  
CD4+ TH cells are of central importance in the development of adaptive immunity against 
infectious pathogens (Figure 1.9), due to the assistance they provide to specific B cells and 
CTLs (Castellino and Germain 2006; Simpson 2008).  Under the influence of cytokines IL-12 or 
IL-4, naïve CD4 cells can differentiate into Type I or Type II effector TH cells (Doherty et al 
1997; Murtaugh and Foss 2002).  More recently, a third type of CD4+ TH cell, TH17, has been 
described in response mainly to bacterial infections and was named after its ability to secrete IL-
17 (Kaiko et al 2007).   
 
Type I TH cells (TH1) secrete IFN-γ, IL-2 and TNF-α, which promote the clonal expansion of 
virus-specific CTLs and the production of IgG2a (Fazekas et al 1994).  An in vitro study using 
human PBMCs demonstrated that IL-2 is the major cytokine responsible for the generation of 
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effective CTL responses (Boon et al 2005).  Type II TH cells (TH2) produce IL-4, IL-5 and IL-13 
to provide help for an effective B-cell response and, in particular, to drive IgG1 production 
(Brown et al 2004).  Because TH cells recognise many epitopes on influenza viral proteins (both 
surface and internal), they are able to provide assistance to B cells and CTLs during primary, 
secondary and memory responses to influenza viruses.   
 
During primary infections in mice, low-level CD4+ T cell responses are broadly heterogeneous. 
They commence in the MLN and CLN, followed by spleen, and then spread to other secondary 
lymphoid sites (i.e. NALT and BALT).  By day 6-7 p.i., effector CD4+ T cells are recruited to 
the lungs and BAL (Roman et al 2002; Eichelberger et al 2006).  Their response then declines 
rapidly in parallel with viral clearance.  When effector CD4+ T cells migrate to infected lungs, 
they undergo phenotypic changes that include: (1) loss of CD62L, down-regulation of the CCR7 
homing marker; (2) stable expression of adhesion molecules such as CD44 and CD49d; and (3) 
discontinuance of IL-2 secretion (Baumgarth et al 1994; Brown et al 2004).  Only fully divided 
and differentiated effector cells are available in the lungs and BAL for combating local 
infections.   
 
Furthermore, in primary response to influenza infection, TH cells are not the only source of help 
for the development of primary CTL responses, since DCs can also stimulate naïve CD8+ cells 
(Diebold et al 2004).  Consequently, CD4+ T cells are not essential for the development of an 
effective CMI during primary influenza infections.  This was confirmed from earlier studies in 
which CD4-depleted mice were able to clear virus from lungs following primary infections, but 
with a delay of ~4 days compared with intact mice (Allan et al 1990; Eichelberger et al 1991).   
 
However, TH cells play a vital role in secondary CTL responses to influenza infections, 
especially in the establishment of immunodominance (Mintern et al 2002).  Without the help 
from specific TH cells induced during the primary response, memory CTLs and robust secondary 
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CTL responses cannot be generated (Riberdy et al 2000; Thomas et al 2006).  Moreover, 
throughout the secondary influenza infections, specific TH responses are relatively weak (2-3-
fold less in the BAL) than CTL responses and immunodominance does not appear to be present 
(Wohlleben et al 2003; Eichelberger et al 2006; La Gruta et al 2007).  These observations are 
inconsistent with the view that most viral infections favour cytotoxic Type I immune responses 
for the control of intracellular infections.   
 
It has been recognised since the 1960s that TH cells can help B cells in the production of Ab.  
With influenza infections, apart from natural IgM Abs, the specific Ab responses are in a TH-
dependent mode.  Accordingly, the production of isotype-switched, high affinity anti-influenza 
neutralizing Abs requires the presence of TH cells (Baumgarth and Kelso 1996).   In addition, 
CD4+ TH cells are necessary for the generation of specific memory B cells (Gerhard 2001).  TH 
cells recognise both surface and internal proteins from influenza viruses.  Specific TH cells and 
ASCs recognise the viral epitopes derived from limited regions of the HA1 subunit.  In addition, 
TH cells that recognise M or NP can provide help to B cells for the production of HA-specific 
Abs (Marshall et al 1999).  This feature of TH cells has been useful in providing a mechanism 
for cross-protection against drift variants (Wright et al 2007).   
 
Besides providing help for B and CD8+ T cells, some CD4+ TH cells (less than 2% of the total 
CD4+ T cell population) have been found to have direct cytotoxic effector function during 
herpesvirus, HIV and influenza infections (Eichelberger et al 1991).  For influenza infections, 
CD4+ CTLs appear early and before the production of specific-Abs.  It was demonstrated in 
earlier studies that CD4+ CTL cell lines isolated from the human PBMC were HA- and NA-
specific (Sterkers et al 1985; Jameson et al 1998). They are strong IFN-γ producers, possess 
reduced proliferative capacity and do not provide help with the B cell differentiation.  Several 
studies have demonstrated that a subset of CD4+ T cells is able to kill infected cells by perforin-
mediated cytolysis, as also occurs in CD8+ CTLs and NK cells (Appay 2002; Brown et al 2006).  
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However, influenza-specific CD4+ CTLs, alone, were shown to be insufficient to control 
relatively mild influenza infections (Topham and Doherty 1998; Thomas et al 2006).       
 
• CD8
+
 cytotoxic T ( TC or CTL) cell responses 
Specific CTL responses are critical components of the defence against influenza infections; they 
allow the host to recognize and eliminate infected cells (Ennis et al 1978; McMichael et al 
1986).  More significantly, such responses are able to cross-react with cells infected with 
homologous and heterologous viruses (Webster and Askonas 1980; Lin and Askonas 1981).  
Through mainly CD95 (Fas) - or perforin-and granzyme-mediated cytotoxicity, effector CTLs 
are capable to kill target cells and subsequently terminate viral replication.  In addition, certain 
cytokines (i.e. IFN-γ and TNF-α) produced by CTLs also play a role in the control of infections 
and in some cases can directly cause lung immunopathology (Carding et al 1993; Barry et al 
2002; Xu et al 2004). 
 
Previous studies have indicated that viral infectivity is essential for inducing specific CTL 
responses in vivo (Braciale and Yap 1977; Ada et al 1981).  Sialic acid receptors with an alpha 
2,6 linkage (SAα2, 6Gal) are specific for most human influenza viruses.  Due to the differences 
in viral receptor distribution, viral replication in humans (except for H5N1 viruses) is usually 
restricted to the URT, whereas in mice replication largely occurs in the LRT.  In addition, most 
healthy adults, unlike mice, have been exposed to influenza viruses many times and even partial 
pre-existing immunity probably reduces the chance of developing pneumonia following 
infection.  In mice, peak CTL activity coincides with acute pneumonia and decreases during its 
resolution (Ennis et al 1978; Eichelberger et al 1991; Baumgarth et al 1994; Belz et al 1998).   
 
There are further differences in the patterns of CTL responses following influenza infections of 
humans and mice.  Bennink and Yewdell (1988) suggested that, because of the highly 
polymorphic nature of the human MHC gene, the peptides recognised by CTLs should vary 
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considerably in humans.  This contrasts to the limited response (or immunodominance) observed 
following infection of inbred mice.  By stimulating PBMCs with A/PR8 (H1N1), 
A/Japan/305/57 (H2N2) and A/Johannesburg/33/94 (H3N2) separately in vitro, human memory 
CTL responses to influenza A viruses were shown to be broadly directed to a range of epitopes 
derived from several different viral proteins (Jameson et al 1998).  Ten CTL lines isolated from 
the PBMCs of three donors were shown to be specific for the epitopes of several viral proteins 
(including NP, M1, M2, NS1, PB1, PB2, and HA, NA), which may account for their subtype-
specific and cross-reactive specificities (Jameson et al 1998).   
 
An immunodominance hierarchy can be established during the influenza virus infections within 
several different inbred mice strains, including BALB/c (H-2Dd), C57BL/6 (H-2Db), CBA/Ca 
(H-2DK) (Tourdot et al 2001; Chen et al 2000 and 2002).  However, specific CTL responses are 
directed at only a few epitopes and especially following secondary infections (Section 1.2.1.5).  
Individual epitopes differ in their capacity to induce T cell responses and, therefore, can be 
classified as dominant, codominant, or subdominant, according to their relative contributions to 
the total T cell response (Crowe et al 2003).  However, in general, the immunodominance status 
is only a relative phenomenon and elimination of a dominant epitope can cause elevation of a 
subdominant epitope to the status of dominance (Belz et al 2000).    
 
Following primary i.n. challenge of C57BL/6 mice with HK×31 (H3N2) virus, two CTL 
dominant epitopes (NP366-374 and PA224-233) and four subdominant epitopes (PB1703-711, NS2114-
121, M1128-135, PB1-F262-70) were identified (Belz et al 2000 and 2001; Table1.3).  The 
CD8+DbNP366
+, CD8+DbPA224
+ and CD8+KbPB1703
+ sets were detected by tetramer staining and 
comprised less than 5% of CD8+ T cells in the spleen but more than 30% in the BAL.  However, 
the secondary CTL response following i.n. infection with A/PR8 (H1N1) was shown to mostly 
take place in the CD8+DbNP366
+ population, accounting for more than 70% of the total CD8+ T 
cells in the BAL (Belz et al 1998).       
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Relationships between humoral and cellular immunity  
The concept that Ab-mediated humoral immunity protects against extracellular pathogens and 
that CMI protects against intracellular pathogens is widely accepted (Abbas and Lichtman 
2003).  Many studies have demonstrated an inverse or sometimes antagonistic relationship 
between these two arms of the immune system (Casadevall 2003).  In recent years, these 
relationships have been extended in mice by studies demonstrating the presence of TH1/TH2 or 
Type I/Type II systems (Figure 1.9).  It would be highly desirable to understand the relative 
contributions of humoral and cellular immunity by the host and to examine the role of these 
relationships in the control of individual infections by vaccination. 
 
Influenza infections of the respiratory tract in both mice and humans initiate mixed Type I 
(CTL) and Type II (neutralizing Ab) responses, which are consistent with the need to eliminate 
virus at both the intracellular and extracellular phases of the virus life cycle.  For the optimal 
control of infections, both humoral and cellular immunity is required (Table1.4; Bachmann and 
Kopf 1999; Gerhard 2001).  Some controversy exists as to whether CMI (which induces 
heterosubtypic responses) is less effective than the more strain-specific humoral immunity 
(Gerhard 2001).  CMI responses, by themselves, in a mouse model have been shown to be less 
efficacious than humoral responses against the highly pathogenic mouse-adapted influenza 
strain A/PR8 (H1N1) (Subbarao et al 2006).  However, without CMI responses, A/HK (H3N2)-
primed mice did not survive lethal challenge with A/PR8 (Brown et al 2006).  This indicates that 
CMI plays a critical role in eliciting a heterotypic, or memory-induced, protective immune 
response (Figure1.10).   
 
While there is a general consensus that TH cells promote specific-B cell responses (Jeurissen et 
al 2004), B cells also play a key role in promoting optimal and sustained T cell responses 
(Christensen et al 2003; Martin and Chan 2006).  Using B cell-deficient mice infected i.n. with 
A/PR8, a significantly reduced CD4+ cell response was observed (Kopf et al 2002).  In further 
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study, DC-deficient mice were able to generate NP-specific CTL responses after receiving NP-
expressing spleen B cells (Langlade-Demoyen et al 2003).  This evidence is consistent with 
earlier observations that B cells can process and present endogenous peptides to CD8+ T 
lymphocytes and, therefore, serve as APCs for the priming of specific-CTL responses (Billetta 
et al 1995).   
 
Further evidence suggests that humoral responses can partially compensate for deficient CMI 
responses.  An enhanced IgG antibody response was reported after naïve mice had been infected 
i.n. with influenza virus constructs (prepared by reverse genetics) with point mutations in their 
NP and PA genes (Webby et al 2003).  One possible explanation is that mutations in the regions 
of immunodominant epitopes allowed these viruses to escape CTL activity (i.e. CD8+DbNP366
+ 
or PA224
+) and to grow to significantly higher titres, in comparison with wt virus.  Therefore, the 
prolonged antigen-presenting process in the LNs and spleen may allow greater CD4+ T cell and 
B cell stimulation.  Interestingly, an increase in the size of the minor CD8+KbPB1703
+ population 
appeared following infection with the NP/PA double mutant.  Collectively, B and T cells can 
influence each other through several different pathways.  Consequently, the relationship 
between protective humoral and cellular immunity is complicated, and interactions between the 
two can lead to variable outcomes.   
 
1.2.2.2  Memory and cross immune responses to influenza infections  
Immunological memory, the basis for vaccination, can be generated only by adaptive immune 
responses (Kaech et al 2002; Esser at al 2003).  Naïve B and CD8+ TC cells can differentiate into 
effector cells during primary infection and in mice most die once the pathogens have been 
eliminated (Westermann et al 2001; Baz et al 2005).  However, some survive and differentiate 
into long-lived memory cells with the assistance from CD4+ TH cells (Belz at al 2002; Swain 
2005; Willams and Bevan 2006).  At present, the mechanisms behind the generation and 
maintenance of antigen-specific memory lymphocytes are largely unknown.   
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Memory lymphocytes confer immediate protection in peripheral sites and mount recall 
responses to both homologous- and heterologous-antigens in secondary lymphoid tissues 
(Sallusto et al 2004).  Cross-reactivity is particularly important in providing protection against 
pathogens that exhibit frequent antigenic variation, such as influenza viruses.  Because of 
immunological memory, children who have previously experienced natural influenza infection 
or who received a live influenza virus vaccines exhibit a substantial reduction in both the 
amount and duration of virus shedding (Wright et al 2007).   
 
Specific memory responses against influenza viruses 
• Memory B cells 
Specific memory B cells and the high levels of serum Abs are responsible for serological 
memory.  Immunocompetent individuals who have recovered from respiratory infection with 
influenza A virus show long-lasting, high levels of sterilizing immunity to homologous viral 
challenge (15 months in mice; 20-25 years in humans) which is mainly mediated by anti-HA 
neutralizing Abs (Gerhard 2001; Zinkernagel 2002).  These Abs are produced by influenza-
specific ASCs that differentiate from the activated memory B cells after re-encounter with the 
same virus.  These properties are used for the measurement of specific-resting memory B cells 
in ELISPOT assays using antigen restimulation (Welsh et al 2004).  Nevertheless, because of 
high strain specificity, memory B cell responses are not efficient in providing protection from 
influenza infections caused by drift or shift strains (Figure 1.10). 
 
• Memory CTLs 
Memory CD8+ T cells can mediate an accelerated and enhanced recall response to secondary 
virus infections.  Acceleration is caused by increased numbers (~1000-fold) of antigen-specific 
T cells; enhanced responsiveness is caused by reduced co-stimulatory requirements and the 
higher activation state of the cells (Kambayashi et al 2003).   
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Table 1.4 All cell components of host adaptive immune responses were required for the optimal                   
recovery from primary influenza virus infection in mouse (Gerhard 2001) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   CMI Cellular mediated immunity 
TCID50 50% mouse infectious dose 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.10 The role of cellular and humoral immune responses during secondary influenza infection              
(modified from Gerhard 2001) 
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  RT respiratory tract 
 
CMI Humoral Recovery from i.n. infection with A/PR8 
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+ + + 7-10 100 80 
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 Memory CD8+ T cells (mostly CD44high) have been broadly classified into (1) central memory 
cells (TCM CD62L
high CCR7+) found in lymphoid organs that have no immediate lytic activity 
and (2) effector memory cells (TEM CD62L
low CCR7-) that reside in nonlymphoid tissues with 
lytic functions (Sallusto et al 1999, Mackay 1999; Selin and Welsh 2004; Wherry and Ahmed 
2004).  Furthermore, optimal memory CTL-mediated protection against secondary influenza 
infection largely depends on the strength of TEM responses which occur during the first 2-3 days 
of re-infection (Christensen et al 2000; Willams and Bevan 2006). 
 
Compared with memory B cells that are able to mediate sterilizing immunity, the protection 
mediated by memory CTLs is infection-permissive which is required for the activation of resting 
CTLs (Gerhard 2001).  Memory CTLs are more efficient than memory B cells in the induction 
of cross-reactive responses against influenza variants (Figure 1.10).  Earlier studies 
demonstrated that memory CTL-mediated cross-reactivity can be maintained for at least 3 years 
following influenza infections (Doherty et al 1996; Flynn et al 1998).   
 
Cross-immune responses to influenza virus infections 
It has long been recognised that cross-immunity to other viruses within the influenza A sub-type 
occurs following recovery from any influenza A virus infection (Jordan et al 1958; Armerding 
and Liehl 1981; Tannock and Paul 1987).  Cross-immunity between different drift strains within 
the same subtype is referred to as homosubtypic immunity; cross-immunity between different 
subtypes or shift strains is referred to as heterosubtypic immunity.  Cross-immunity is mediated 
by pre-existing Abs and memory B and T cells that recognise conserved viral protein sequences 
shared by different variants (Epstein et al 1998).  Although it cannot provide complete 
protection against influenza infections, it is vital in reducing morbidity and mortality (Doherty 
2007). 
There are quantitative and qualitative differences between homosubtypic and heterosubtypic 
responses against influenza A viruses.  In cotton rats 25% of all cells recovered from the BAL as 
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part of the heterosubtypic response were specific CD4+ T cells, compared with 70% for the 
homotypic response (Eichelberger et al 2006).  A further study demonstrated that the homotypic 
Ab response requires a less diversified Ab repertoire than is necessary for the heterosubtypic Ab 
response (Nguyen et al 2007).  These results indicate that a strong Ab response is induced by 
homotypic challenge and a strong CTL but weaker Ab response by heterosubtypic challenge.  
Furthermore, studies in mice infected i.n. with cold-adapted (ca) live-attenuated influenza 
vaccine (LAIV) virus demonstrate that heterotypic immunity, compared with homotypic 
immunity, is relatively short-lived, indicating the involvement of different effector pathways 
(Tannock and Paul 1987). 
 
Influenza virus-specific CD8+ T cells that recognise viral internal proteins (mainly NP and PA) 
are highly cross-reactive and are the primary contributors to heterosubtypic immunity in mice 
(Yewdell et al 1985; Bennink et al 1986 & 1987).  A/PR8 H1N1-primed mice with relatively 
small numbers of influenza virus-specific memory CD8+ T cells (<1% of total CD8+ cells) were 
shown to clear A/HK×31 H3N2 infection 1-2 days earlier than naïve mice following i.n. 
challenge (Doherty et al 2006).  In another study, pre-existing cross-reactive specific-memory 
CTLs, from A/HK×31 (H3N2)-primed mice were shown to have a higher survival rate (87.5%) 
than naïve mice (33%) 7 days p.i after challenge with a lethal dose of A/PR8 (H1N1) (Kreijtz et 
al 2007).   
 
Several studies have demonstrated that the proportion of pulmonary specific CTLs determines 
the extent of cross-immunity (Riberdy et al 1999; Seo et al 2002).  Therefore, heterosubtypic 
immunity can be enhanced by increasing specific memory in the CTL population.  In support of 
this, mice primed i.n. with H1N1 and then boosted with H3N2 exhibited only transient weight 
loss and survived following i.n. challenge with highly pathogenic H5N1 and H7N7 viruses 
(Christensen et al 2000).   
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Generally, memory T cell-mediated heterosubtypic responses are weak and are easily 
overwhelmed by severe influenza infections and, to survive lethal influenza challenge, both 
memory B cells and pre-existing Abs are required.  B cell and Ab-mediated heterosubtypic 
immunity can slow viral replication and thus facilitate the expansion of responding memory 
CTLs (Rangel-Moreno et al 2008).  Cross-protection against secondary heterosubtypic 
infections of mice is related to levels of local sIgA Abs (Liew et al 1984).  Strong Ab-mediated 
heterosubtypic immunity exists between influenza A H1 and H2 subtypes from the same clade 
(Figure 1.5).  Similar observations have been found for influenza B viruses, with sIgA Abs 
providing strong cross-protection against strains from different lineages (Asahi-Ozaki et al 
2004).  Other Abs specific to viral NA, NP and M2 are also involved in the heterosubtypic 
responses to influenza variants (Kilbourne 2006; Straight et al 2008).  
 
Significantly, several ex vivo studies have demonstrated the existence of heterosubtypic T cell 
and Ab responses against avian H5N1 influenza viruses in individuals who had been exposed to 
influenza H1N1 and H3N2 viruses through seasonal vaccination or infection (Goy et al 2007; 
Roti et al 2008; Kreijtz et al 2008).  In one human study, it was reported that 58% of UK donors 
and 74% of Vietnamese donors exhibited detectable H5N1-specific CD4+ and CD8+ T-cell 
responses (Lee et al 2007).  Currently, with the threat of possible influenza pandemic, a range of 
vaccines that are able to enhance heterosubtypic immunity and promote broad protection are 
under development (Ansaldi et al 2008; Quan et al 2008; Bright et al 2008; Zanvit et al 2008; 
Baras et al 2008). 
 
1.2.2.3  Host local and systemic immune responses against influenza infection 
The respiratory tract mucosa is both the primary site for influenza infection and for the induction 
of protective mucosal and systemic immune responses, involving the MALT and draining LNs 
(Section 1.2.1.2; Haanen et al 1999).  For many years, local immunity has been considered in 
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isolation from humoral immunity but recent studies indicate that effective mucosal immunity 
depends on antigen-priming of both B and T cells (Woodland 2002).   
Local and systemic humoral immune responses 
For influenza, local specific humoral immunity involves the action of Abs (mainly sIgA and to a 
lesser extent IgG) and ASCs in the respiratory mucosa (Fokkens and Scheeren 2000; Renegar et 
al 2003).  Following influenza virus infection, B cells were shown in mice to comprise up to 
18% of cells isolated from mice lungs (Baumgarth and Kelso 1996); most long-term ASCs are 
present in the lung interstitium, giving rise to local Ab responses (Bice et al 1993).  ASCs from 
draining or distant LNs or from the spleen play little or no role in the maintenance of local Ab 
memory responses to influenza infections.  These cells produce most neutralizing Abs in the 
serum, and constitute the systemic humoral immunity.   
 
Compared with sIgA Abs which acts primarily in the URT, serum Abs provide protection 
against influenza infections in the LRT.  Recovery from infection in the LRT is related to the 
induction of a serum Ab response.  Serum HI titres of 40 or greater are closely associated with 
protection against infections by influenza A viruses (Gross et al 1977).  During primary i.n. 
infections of mice, the number of lymphocytes in the MLN was shown to increase from ~0.5- to 
6-12 × 106 within the first 3 days, and to reach a peak of 15-20 × 106 by day 7 p.i (Gerhard 2001; 
Sealy et al 2003).  These increases coincide with a significant increase in serum Ab titre.  Such 
increases usually occur 1 week after primary infections (Gerhard 2001).   
 
However, serum IgG Abs were found to have contributed little to mucosal immunity through 
passive transudation into the respiratory mucus (Wagner et al 1987).  Compared with 
unanaesthetised mice, levels of IgG Abs in serum were found to be markedly higher in 
anaesthetised mice following i.n. challenge with influenza viruses; no differences in sIgA Ab 
levels were found (Jannkova et al 2002).  Overall, during natural influenza infection, the 
stimulation of serum Ab is related to the extent of viral replication that occurs in the LRT.    
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Local T cell responses and mucosal vaccination 
Influenza virus infections of mice result in both local and systemic T cell responses.  Earlier 
studies showed that the ratio of CD4:CD8 T cells was 1:2 in airways, 1:1 in the lung 
parenchyma and 2:1 in the draining LNs following infection (Baumgarth and Kelso 1996).  
Following primary infection, the majority of specific memory CD8+ T (TEM) cells found in the 
in airways and the lung parenchyma (BALT) were able to provide prompt local cellular 
responses against secondary infection over long periods (Ely et al 2003) and to establish a 
second generation of memory T cells (Marsland et al 2004; Roberts and Woodland 2004).  
Importantly, memory CTLs in the MALT were associated with local protection against lethal 
heterosubtypic challenge (Nguyen et al 1999).  However, local memory CD8+ T cells (TEM) 
have a half-life of about 40 days and their protective efficacy wanes over time in both humans 
and mice (Woodland 2002).   
 
LAIVs or adjuvanted inactivated vaccines administered directly to the respiratory mucosa are 
able to promote local memory T cell pools in addition to stimulating systemic immunity 
(Tannock and Paul 1987; Asnuma 2001).  Such presentation of antigens (Ags) to both the URT 
and LRT is referred as total respiratory tract immunization.  In mice, this can be achieved by 
using i.n. inoculation administered under general anaesthesia and in humans by inhaling the Ags 
in the form of an aerosol (Janakova et al 2002).  Total respiratory tract immunization has been 
found to be the only route that induces and maintains a significant memory CTL response in the 
MALT (Nguyen et al 1999; Haanen et al 1999).   
 
1.2.2.4  Adaptive immune responses to influenza infections in aged populations 
Aged individuals typically have an impaired capacity to clear infections and a lowered capacity 
to respond to vaccines, which coincides with declining innate and adaptive immunity (Kumar 
and Burns 2008; Nogusa et al 2008).  Declining systemic and local Ab responses were observed 
following i.n. administration of cholera toxin-combined inactivated A/PR8 vaccines combined 
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with cholera toxin to 18-month old mice (Asanuma et al 2001).  Another study demonstrated a 
marked decline in the frequency of memory B cells in 8-month- compared with 6-week-old 
mice- related to their reduced responsiveness to IL-7, which is required for sustaining memory 
responses (Miller and Allman 2003).  
 
For primary T cell responses, it has been shown that numbers of peripheral naïve T cells decline 
throughout life and this decline is associated with severe functional defects.  In 22-month-old 
mice, these include: (1) decreased T cell repertoire diversity leading to the development of 
immunodominance during the primary response, which impairs heterosubtypic immunity during 
secondary infections; (2) reduced reactivity to viral epitopes and (3) a 4-day delay in the 
maximum expansion of NP-specific CTLs (Po et al 2002; Yager et al 2008).  Other impacts of 
age on the secondary T cell response to influenza infections are: (1) a significant loss of TEM 
cells at peripheral sites over time; (2) an impaired rate of Ag-specific proliferation and (3) a 
decrease in the lytic capacity of effector cells (Boon et al 2002; Kang et al 2003; Ely et al 2007).  
These age-associated immunity changes need to be addressed when considering vaccination 
strategies against influenza infections in the elderly. 
 
 
1.3 INFLUENZA VACCINES  
 
Although specific immune responses occur in response to infection, influenza remains the major 
recurrent respiratory disease of humans because the viruses responsible have evolved several 
strategies to evade host defences.  In addition to new pandemics, seasonal influenza epidemics 
cause significant morbidity and mortality.  They account for, on average, 226,000 hospitalized 
cases and 36,000 excess deaths each winter in US (Subbarao and Murphy 2006) and 10,000 
excess deaths in the UK (Barclay 2006), alone.   
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Measures for the control of influenza include: the development of global surveillance networks, 
fast diagnostic techniques, antivirals and vaccines (Wood 2002).  Of these, vaccination has been 
proven to be the most cost effective and is most commonly used for high-risk populations 
(Table1.5) in developed countries.  Currently, vaccination rates in all groups in US are <35%, 
compared with 60% in those aged >65 years (CDC 2007).  Rates of vaccination have increased 
in recent years and the world market for seasonal vaccines is expected to increase to US$3.6 
billion by 2009 as a consequence of recent WHO recommendations (Quigley 2006).   
 
1.3.1 Inactivated trivalent influenza vaccines (TIVs) 
Current vaccines are usually trivalent and contain representative influenza A H1N1, H3N2 and 
influenza B surface Ags, which are re-evaluated each year to ensure that there is antigenic match 
with current epidemic strains (Table 1.6).  The majority of viruses used in the preparation of 
inactivated vaccines are still prepared by growth in the allantoic cavity of embryonated chicken 
eggs.  Allantoic virus is purified, concentrated and inactivated.  Reactogenicity associated with 
purified influenza virus is greatly reduced by treatment with a detergent or splitting agent (split 
vaccines).  An additional step, involving the isolation and purification of surface glycoprotein 
Ags, is used by some vaccine manufacturers (subunit vaccines).   
 
Purified whole virus vaccines are more immunogenic than split/subunit vaccines but are not 
widely used in interpandemic immunization programmes because of their reactogenicity.  
Influenza vaccines may still contain trace amounts of potentially reactogenic endotoxins, egg 
proteins, formaldehyde and preservative.  Yields of egg-adapted viruses are usually high, but 
there are a number of problems associated with the use of eggs, which include (1) the limited 
flexibility they afford for expanded vaccine manufacture; (2) interruption of the embryonated-
egg supply chain due to the presence of diseases in layer flocks; (3) the possibility of sterility 
problems arising during the processing of infected allantoic fluids; and (4) poor growth of some 
reassortant and non-reassortant vaccine strains in eggs.   
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Additionally, the growth of epidemic viruses in eggs often selects variants that differ in their 
glycosylation patterns from the original clinical isolates that are antigenically distinct.  These 
problems do not occur with viruses isolated in the Madin-Darby canine kidney (MDCK) and 
African Green monkey kidney (Vero) continuous cell lines.  The use of stable cell lines for 
vaccine virus growth could largely overcome these problems if yields were satisfactory and 
safety issues could be successfully addressed.   
 
Many adjuvants are currently under examination to boost responses and reduce the amount of 
Ag required.  These include immune-stimulating complexes (ISCOMS, liposome-like 
preparations or VLPs) and synthetic adjuvants (e.g. lipid A, muramyl peptide derivatives and 
cationic molecules).  MF59 has been licensed in several European countries for use in pandemic 
influenza vaccines (Guy 2007; Aguilar and Rodríguez 2007).  Other strategies under 
consideration to improve killed vaccines include the use conserved viral proteins (e.g. M2 or 
NP) (so-called universal vaccines), DNA vaccines and adjuvanted vaccines administrated by the 
i.n. route. 
 
1.3.2 Cold-adapted live-attenuated influenza vaccines (ca LAIVs) 
Live influenza vaccines are promising alternatives to inactivated vaccines (Subbarao et al 2006).  
They are administered i.n. and are, therefore, able to mimic natural infection.  Restricted viral 
replication in the respiratory tract can induce both specific humoral and CMI, local and systemic 
and memory cross-immune responses (Section1.2.2; Wareing and Tannock 2001).  LAIVs have 
been proposed for over 50 years as alternatives to intramuscular (i.m.) administered inactivated 
vaccines.   
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Table 1.5  Annual vaccine recommendations (CDC, October 23, 2007) 
General group: 
• all persons, including school-aged children, who want to reduce the risk of becoming 
ill with influenza or of transmitting influenza to others;  
High risk groups: 
• all persons aged 50 years and older;  
• all children aged 6–59 months (i.e., 6 months–4 years);  
• women who will be pregnant during the influenza season;  
• children and adolescents (aged 6 months–18 years) receiving long-term aspirin 
therapy who therefore might be at risk for experiencing Reye syndrome after 
influenza virus infection;  
• adults and children who have chronic pulmonary (including asthma), cardiovascular 
(except hypertension), renal, hepatic, hematological or metabolic disorders (including 
diabetes mellitus);  
• adults and children who have immunosuppression (including immunosuppression 
caused by medications or by human immunodeficiency virus;  
• adults and children who have any condition (e.g., cognitive dysfunction, spinal cord 
injuries, seizure disorders, or other neuromuscular disorders) that can compromise 
respiratory function or the handling of respiratory secretions or that can increase the 
risk for aspiration;  
• residents of nursing homes and other chronic-care facilities;  
• health-care personnel;  
• healthy household contacts (including children) and caregivers of children aged <5 
years and adults aged 50 years and older, with particular emphasis on vaccinating 
contacts of children aged <6 months; and  
• healthy household contacts (including children) and caregivers of persons with 
medical conditions that put them at higher risk for severe complications from 
influenza.  
 
 
 
 
 
Table 1.6 Recommended composition of seasonal human influenza virus vaccines used in northern hemisphere during 
recent four influenza seasons 2005-2009 (CDC Website 2008).  It demonstrates the updating at least one 
component on a yearly base is required.  
 
Type A  
Subtype H1N1 Subtype H3N2 
Type B 
2005-2006 A/New Caledonia/20/99 -like A/California/7/2004 -like B/Shanghai/361/2002 -like 
2006-2007 A/New Caledonia/20/99 -like A/Wisconsin/67/2005 -like B/Malaysia/2506/2004 -like 
2007-2008 A/Solomon Islands/3/2006 -like A/Wisconsin/ 67/2005 -like B/Malaysia/2506/2004 -like 
2008-2009 A/Brisbane/59/2007 -like A/Brisbane/10/2007 -like B/Florida/4/2006 -like 
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Table 1.7 Phenotypes of the cold-adapted master donor virus used as attenuation markers for evaluating LAIVs 
(Maassab et al 1968; Wright at al 2007) 
 
 
Phenotypes Definitions 
cold-adapted (ca) 
 
Replicating efficiently (compatible to at 33ºC) in tissue culture at 25ºC, whereas 
no replication occurred for wild-type virus 
 
temperature sensitive (ts) 
 
Restricted replication at higher temperatures (37 ºC for Type B and 39ºC for Type 
A; temperatures permissive for the replication of wild-type virus) 
 
attenuated (att) 
 
Limited replication at upper respiratory tract and no replication in the lungs of 
infected ferrets (ferret attenuation assay); and is safe and attenuated in children 
and adults 
 
 
 
  
 
 
Table 1.8  Mutations present in the ca A/Ann Arbor/6/60 master donor virus (Buonaguria et al 2006) 
 
Nucleotidea Amino acidb 
RNA segment Coding region 
[wt → ca] [wt → ca] 
Phenotype(s) assigned to 
master donor virus residue 
1 PB2 A821G N265Sc att, ts 
2 PB1 A1195G K391Ec att, ts 
  G1395T E457D  
  A1766G E581G
c att, ts 
  G2005A A661T
c att, ts 
3 PA A1861G K613E att, cad 
  TT2167/8CC L715P  
5 NP A146G D34G
c
 att, ts 
7 M1 None   
 M2 G969T A86S att 
8 NS1 G483A A153T  
 NS2/NEP None   
 
 
 a)  Number indicates nucleotide position in the designated RNA segment; 
 b) Number indicates amino acid position in the designated protein; 
 c)  Loci identified by reverse genetics as being major determinants of the att phenotype of master donor virus; 
 d)  ca phenotypes have been assigned to the PA segment, but the amino acid responsible for this phenotype  
                     has not been identified. 
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Vaccines used today consist of reassortants are prepared from an attenuated donor strain 
(usually an antigenically distinct H2N2 strain) and a recent epidemic strain.  Reassortants are 
selected for influenza A and B vaccines that contain the internal genes from donor strain and the 
surface Ag genes of the epidemic strain.  Several strategies have been used to prepare attenuated 
donor strains.  These include the use of: (1) ca mutants, (2) mutants containing a deletion in the 
NS1gene, and (3) replication-defective particles (Watanabe et al 2002; Müllbacher et al 2006; 
Wang et al 2008).   
 
Reassortants prepared from attenuated ca donor strains are the only LAIVs licensed for human 
use in the US and Russia.  The US vaccine (FluMist®) was first licensed in 2003 by the Food 
and Drug Administration (FDA) for use in humans aged 5-49 years.  Licensure has since been 
expanded to 2-49 years (CDC 2008; Luce et al 2008; Table 1.9).  In addition, ca LAIVs for use 
as vaccines against equine and avian influenza viruses are currently under development (Song et 
al 2007).  
 
1.3.2.1  Development and characteristics of ca donor strains 
Although ca LAIVs were only recently licensed for use in US, the isolation of ca attenuated 
influenza A and B donor strains (used to prepare reassortant vaccine strains that comprise the 
FluMist® vaccine) was described more than 40 years ago (Maassab et al 1967 & 1968).  Wild-
type A/Ann Arbor/6/60 (A/AA/6/60) H2N2 virus is a naturally ca virus, capable of growing at 
both 25°C and 39°C and was found to be attenuated in ferrets (Herlocher et al 1993).  However, 
further cold adaptation was required before it was considered for use as a donor strain.  This was 
achieved by a stepwise lowering of the growth temperature, which allowed the selection of 
multiple lesions in the internal genes (Maassab and DeBorde 1985).   
 
Under laboratory conditions, A/AA/6/60 wt virus was adapted to grow at 25°C by a step-wise 
reduction from 33°C (the permissive temperature) in chicken kidney (CK) cultures.  Further 
   66 
 
serial passage at 25°C was then undertaken until optimum yields of the donor strain (A/AA/6/60 
ca) were obtained.   Similar approach was also used to produce the cold-adapted donor strains, 
A/Leningrad/134/17/57 and A/Leningrad/134/47/57 (H2N2), in the former Soviet Union.  Two 
donor strains were developed by passaging A/Leningrad/134/57 21 times at 33°C followed by 
17 or 47 times in embryonated eggs at 25°C (Kendal et al 1982; Alexandrova et al 1984).  These 
donor strains are referred to as Len/17 and Len/47.   
 
Similar approaches have been used to prepare ca influenza B donor strains using the wt B/Ann 
Arbor/1/66 and B/USSR/60/69 for the preparation of reassortants for inclusion in trivalent 
LAIVs (Wareing and Tannock 2001).  Recently, there have been attempts to develop ca donor 
strains other than A/AA ca.  Human influenza A virus X-31, a high-yielding reassortant with 
genes derived from A/PR8 (H1N1) and A/Aichi/2/68 (H3N2), was successfully cold-adapted in 
both embryonated eggs and MDCK cells (Lee et al 2006; Liu et al 2008). 
 
In general, ca viruses are accompanied by a reduction in virulence, attenuation (att), and 
reduced plaquing efficiency at body core temperatures (37°C in humans) and are referred to as 
temperature sensitive (ts) mutants.  Previous studies have indicated that genetic lesions 
responsible for ca/ts/att phenotypes are all derived from the six internal genes (Cox et al 1988; 
Herlocher et al 1996).  Importantly, the ts phenotype is responsible for the restricted replication 
of viruses in the URT and is associated with attenuation and vaccine safety.  Recent site-directed 
mutagenesis analysis using reverse genetics has shown that the ts phenotype of A/AA/6/60 ca is 
associated with five major loci: PB11195, PB11766, PB12005, PB2821, and NP146 (Table1.8; Jin et al 
2003).  These results indicate that the ts phenotype is a stable trait that requires mutations from 
three different gene segments (PB1, PB2 and NP) to act synergistically.  The ts loci of 
A/AA/6/60 ca were found to be unusually stable during passage in CK cultures (Herlocher et al 
1993).  One possible explanation is that the lower temperature of 25°C slows down viral 
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replication and makes the viral polymerase less error-prone.  These multiple genetic loci are the 
molecular markers for vaccine stability (Jin et al 2003; Chan et al 2008).   
 
Similar findings were also observed with Russian ca donors Len/17 and Len/47, where a total of 
ten genetic lesions and eight amino acid substitutions from all six internal genes were shown to 
contribute to their ca/ts/att phenotypes (Kilmov et al 1992).  Genetic stability studies found no 
aa changes occurred in these lesions after passage through ferrets (Marsh et al 2003).   
 
1.3.2.2  Preparation of ca LAIVs 
It has been was known for many years that certain characteristics of influenza A viruses can be 
transferred between different strains by genetic reassortment (Kilbourne 1975).  Such an 
approach has been used for over 20 years for the generation of high-yielding influenza A viruses 
for use in inactivated vaccines that contain the internal genes of A/PR8 and the surface Ag genes 
of epidemic strains.  The same approach is used for the development of attenuated vaccine 
reassortants that possess the 6 internal genes that specify ca/ts/att phenotype (from well-
characterised ca donor strains) and the surface Ag genes of the epidemic strain.  Currently, ca 
LAIV reassortants are prepared by (1) traditional co-infection, or (2) the application of reverse 
genetics (Figure 1.11).  
 
Using classical genetic reassortment, new ca LAIVs are generated by co-infection of eggs or 
cell cultures with a ca donor virus and a contemporary virulent wt virus, followed by selection 
of reassortant progeny at 25°C in the presence of an antiserum to the H2N2 donor strain.  To 
generate ca LAIV by reverse genetics, six plasmids encoding the internal genes of the attenuated 
donor virus are mixed with two plasmids encoding the HA and NA genes of a nominated 
epidemic virus. Accredited cells are transfected with the plasmids and the attenuated reassortant 
virus is isolated.  Recently, the FDA has granted approval for the use of reverse genetics to 
prepare seasonal influenza vaccines, including FluMist® (Marsh and Tannock, 2005). 
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              (1) 
 
                                                 (2) 
 
 
Figure 1.11 Two different systems for the generation of cold-attenuated LAIVs (Luke and Subbarao 2006)               
(1) Generation of live, attenuated pandemic influenza vaccine viruses with the 6 internal genes from the attenuated donor virus 
bearing attenuating mutations (*) and the HA and NA genes from circulating avian virus by classical reassortment.  The 6:2 
reassortants generated by this method are selected in the presence of antiserum specific for HA and NA of the attenuated donor 
virus.  (2) The 8-plasmid reverse genetics system to generate recombinant, live, attenuated pandemic influenza vaccines. 
   69 
 
 
 
Table 1.9  The immunologic differences between US FDA-approved ca LAIV and TIV (CDC 2007) 
Immunology ca LAIV  TIV 
Serum anti-HA Abs  Yes Yes 
CMI (specially T cell) Yes Not detectable 
Mucosal IgA Yes No 
Cross-subtypes Yes No 
Cross-strains (within same subtype) Yes Yes but with less extent 
Vaccine-induced 
immune responses 
Long term specific-T and B memory 
cell  
 
Yes  Yes but with much less 
extent  
Correlate with  Anti-HA Abs, mucosal IgA Anti-HA Abs 
Evaluation Assays Serologic assays, T / B cell 
assays (not available 
clinically yet) 
 
Serologic assays 
Young (15mo - 6yrs seronegative) 89% with one dose; 93% 
with two doses  
 
27% 
Adults (18 - 64 yrs seropositive, 
against drifted strain) 
 
86% 71% Protection rates 
Elderly (≥ 65 yrs) Not available 48% 
 
LAIV  live-attenuated influenza vaccine 
TIV trivalent influenza vaccine 
 
 
Table 1.10 Major differences between US FDA-approved seasonal influenza ca LAIV and TIV vaccines                        
for using in humans (CDC 2008) 
Factor ca LAIV  TIV 
Route of administration Intranasal spray (i.n) Intramuscular injection (i.m) 
Type of vaccine Live virus (106.5-7.5 TCID50 per strain) Killed virus (15µg HA per strain) 
No. of included virus strains 3 (2 influenza A, 1 influenza B)  3 (2 influenza A, 1 influenza B) 
Vaccine virus strains updated Annually  Annually 
Frequency of administration Annually  Annually 
Approved age and risk groups Healthy persons aged 2 – 49 yrs  Persons aged 6 months and older 
Interval between 2 doses 
recommended for children aged < 9 
years who are receiving influenza 
vaccine for the first time 
6 –10 weeks  4 weeks 
   
TCID50  median tissue culture infectious dose 
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Reverse genetics involves the creation of infectious copy of the genome of negative-stranded 
RNA viruses from a full-length viral cDNA of their genome (so-called infectious cloning; Lee 
and Suarez 2008).  Therefore, ca LAIVs could also be generated by direct attenuation through 
reverse genetics without the need to prepare reassortants.  The introduction of five ts loci was 
found to be sufficient to confer the ts phenotype in vitro and the att phenotype in ferrets on 
A/PR8 wt and A/Guinea Fowl/HK/WF10/99 (H9N2) viruses (Jin et al 2004; Song et al 2007).  
Reverse genetics has also been used to allow the direct modification of influenza genome in 
order to remove the virulent motif from HA gene of the highly pathogenic avian influenza virus 
(Marsh and Tannock, 2005).  It has also been used to generate recombinant LAIVs that carry 
foreign target genes.  Such recombinant LAIVs can be used as gene delivery vectors for 
promoting specific mucosal and CMI responses.  Currently, some recombinant LAIVs are under 
development as vectors for vaccines against pathogens such as malaria and Chlamydia 
trachomatis and range of cancers (Efferson et al 2003; González-Aseguionolaza et al 2003; 
Nimmerjahn et al 2003; He et al 2007). 
 
1.3.2.3  The immunology of ca LAIVs 
Restricted viral replication of ca LAIVs in the respiratory tract can induce both specific humoral 
and CMI, and local and systemic and memory cross-immune responses which are a feature of 
natural infections (Section1.2.2; Wareing and Tannock 2001).  Consequently, ca LAIVs have 
several advantages over inactivated vaccines (Table 1.9).  Of these, high vaccine efficacy in 
children is significant (Belshe et al 1998 & 2000; Jefferson et al 2008).  Non-immune children 
play a central role in the transmission of influenza viruses (Bradshaw and Wright 2002) and here 
ca LAIVs could have a role in limiting the speed of transmission or even preventing an 
epidemic.  However, in adults lower levels Ab responses are induced by i.n administered LAIVs 
compared with parenterally administered inactivated vaccines, possibly due to the presence of 
pre-existing neutralizing Abs (Edwards et al 1994).  Despite this, ca LAIVs potentially provide 
better protection because they induce a broader range of immune responses (Belshe 2002).  
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These include vaccine-induced T cell and mucosal immunity but the role of other factors, such 
as the presence of particular vaccine genes and the age of vaccinees, on these responses is 
largely unknown (Greenberg 2006).  
 
 
1.4 CONCLUSIONS AND RESEARCH AIMS 
 
Vaccination remains the most cost-effective means for the control of influenza.  However, 
vaccine efficacy is constrained by the capacity of influenza viruses to undergo antigenic 
variation.  To increase protection rates ca LAIVs (FluMist®) are now used in the US in addition 
to traditional inactivated TIVs (Table 1.10).  Ca LAIVs, unlike inactivated vaccines, are able to 
induce responses in all arms of the host adaptive immune response.  These include humoral and 
cellular, local and systemic responses; which are required for optimal protection against 
influenza.   
 
The immunogenicity of ca LAIVs depends on viral infectivity for the host, which determines the 
extent of immune stimulation.  The immunogenicity of live vaccines is influenced by several 
viral and host factors.  Viral factors include the nature of both internal and surface Ags.  The six 
internal genes derived from ca donor strains are responsible for the attenuation phenotype of 
vaccine reassortants.  Consequently, 6:2 ca reassortants are less immunogenic than their wt 
parental viruses.  Earlier protection studies have shown that the surface HA glycoprotein is the 
major protective immunogen (Tannock et al 1984 & 1991; Marsh et al 2003; Wareing et al 
2005).   
 
However, CMI responses induced by internal Ags and their impact on the overall vaccine 
immunogenicity have not been examined in detail.  With recent technological advances, such as 
the use of MHC tetramer techniques to measure T-cell responses, it is now possible to examine 
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mechanisms of CMI in the respiratory tract of mice and to provide further insights in the 
improvement of vaccine efficacy.  The use of these techniques in examining responses to ca 
LAIVs in mouse models forms the basis of this thesis.   
 
Specific research aims of this study are: 
1) To examine the infectivity and pathogenicity of ca LAIVs;   
2) To evaluate recent developed techniques (e.g. tetramer staining and I-PCR) in the 
measurement of specific T-cell response to ca LAIVs;  
3) To investigate the role of the HA and NA viral surface Ags on CMI responses;  
4) To compare the specific T- and B-cell responses to ca LAIVs in different mouse strains 
possessing different MHCs;  
5) To investigate the B cell-mediated heterosubtypic immunities which induced by ca 
LAIVs.    
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Chapter 2:  Materials and Methods 
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2.1  CHEMICALS 
2.1.1 Inorganic chemicals 
Aluminum potassium sulphate (alum) BDH Chemicals, Poole, UK 
Ammonium chloride (AnalaR)  BDH Chemicals, Poole, UK 
Calcium chloride    BDH Chemicals, Poole, UK 
Hydrochloric acid (Univar)   Ajax Chemicals, Auburn, NSW 
Magnesium chloride (AnalaR)  BDH Chemicals, Poole, UK 
Magnesium sulphate, heptahydrate   BDH Chemicals, Poole, UK 
(AnalaR)  
Potassium chloride    Ajax Chemicals, Sydney, NSW 
Potassium dihydrogen orthophosphate BDH Chemicals, Poole, UK 
Sodium azide     ICN Biomedicals Australia Pty Ltd,  
Seven Hills, NSW 
Sodium bicarbonate    BDH Chemicals, Poole, UK 
Sodium borate, anhydrous   BDH Chemicals, Poole, UK 
Sodium carbonate    BDH Chemicals, Poole, UK 
Sodium chloride (AnalaR)   Ajax Chemicals, Auburn, NSW 
tri-Sodium citrate (AnalaR)   BDH Chemicals, Poole, UK 
Sodium dihydrogen phosphate (AnalaR) BDH Chemicals, Poole, UK 
Sodium hydrogen carbonate (AnalaR) BDH Chemicals, Poole, UK 
di-Sodium hydrogen orthophosphate   BDH Chemicals, Poole, UK 
(AnalaR) 
Sodium hydroxide (AnalaR)   BDH Chemicals, Poole, UK 
Sodium iodide     BDH Chemicals, Poole, UK 
 
2.1.2 Organic chemicals 
Acetic acid, glacial (AnalaR)   BDH Chemicals, Poole, UK 
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Acrylamide (N,N’–methylenbisacrylamide) Bio-Rad Laboratories, Hercules, CA, USA 
Agarose (molecular biology grade)   Promega Corporation, Annandale, NSW 
Ammonium persulphate (APS)  Sigma-Aldrich Inc., St. Louis, MO, USA 
2-Amino-2-methyl-1-propanol (AMP) Sigma-Aldrich Inc., St. Louis, MO, USA 
L-Arginine hydrochloride   Sigma-Aldrich Inc., St. Louis, MO, USA 
Brefeldin A (BFA)    Sigma-Aldrich Inc., St. Louis, MO, USA 
5-Bromo-4-chloro-3-indolyl phosphate  Sigma-Aldrich Inc., St. Louis, MO, USA 
(BCIP)    
Bromophenol Blue    Sigma-Aldrich Inc., St. Louis, MO, USA  
Coomassie Brilliant Blue R250®   Sigma-Aldrich, Inc., St. Louis, MO, USA  
Choral hydrate    BDH Chemicals, Poole, UK 
Citric acid     BDH Chemicals, Poole, UK 
D-glucose (AnalaR)    BDH Chemicals, Poole, UK 
DE52 DEAE cellulose   Whatman Inc., Florham Park, NJ, USA 
Diethylaminoethyl (DEAE) -Sepharose®  Sigma-Aldrich Inc., St. Louis, MO, USA 
Diethyl polycarbonate (DEPC)  Sigma-Aldrich Inc., St. Louis, MO, USA 
Dimethyl sulphoxide (DMSO) (AnalaR) BDH Chemicals, Poole, UK 
Dithiothreitol (DTT)    Progen Industries Ltd., QLD 
DPX mountant     Sigma-Aldrich Inc. St. Louis, MO, USA 
Ethanol (ethyl alcohol)   BDH Chemicals, Poole, UK 
Ethidium bromide (EB)   Sigma-Aldrich Inc., St. Louis, MO, USA 
Ethylenediamine tetra-acetic acid   BDH Chemicals, Poole, UK 
(EDTA), disodium salt (AnalaR) 
Formalin (40% formaldehyde)  Sigma-Aldrich Inc., St. Louis, MO, USA 
L-Glutathione oxidized   Sigma-Aldrich Inc., St. Louis, MO, USA 
L-Glutathione reduced   Sigma-Aldrich Inc., St. Louis, MO, USA 
Glycerol (AnalaR grade)   BDH Chemicals, Poole, UK 
Glycine (AnalaR grade)   BDH Chemicals, Poole, UK 
Guanidine hydrochloride (GuHCl)  Sigma-Aldrich Inc., St. Louis, MO, USA 
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N-(2-Hydroxyethyl) piperazine-N’-   Research Organics Inc., Cleveland, OH, USA 
(2-ethanesulphonic acid) (HEPES) 
Isopropyl-β -D-thiogalactopyranoside  Progen Industries Ltd, QLD 
(IPTG) 
Magnesium acetate    Sigma-Aldrich Inc., St. Louis, MO, USA 
Methanol (AnalaR)    BDH Chemicals, Poole, UK 
Paraffin     Sigma-Aldrich Inc., St. Louis, MO, USA 
Pepstatin A     Sigma-Aldrich Inc., St. Louis, MO, USA 
Phenol Red     Sigma-Aldrich Inc., St. Louis, MO, USA 
Polyethylene-sorbitan monolaurate   Sigma-Aldrich Inc., St. Louis, MO, USA 
(Tween-20) 
Phenylmethylsulphonylfluoride (PMSF) Sigma-Aldrich Inc., St. Louis, MO, USA 
Pyruvic acid     Sigma-Aldrich Inc., St. Louis, MO, USA 
PVA glue     UHU Australia Pty Ltd, Smithfield, NSW 
Saponin     Calbiochem Corporation, La Jolla, CA, USA 
Sodium azide     Sigma-Aldrich Inc., St. Louis, MO, USA 
Sodium deoxycholate (DOC)   Sigma-Aldrich Inc., St. Louis, MO, USA  
Sodium dodecyl sulphate (SDS)  BDH Chemicals, Poole, UK 
Sucrose (AnalaR)    BDH Chemicals, Poole, UK 
Tetramethylethylenediamine (TEMED) Sigma-Aldrich Inc., St. Louis, MO, USA 
Tris (hydroxymethyl) aminomethane  Research Organics Inc., Cleveland, OH, USA 
(Tris-HCl) 
Triton X-100     Sigma-Aldrich Inc., St. Louis, MO, USA 
Triton X-405     Sigma-Aldrich Inc., St. Louis, MO, USA 
Xylene      Sigma-Aldrich Inc., St. Louis, MO, USA 
Xylene cyanol FF    Bio-Rad Laboratories Pty Ltd, Regents Park, NSW 
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2.1.3 Antibiotics and anaesthetics 
Amphotericin B (fungizone)   Sigma-Aldrich Inc., St. Louis, MO, USA 
Chloramphenicol    Sigma-Aldrich Inc., St. Louis, MO, USA  
Ketamine (hydrochloride)   Troy Laboratries (Australia) Pty Ltd, Smithfield, 
NSW 
Kanamycin sulphate    Roche Diagnostics GmbH, Mannheim, Germany 
Penicillin G     CSL Ltd, Parkville, VIC 
Ilium Xyalzine-20 (hydrochloride) Troy Laboratories (Australia) Pty Ltd, Smithfield, 
NSW 
Streptomycin sulphate   CSL Ltd, Parkville, VIC 
 
2.1.4 Cell culture media 
Eagle’s Minimal Essential Medium   ICN Biomedicals (Austtalia) Pty Ltd,  
Seven Hills, NSW 
(MEM) (modified)   
Leibovitz (L15) medium   Trace Biosciences, Sydney, NSW 
RPMI-1640 medium    Trace Biosciences, Castle Hill, NSW 
 
2.1.5 Dyes 
Neutral Red (cell culture tested)  Sigma-Aldrich Inc., St. Louis, MO, USA 
Trypan Blue ICN Biomedical (Australia) Pty Ltd, Seven Hills, 
NSW 
Haematoxylin     Sigma-Aldrich Inc., St. Louis, MO, USA 
Eosin Y     Sigma-Aldrich Inc., St. Louis, MO, USA 
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2.2  BIOLOGICAL REAGENTS 
2.2.1 Virus stocks 
The ca donor strain (A/AA/6/60 ca) and six ca reassortants, derived from A/AA/6/60 ca, were 
used in the present study.  Table 2.1 summarises the origin and gene composition of these 
reassortants and the wt parental viruses that were used to prepare each reassortant (Tannock et al 
1984 & 1995).  CR6, CR18, CR29 and CR35 were obtained by co-infection of primary chicken 
embryo kidney (CEK) cultures with a wt virus; A/AA/6/60-ca was derived from the wt 
A/AA/6/60 (Maassab 1969) by adaptation to growth at 25ºC.  A/AA/6/60 ca, CR6, CR18, CR29 
and CR35 and the wt parental viruses A/AA/6/60 (H2N2), A/Qld/6/72 (H3N2), A/HK/123/77 
(H1N1) were generously provided by Prof. H. F. Maassab, Department of Epidemiology, School 
of Public Health, University of Michigan, Ann Arbor, USA.  CR6/35/1/19 and CR6/35/2/9 were 
prepared by co-infection of CEK cells with CR6 and CR35 (Tannock et al 1995). 
 
The influenza viruses A/PR/8/34 (H1N1) and A/HK×31 (H3N2) were used as reagent controls 
for the tetramer staining technique.  A/HK×31 was obtained from Dr. S. J. Turner, Dept. 
Microbiology and Immunology, University of Melbourne.  The A/HK×31 and A/PR/8/34 
viruses differed in their surface HAs and NAs, but shared the internal genes of A/PR/8/34 
(Turner et al 2006).  All viruses were passaged 1-2 times in 10 - or 11-day-old non-specific-
pathogen-free (non-SPF) fertile chicken eggs for 2 or 3 days at 33-34°C.  The allantoic virus 
was harvested and stored in 2mL aliquots at - 80°C.  
 
2.2.2 Primary and continuous cell cultures 
Primary CEK cells were prepared from 18-day-old chicken embryo kidneys using the method of 
Tannock et al (1985).  The MDCK line was obtained from CSL Ltd, Parkville, VIC and stored 
in liquid nitrogen and was shown to be free of Mycoplasma.  MDCK cultures prepared from 
resuscitated cells were passaged 25 times and then discarded in order to minimise the chances of 
further contamination.   
   79 
 
 
 
 
Table 2.1  Gene composition of A/AA/6/60-ca and ca reassortants (CR) used in this study (Tannock et al 1984 & 1995). 
 
Derivation of genes
a 
 
 
ca Virus 
 
Surface 
antigen 
 
 
Parent viruses 
 HA NA PA PB1 PB2 NP M NS 
A/Ann Arbor (AA)/6/60 ca H2N2 A/AA/6/60 wt 
 
 
Ab A A A A A A A 
AA-CR6 H3N2 A/Queensland (Qld)/6/72 wt 
and A/AA/6/60 ca 
 
Wc W A A A A A A 
AA-CR18 H3N2 A/Scotland (Scot)/840/74 wt 
and A/AA/6/60 ca 
 
W W A A A A A W 
AA-CR29 H3N2 A/Alaska/6/77 wt 
and A/AA/6/60 ca 
 
W W A A A A A A 
AA-CR35 H1N1 A/HongKong (HK)/123/77 wt 
and A/AA/6/60 ca 
 
W W A A A A A A 
AA-CR6/35/1/19 
 
H1N2 CR6 and CR35 W W A A A A A A 
 
AA-CR6/35/2/9 
 
H3N1 CR6 and CR35 W W A A A A A A 
 
 
a HA, haemagglutinin; M, matrix protein; NA, neuraminidase; NS, nonstructural protein; PA, PB1 and PB2 polymerase; NP, nucleoprotein. 
b A indicates gene derived from A/AA/6/60-ca. 
c 
W indicates gene derived from the wild-type parent. 
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2.2.3 Enzymes 
BirA biotinlyation enzyme (recombinant) Prepared and supplied by Dr. A. G. Brook, 
Department of Microbiology & Immunology, 
University of Melbourne, Parkville, VIC 
Collagenase A, 0.18 U mg-1   Roche Diagnostics GmbH, Mannheim, Germany 
DNase I, 2000 U mg-1    Roche Diagnostics GmbH, Mannheim, Germany 
Lysozyme     Sigma-Aldrich Inc., St. Louis, MO, USA 
Receptor destroying enzyme (RDE) - Denka Seiken Co., Ltd., Tokyo, Japan 
crude V. Cholerae filtrate, lyophilised  
Trypsin (crystalline)    Difco Laboratories, Detroit, MI, USA 
Taq DNA Polymerase    Invitrogen Corp., Carlsbad, CA, USA 
 
2.2.4 Antibodies 
2.2.4.1  Primary antibodies 
Monoclonal rat anti-mouse IFN-γ   Sigma-Aldrich Inc., St. Louis, MO, USA 
(IgG2a isotype) 
Polyclonal goat anti-mouse IgA   Sigma-Aldrich Inc., St. Louis, MO, USA 
(α-chain specific)  
Polyclonal goat anti-mouse IgG2a   Sigma-Aldrich Inc., St. Louis, MO, USA 
(heavy chain-specific) 
 
2.2.4.2  Conjugated antibodies 
Alkaline phosphatase (AP) conjugated: 
Rabbit anti-goat IgG    Sigma-Aldrich Inc., St. Louis, MO, USA 
Biotin conjugated: 
Polyclonal rabbit anti-mouse   PeproTech Inc., Rocky Hill, NJ, USA 
interferon-gamma (IFN-γ)  
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Fluorescein isothiocyanate (FITC) conjugated: 
Monoclonal mouse anti-mouse CD44  Beckman Coulter Australia Pty Ltd, Gladesville,  
(IgG1 isotype)     NSW 
Monoclonal rat anti-mouse CD4 (Ig   Beckman Coulter Australia Pty Ltd, Gladesville,  
G2b), CD8 (IgG2a) and INF-γ (IgG1)  NSW  
 
R-phycoerythrin (PE) conjugated:  
Monoclonal rat anti-mouse CD4   Beckman Coulter Australia Pty Ltd, Gladesville,  
(IgG2b) and CD8 (IgG2a)   NSW 
 
2.2.4.3  Isotype controls 
Rat IgG1, IgG2a FITC conjugated Beckman Coulter Australia Pty Ltd, Gladesville, 
NSW 
Rat IgG2a, IgG2b PE conjugated Beckman Coulter Australia Pty Ltd, Gladesville, 
NSW 
 
2.2.5 Recombinant cytokine  
Recombinant mouse IFN-γ   PeproTech Inc., Rocky Hill, NJ, USA   
 
2.2.6 Bovine products 
Bovine serum albumin, Fraction V (BSA) Trace Biosciences, Castle Hill, NSW 
Gelatin, type B (cell culture tested)  Sigma-Aldrich Inc., St. Louis, MO, USA 
Foetal bovine serum (FCS)    Thermo Trace Ltd, Melbourne, VIC   
 
2.2.7 Products for biotinylation  
Protein assay kit    Bio-Rad Laboratories Pty Ltd, Regents Park, NSW 
Streptavidin beads    Sigma-Aldrich Inc., St. Louis, MO, USA 
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Extravidin® -R - phycoerythrin (PE)  Sigma-Aldrich Inc., St. Louis, MO, USA 
 
2.2.8 Products for Immuno-PCR 
QIAGEN Multiplex PCR Kit   QIAGEN Pty Ltd, Clifton Hill, VIC 
QIAfilterTM Plasmid Midi Kit   QIAGEN Pty Ltd, Clifton Hill, VIC 
QIAquick® PCR purification kit  QIAGEN Pty Ltd, Clifton Hill, VIC 
Salmon testis DNA (for hybridization); Sigma-Aldrich Inc., St. Louis, MO, USA 
9.0 mg mL-1  
Streptavidin (1mg mL-1)   Amersham International Plc, Buckinghamshire, UK 
Streptavidin-horseradish peroxidzae  Amersham International Plc, Buckinghamshire, UK 
conjugated  
 
2.2.9 Oligonucleotides       
Oligonucleotides were purchased as desalted preparations of approximately 30 nmol from 
GeneWorks Pty Ltd, Thebarton, SA.  A summary of all oligonucleotides used in Immuno-PCR 
assays is presented in Table 2.2.  
 
2.2.10 Viral peptide 
 A/A A/6/60 NP366-374    Synthesised by Auspep Pty. Ltd., Parkville, VIC 
 
2.2.11 Plasmids 
Db – KanR (used for the expression of supplied by Dr. S. J. Turner, Department of 
MHC heavy chain of C57BL/6 mouse Microbiology & Immunology, University of 
and bearing the kanamycin-resistance gene Melbourne, Parkville, VIC 
as a selectable marker) 
pBluescript® KS (used for the preparation Novagen, Merck Pty. Limited, Kilsyth, VIC 
of reporter DNA in Immuno-PCR assays) 
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2.2.12 Bacterial strain  
BL21 (DE3) pLysS (competent E. coli, Novagen, Merck Pty. Limited, Kilsyth, VIC 
used for the expression of MHC) 
 
2.2.13 MHC light chain  
Human MHC β2m  Department of Microbiology and Immunology, 
University of Melbourne, Parkville, VIC  
 
2.2.14 Tetramers 
Db/hβ2m/NP366-374 and    Department of Microbiology and Immunology, 
Db/hβ2m/PA224-236      University of Melbourne, Parkville, VIC    
 
The sequences of all the peptides used in the tetramers are listed in the Table 2.3. 
 
2.2.15 Molecular weight markers 
DNA marker, 1 kb Plus (100 bp – 10 kb) Invitrogen Corp., Carlsbad, CA, USA 
Protein marker, Kaleidoscope (prestained;  Bio-rad Laboratories, Hercules, CA, USA 
210 – 7.0 kDa) 
 
 
2.3  MICE AND EMBRYONATED EGGS 
Non-SPF embryonated eggs   Research Poultry Farm, Research, VIC 
SPF female C57BL/6 mice   Monash Animal Services, Clayton, VIC 
SPF female BALB/c mice    Monash Animal Services, Clayton, VIC 
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Table 2.2  Oligonucleotides used in immuno-PCR assays 
 
Oligo Name DNA Sequence (5’ → 3’) 
M13-20 Biotin-GT AAA ACG ACG GCC AGT 
M13 GGA AAC AGC TAT GAC CAT G 
IF AGC GCG CGT AAT ACG ACT C 
IR ACC ATG ATT ACG CCA AGC G 
 
 
 
 
 
 
 
 
Table 2.3  Peptides used in tetramer staining assays 
 
Peptide  Virus Origin Amino Acid Sequence (H → OH) 
NP366-374 A/AA/6/60 ca Ala-Ser-Asn-Glu-Asn-Met-Asp-Thr-Met 
NP366-374    A/PR/8/34 Ala-Ser-Asn-Glu-Asn-Met-Glu-Thr-Met 
PA224-236   A/PR/8/34 Ser-Ser-Leu-Glu-Asn-Phe-Arg-Ala-Tyr-Val 
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Previous studies indicated that male mice allow more rapid rates of multiplication of influenza A 
than female mice and were used in immunologic study for ca reassortants (Tannock et 
al1984&1987; Wareing 2001&2005).  However, female inbred mice have been used intensively in 
the studies of specific-CTL responses to influenza virus (Altman et al 1996; Doherty et al 1997; 
Belz et al 2000&2001).  In a previous study (L. Xue, M. App. Sc. Thesis, RMIT University, 2003) 
no differences were found between serum Ab and lung B cell responses to ca viruses in male and 
female BALB/c mice.     
 
2.4  BUFFERS AND SOLUTIONS 
All buffers and solutions were prepared using Milli-Q water, unless otherwise specified. 
2.4.1 Egg inoculation reagents 
Dulbecco’s Phosphate Buffered Saline  0.14 M NaCl, 30 mM KCl, 82.1 mM  
(PBS; pH 7.2)     Na2HPO4.12H2O, 14.7 mM KH2PO4  
Virus diluent Chilled sterile PBS with 0.1% (v/v) penicillin (60 µg 
mL-1) and 0.1% (v/v) streptomycin (100 µg mL-1) 
2.4.2 HA and HAI reagents 
Calcium saline (pH 5.6)   68.01 mM CaCl2.H2O, 1.54 M NaCl, 0.19 M H3BO3,  
2.60 mM Na2B4O7.10H2O 
1.5% (w/v) sodium citrate   5.44 mM Na3C6H5O7.2H2O in PBS 
Receptor destroying enzyme    One part RDE and one part calcium saline solution 
(RDE) solution  
Chicken red blood cells (RBC)   0.5% (v/v) chicken RBC suspended in PBS 
 
2.4.3 CEK and MDCK plaque assay reagents 
Citrate Saline     1.07 M NaCl, 27.8 mM KCl, 14.7 mM KH2PO4, 
      0.1 M D-glucose, 0.27 M Na3C6H5O7.2H2O, 
      82.1 mM Na2HPO4.12H2O 
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0.1% (w/v) Neutral Red   0.1 g Neutral Red in 100 mL H2O 
0.1% (w/v) crystalline trypsin  0.1 g crystalline trypsin in 100 mL H2O 
Trypsin/Versene (T/V)   0.5 mM EDTA, 0.1% (w/v) trypsin in PBS 
Trypsinising Solution 1.25% (w/v) trypsin in citrate saline solution 
containing 60 µg mL-1 penicillin, 100 µg mL-1 
streptomycin, and 1 µg mL-1 amphotericin B 
2.4.4 Virus purification reagents 
TNE Buffer (pH 7.4)    0.05 M Tris-HCl, 0.15 M NaCl, 1 mM EDTA 
60% (w/v) sucrose in TNE Buffer  Autoclaved at 108°C for 30min 
30% (w/v) sucrose in TNE Buffer  Autoclaved at 108°C for 30min 
 
2.4.5 Reagents for lung cell suspensions 
ATC Buffer (pH 7.2)    0.15 M NH4Cl, 17 mM Tris-HCl 
Hank’s Balanced Salt Solution (HBSS) 0.137 M NaCl, 5.4 mM KCl, 0.25 mM Na2HPO4, 0.44 
mM KH2PO4, 1.3 mM CaCl2, 1.0 mM MgSO4, 1.0 
mM MgCl2, 4.2 mM NaHCO3, 0.1 M D-glucose and 
0.01‰ (w/v) Phenol Red, pH 7.2 
Lung Digestion Solution 100 mg collagenase A, and 5 mg DNase I in 50 mL 
HBSS with 60 µg mL-1 penicillin, 100 µg mL-1 
streptomycin, and 1 µg mL-1 amphotericin B 
0.4% (w/v) Trypan Blue   0.4 g Trypan Blue in 100 mL PBS 
 
2.4.6 ELISPOT reagents 
PBS-T      0.05% Tween-20 in PBS 
BSA5PBST     0.5% (w/v) BSA in PBS-T 
BSA10PBS     1.0% (w/v) BSA in PBS-T 
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PBSN3      0.02% (w/v) NaN3 in PBS 
AMP Buffer (pH 10.25)   2.69 M AMP, 1.84 mM MgCl2.6H2O, 0.04 M NaN3,  
0.01% TritonX-405 
Substrate Solution (BCIP) 1 mg mL-1 5-bromo-4-chloro-3-indolyl phosphate in 
AMP buffer 
 
2.4.7 Flow cytometry reagents 
2.4.7.1  T lymphocyte phenotype reagents 
Cell Wash and Staining Buffer  2% (v/v) FCS, 0.1% (w/v) NaN3 in PBS 
Cell Fixation Wash Buffer   0.02% (w/v) gelatine, 0.1% (w/v) NaN3 in PBS 
Cell Fixation Buffer    2% paraformaldehyde (w/v) in PBS 
 
2.4.7.2  Intracellular cytokine cytometry (ICC) reagents 
ICC Cell Wash Buffer    2% (v/v) FCS in PBS 
ICC Cell Fixation Wash Buffer  0.02% (w/v) gelatine, 0.1% (w/v) NaN3, 2.5 µg/mL 
BFA in PBS 
ICC Cell Staining Buffer  2% (v/v) FCS, 0.1% (w/v) NaN3, 5 µg/mL BFA in 
PBS  
ICC Cell Permeablisation Buffer 2% (v/v) FCS, 0.1% (w/v) NaN3, 0.5% (w/v) saponin 
in PBS 
ICC Fixation Buffer 2% paraformaldehyde (w/v), 5 µg/mL BFA in PBS 
 
 
2.4.8 Reagents for mouse MHC class I expression, refolding and tetramer formation 
2.4.8.1  Inclusion body reagents 
 
Resuspension Buffer (pH8.0) 50 mM Tris-HCl (pH8.0), 25% (w/v) sucrose, 1mM 
EDTA and 0.1% (w/v) NaN3  
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Resuspension Solution I 0.2 mM PMSF, 0.001‰ (w/v) pepstatin A and 10 
mM DTT in resuspension buffer 
Resuspension Solution II 0.2 mM PMSF, 0.001‰ (w/v) pepstatin A and 10 
mM DTT in H2O 
Lysis Buffer (pH8.0) 50 mM Tris-HCl (pH8.0), 1% (w/v) Triton-X 100, 
1% (w/v) NaDOC, 100 mM NaCl and 0.1% (w/v) 
NaN3  
Lysis Solution 0.1% (w/v) lysozyme, 0.02% (w/v) DNase I, 5 mM 
MgCl2 and 10 mM DTT in lysis buffer 
Wash Buffer I (pH 8.0) 50 mM Tris-HCl (pH8.0), 0.5% (v/v) Triton-X 100, 
100 mM NaCl, 1 mM NaEDTA, 1 mM DTT and 
0.1% (w/v) NaN3  
Wash Buffer II (pH 8.0) 50 mM Tris-HCl (pH8.0), 1 mM NaEDTA, 1 mM 
DTT and 0.1% (w/v) NaN3  
 
2.4.8.2  SDS-PAGE reagents  
Lower (separation)  Gel Buffers (pH 8.8) 18% (v/v) acrylamide, 1.5 M Tris-HCl, 0.4% SDS, 
0.05% APS and 0.1% (v/v) TEMED 
Upper (stacking) Gel Buffers (pH 6.8)  1.25% (v/v) acrylamide, 0.5 M Tris-HCl, 0.4% SDS, 
0.05% APS and 0.1% (v/v) TEMED 
2 × Loading Buffer 100 mM Tris-HCl (pH 6.8), 4% SDS, 0.2% 
Bromophenol Blue, 20% glycerol with 200mM DTT 
added before use 
5 × Electrophoresis Buffer (pH 8.3)  25 mM Tris, 250 mM glycine and 0.1% SDS 
Coomassie Blue Gel Stain Buffer 0.1% R250 Coomassie Blue, 40% methanol and 10% 
acetic acid 
Gel Destaining Buffer    40% methanol and 10% acetic acid 
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2.4.8.3  Monomeric MHC class I complex refolding reagents  
Guanidine Buffer 6 M GuHCl in resuspending solution II, with 0.2 mM 
PMSF, 0.001‰ (w/v) pepstatin A with 10 mM DTT 
added immediately prior to use 
Refolding Buffer (prepared fresh in an ice bath) 
 100 mM Tris, 2 mM EDTA (pH8.0), 400 mM L-
arginine-HCl, 0.5 mM oxidised glutathione, 5mM 
reduced glutathione, with 0.2 mM PMSF, 0.001‰ 
(w/v) pepstatin A added immediately prior to use 
2.4.8.4  Dialysis reagent 
Dialysis Buffer 1 mM Tris-HCl (pH 8.0) in cold H2O and stirred at 
4°C for 12-24 hr before use  
2.4.8.5  Biotinylation reagents 
10 × BioMix Buffer A   5 M Tris-HCl in H2O 
10 × BioMix Buffer B 100 mM ATP and 100 mM magnesium acetate in 
H2O 
2.4.8.6  Tetramer forming reagent 
Wash Buffer for streptavidin beads 10 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1% Triton 
X-100 and 0.5 mM EDTA  
 
2.4.9 Immuno-PCR reagents 
Carbonate Coating Buffer (pH 9.6) 0.15 M Na2CO3, 0.35 M NaHCO3 and 0.03 M NaN3 
in PBS 
Blocking Buffer  0.1 mg mL-1 salmon sperm DNA, 1% (w/v) BSA and 
0.02% (w/v) NaN3 in PBS 
Washing Buffer    0.05% Tween-20 (v/v) and 0.02% (w/v) NaN3
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Antibody and antigen diluent 1% BSA (w/v), 5% FCS (v/v) and 0.02% (w/v) NaN3 
in PBS 
Free Streptavidin Solution 1 mg mL-1 streptavidin and 1% (w/v) BSA in PBS 
Reporter DNA Solution 1 ng L-1 DNA and 0.1% (w/v) BSA in PBS 
DEPC H2O     1% (v/v) diethyl pyrocarbonate (DEPC) in H2O 
Ethidium Bromide Solution   0.5 µg mL-1 ethidium bromide in H2O 
DNA Loading Buffer (6 ×)   0.25% (w/v) Bromophenol Blue, 0.25% (w/v) xylene  
cyanol FF and 30% (v/v) glycerol 
TAE Buffer (1 ×)    40 mM Tris acetate and 10mM EDTA (pH 7.6) 
 
2.4.10 Reagents for mouse lung histopathology  
10% neutral buffered formalin (NBF) 10% (v/v) formalin in PBS 
Mayer’s Haematoxylin Solution  5% (w/v) alum, 5% (w/v) choral hydrate and 0.1% 
(w/v) haematoxylin in distilled water 
Eosin Y Solution  1% (w/v) Eosin Y in distilled water 
 
 
2.5  MEDIA 
All media were prepared using Milli-Q water, unless otherwise specified. 
 
2.5.1 Cell culture media 
2× L15 maintenance medium     2× L15 (with L-glutamine), 40 mM HEPES (pH 6.8),  
0.056% (w/v) sodium bicarbonate, 60 µg mL-1 
penicillin, 200 µg mL-1 streptomycin, 2 µg mL-1 
amphotericin B 
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MEM maintenance medium MEM (pH 7.2) with 20 mM Hepes, 0.14% (w/v) 
sodium bicarbonate, 60 µg mL-1 penicillin, 100 µg 
mL-1 streptomycin, and 1 µg mL-1 amphotericin B 
MEM growth medium   MEM maintenance medium with 5% (v/v) heat- 
inactivated (56°C for 30 min) FCS for MDCK 
cultures; 10% for primary CEK cell cultures 
T-cell medium (TCM)   RPMI medium (pH 7.2, with L-glutamine), 10% FCS,  
2 mM sodium pyruvate, 6 mM HEPES (pH 6.8), 
0.056% (w/v) sodium bicarbonate, 60 µg mL-1 
penicillin, 100 µg mL-1 streptomycin and 1 µg mL-1 
amphotericin B 
CEK plaque assay overlay   Equal volumes of a 2× concentration of MEM  
 maintenance medium and 1.8% agarose held at 46° C 
and mixed together  
MDCK plaque assay overlay Equal volumes of a 2× concentration of L15 
maintenance Medium containing 100 µL 100 mL-1 of 
0.1% crystalline trypsin and 1.8% agarose were 
mixed together at 46° C. 
Neutral Red staining overlay    Agarose overlay for CEK or MDCK containing 1:  
 12,500 (w/v) final concentration of Neutral Red; held 
at 46° C. 
 
2.5.2  Bacterial culture media 
Luria-Bertani (LB) broth  1% (w/v) Bacto tryptone, 0.5% (w/v) yeast extract, 
1% (w/v) NaCl with 34 µg mL-1 chloramphenicol and 
50 µg mL-1 kanamycin. 
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Luria-Bertani (LB) agar  1% (w/v) Bacto tryptone, 0.5% (w/v) yeast extract, 
1% (w/v) NaCl and 1.5% (w/v) agarose (bacteriology 
grade) with 34 µg mL-1 chloramphenicol and 50 µg 
mL-1 kanamycin. 
 
 
2.6  EQUIPMENT 
 
Analytical balance, Sartorius BP 210S Sartorius AG, Goettingen, Germany 
Centrifuges: 
      Eppendorf centrifuge, 5415C  Eppendorf, Geratebau, Germany 
      Refrigerated bench top centrifuge,  Quantum Scientific Pty Ltd Milton, QLD 
      Sigma 3K10 
      Ultracentrifuge, Optima L-80 XP  Beckman Instruments Inc., Palo Alto, CA, USA 
Camera, Olympus DP70   Olympus Australia Pty Ltd., Mount Waverley, VIC 
Columns: 
    Econo-column®    Bio-Rad Laboratories Pty Ltd, Regents Park, NSW  
    SuperdexTM PD-10 desalting column Amersham Biosciences Co. Piscataway, NJ, USA 
Electrophoresis gel tanks   Bio-Rad Laboratories, Hercules, CA, USA 
Electrophoresis power supply   Bio-Rad Laboratories, Hercules, CA, USA 
Filter units:  
    Acrocap 0.2µm    Gelman Sciences, Ann Arbor, MI, USA 
    Acrodisc syringe filter 0.2µm  Gelman Sciences, Ann Arbor, MI, USA 
    Centricon® centrifugal filter unit  Millipore Australia Pty Ltd., North Ryde, NSW 
    with Ultracel YM-100 membrane  
FALCON® Cell strainer (100 µm Nylon) Becton Dickinson Labware Franklin Lakes, NJ, USA 
Tissue sieve (100 µm Metal)   RMIT Workshop, Melbourne, VIC 
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Flow cytometers: 
FACScan (locate at WEHI) Becton Dickinson, Australia Pty Ltd. North Ryde, 
NSW 
EPICS Altra (located at RMIT) Beckman Coulter, Australia Pty Ltd. Gladesville, 
NSW 
FPLCTM system, Pharmacia LCC-500 Amersham Biosciences Co. Piscataway, NJ, USA 
Haemocytometer, Improved Neubauer  Selby Scientific Instruments, Notting Hill, VIC 
(Brightline) 
Homogenisers: 
    Polytron     Glen Mills Inc., Clifton, NJ, USA 
    Ultraturrax T25 basic   IKA-Werke, Staufen, Germany 
Incubators: 
    CO2 Incubator, Sanyo MCO-17A1  Quantum Scientific Pty Ltd, Milton, QLD 
    CO2 Incubator, Flow 210   Flow Laboratories, Selby-Biolab, Clayton, VIC 
     Electronic egg incubator, Multiplo E1 Multiplo Pty Ltd, Sydney, NSW 
Microscopes: 
     Light microscope, BX45   Olympus Australia Pty Ltd, Mount Waverley, VIC 
     Inverted microscope, IX51  Olympus Australia Pty Ltd, Mount Waverley, VIC 
PCR machine,     Perkin-Elmer Corp., Foster City, CA, USA 
GeneAmp PCR System 2400  
pH meter, ATI Orion Model 420A  Orion Pacific, Frankston, VIC 
Plates:    
    HI & HA plates, 96-well V-bottomed Nalge Nunc International, Rochester, NY, USA 
    Nunc-ImmunoTM plates, 96-well flat- Nalge Nunc International, Rochester, NY, USA 
    bottomed (MaxiSorpTM surface)      
    Cell culture plates 6, 24 & 96-well  Greiner Labortechnik, Frickenhausen, Germany 
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 Vinyl flat-bottomed Microtiter® plates,  Thermo Labsystems, Franklin, MA, USA 
    polyvinyl chloride (PVC)  
Rotary microtome, Leica RM2265  Leica Microsystems Pty Ltd., Gladesville, NSW 
Software:  
    FACS analysis, EXPO32TM  Applied Cytometry Systems, Dinnington, Sheffield, 
UK 
    FACS analysis, FlowGel   Becton Dickinson, Australia Pty Ltd North Ryde, 
NSW 
    Statistic, MINITAB® 14    Minitabs Inc., State College, PA, USA     
    Photo process,     Olympus Australia Pty Ltd., Mount Waverley, VIC 
    DP Controller and Manager  
Cell culture flasks 25, 75 & 175cm2  SARSTEDT Australia Pty Ltd., Technology Park, SA 
Tissue processor, Shandon Pathcentre® Thermo Electron Corporation, Waltham, MA, USA  
Tubes:  
    BD FalconTM round-bottomed test tube  Becton Dickinson, Australia Pty Ltd., North Ryde, 
NSW 
    Polyallomer centrifuge tubes  Beckman Instruments, Inc., Palo Alto, CA, USA 
    Ultra-ClearTM centrifuge tubes  Beckman Instruments, Inc., Palo Alto, CA, USA 
Ultracentrifuge swinging bucket rotor,  Beckman Instruments Inc., Palo Alto, CA, USA 
SW41   
 
2.7  CELL CULTURES 
2.7.1 MDCK cell line 
Cultures of the MDCK line were prepared in MEM growth medium in 75 cm2 cell culture flasks 
and incubated at 37°C in a 5% CO2 incubator.  Confluent monolayers were split at ratios of 1:5 - 
1:10, depending on when they were needed. 
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2.7.2 Primary CEK cultures 
Chicken embryo kidney (CEK) cultures were prepared from 18-day-old chicken embryos by the 
method of Tannock et al (1985).  Kidneys were removed and washed in citrate saline solution 
before being finely minced, transferred to trypsinising solution and held overnight at 4°C.  The 
trypsinised kidneys were then gently shaken to break up clumps, passeded through a pair of 
conical gauze filters, one inside the other, and pelleted at 700 g for 5 min.  The cell pellet was 
washed with chilled PBS and centrifuged to determine the packed cell volume.  A 1:200 dilution of 
CEK cells was prepared in MEM Growth Medium and passeded again through a pair of gauze 
filters.  Finally, 3 mL cell suspension were dispensed into each well of a 6-well plate and incubated 
for 48 hr at 37°C in 5% CO2. 
 
2.8  VIRUS GROWTH 
Viruses were passaged in 10 or 11 day-old embryonated chicken eggs in a 34°C egg incubator for 
2 or 3 days.  
 
2.9  VIRAL TITRATIONS 
2.9.1 HA assays   
HA assays were performed in 96-well V-bottomed microtitre plates using 0.5% chicken RBC.  To 
detect haemagglutination, endpoints were read by tilting the plates at 45°C.  The HA titre was 
defined as the reciprocal of the highest virus dilution at which complete haemagglutination was 
observed. 
 
2.9.2 Plaque assays 
Plaque assays were performed using monolayers of MDCK or CEK cells in 6-well culture plates, 
as described by Tannock et al (1984 & 1985).  Tenfold dilutions were prepared and 200 µL 
aliquots of each were inoculated to washed monolayers. After adsorption for 30 min, 3 mL of 
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overlay were added to each well.  MDCK or CEK cells cultures were incubated for 4 days at 34 
and 39°C, or 10 days at 25°C in the presence of 5% CO2.  Two millilitres of a staining overlay 
were then added to each well.  Any plaques present were counted after further overnight 
incubation. 
 
2.10  VIRUS PURIFICATION 
Allantoic virus was clarified at 3,000 × g for 5 min. The supernatant was then centrifuged at 
100,000 × g for 60 min at 4°C using an SW41 rotor.  The virus pellet was resuspended in a 0.5-1.0 
mL of TNE buffer.  Concentrated virus was then centrifuged onto a 60% sucrose cushion through a 
30% sucrose interface at 100,000 × g for 90 min, using an SW41 rotor (isopycnic 
ultracentrifugation).  Virus appeared as a sharp opalescent band at the interface between the 30% 
and 60% sucrose solutions.   
 
This band was recovered by inserting a syringe needle through the side of the tube and, using a 
syringe, carefully aspirating the opalescent layer (1-2 mL), together with a small amount of the 
adjacent sucrose fractions.  The virus band was diluted 1:5 in TNE buffer and centrifuged at 
100,000 × g for 60 min at 4°C using an SW41 rotor. The pellet was resuspended in a small volume 
of TNE buffer and stored at -80°C after HA assay.  The virus was further purified by velocity 
ultracentrifugation in order to separate free virus from membrane-attached particles of similar 
density.  
 
2.11 MOUSE MHC CLASS I EXPRESSION, REFOLDING AND TETRAMER 
FORMATION 
MHC tetramers consist of complexes of four MHC molecules associated with a specific peptide 
and bound to a fluorochrome (Figure 1.8).   They have been used extensively in studies of 
pathogenicity and vaccine-induced antigen-specific T-cell immunity in humans and in animal 
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model systems (Section 1.2.1.5).  The tetramer Db/hβ2m/NP366-374 specific for influenza A/AA/6/60 
ca was prepared by a modification of the method described in NIH tetramer core facility protocols 
(2003).  
 
2.11.1 Heat shock transformation 
The H-2Db heavy chain expression plasmid was transformed into competent cells BL21 (DE3) by 
heat-shock method.  Competent cells contain the chloramphenicol resistance gene as a selectable 
marker. In a chilled sterile Eppendorf tube, 1 µL of plasmid DNA was mixed with 10 µL of 
competent cells.  The transformation mixture was placed on ice for 30 min and then at 42 ºC for 30 
sec. After this heat-shock step, the mixture was held on ice for a further 2 min to complete 
transformation.  After adding 150 µL of LB medium, the mixture was incubated at 37 ºC for 1 hr 
with constant shaking.  Transformed cells were then pelleted by centrifugation at 5,000 × g for 30 
sec and resuspended in 100 µL LB medium.  Finally, the cells were plated onto LB agar plates 
containing 34 µg mL-1 chloramphenicol and 50 µg mL-1 kanamycin.  Plates were left for 
incubation overnight at 37 ºC. 
 
2.11.2 Induction of mouse MHC (H-2D
b
) heavy chain expression in E. coli 
A single colony was picked from the plate and transferred to a 10 mL LB medium with appropriate 
antibiotics and the suspension incubated overnight at 37 ºC.  Competent BL21 (DE3) cells 
contained an IPTG-inducible T7 RNA polymerase that served to repress basal expression of target 
genes under the control of the T7 promoter.  On the following day, 10 mL cultures were used to 
inoculate a 2 L LB culture.  The inoculated culture was grown by shaking at 37 ºC until an optical 
density (OD) between 0.6 and 0.9 was observed at 600 nm.  At this point, the culture was induced 
with 2 mL of 1 mM IPTG to allow H-2Db heavy chain expression.  After induction at 37 ºC for a 
further 4 hr, cells were harvested and pelleted at 1,000 × g for 20 min at 4 ºC.  The pellet was then 
resuspended in 10 mL of resuspension buffer. 
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2.11.3 Preparation of inclusion bodies from E. coli  
After the IPTG induction, recombinant protein accumulated in E. coli cells as inclusion bodies 
from which the desired protein H-2Db heavy chain could be prepared.  After induction, cells were 
lysed by adding 2.5 mL lysis solution per mL of cell suspension and incubated at room 
temperature for 20 min with constant rocking.  For further cell degradation, the lysate was mixed 
with 0.5 M of EDTA and homogenised for 30 sec.  The inclusion bodies were then pelleted by 
centrifugation at 4 ºC 5,000 × g for 20 min.  After washing twice with 100 mL of Wash Buffer I 
and once with 100 mL Wash Buffer II, inclusion bodies resuspended in 10 mL Resuspending 
Solution II and held at – 70 ºC until next step.  The concentration of inclusion bodies was 
estimated by SDS-PAGE in comparison with dilutions of known quantities of bovine serum 
albumin (BSA).   
 
2.11.4 Estimation of the concentration of inclusion bodies by SDS-PAGE 
Proteins were separated by discontinuous SDS-PAGE.  Polyacrylamide gels consisted of 18% 
separating gel and a 1.25% stacking gel.  Gels were cast as slabs in a Mini-PROTEAN 3 system 
(Bio-Rad, USA).  Ten microlitres of 2 × Loading Buffer were added to 10 µL of each sample and 
heated to 100 ºC for 5 min before loading.  The proteins were then electrophoresed at 200 V for 60 
min or until the Loading Buffer reached the end of the gel.  The SDS-PAGE gels were stained with 
Coomassie Blue for 30 min and then destained for 1 hr at room temperature with constant rocking.  
 
2.11.5 Formation of mouse MHC class I monomer (D
b
/hβ2m/NP366-374)  
Recombinant H-2Db heavy chains were prepared from the inclusion body suspension.  Briefly, the 
thawed suspension of inclusion bodies (6 - 12 mg) was transferred to SS34 rotor tubes and pelleted 
by centrifugation at 5,000 × g for 15 min at 4 ºC.  To release mouse H-2Db heavy chains from 
inclusion bodies, 10 mL of guanidine buffer were added to the pellet and the resulting suspension 
incubated at room temperature for 30 min with constant rocking.  The supernatant was then 
collected after centrifugation 5,000 × g for 30 min at 4 ºC and 8 mg of hβ2m were added. At the 
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same time, peptide was prepared by dissolving 6 mg NP366-374 in 100 µL DMSO before adding 200 
mL of fresh Refolding Buffer. 
 
For monomer refolding, the MHC heavy- and light chain mixture was injected to the refolding 
buffer through a freshly rinsed pump in a 4 ºC room.  The refolding buffer was stirred constantly 
during the injection process.  After injection, the mixture was held for 2 -3 days at 4 ºC to allow 
the monomer (Db/hβ2m/NP366-374) to form.  After refolding, the monomer mixture was transferred 
to dialysis tubing which was placed in 5 L freshly prepared cold Dialysis Buffer.  Dialysis was 
carried out with constant stirring at 4 ºC overnight.  The dialysed monomer was then further 
purified through FPLC. 
 
2.11.6 Purification of MHC class I monomer D
b
/hβ2m/NP366-374 by fast protein liquid 
chromatography (FPLC) 
2.11.6.1  Anion exchange purification 
DEAE sepharose was used to pack the anion exchange column.  Briefly, 50 mL of DE52 resin was 
mixed with 200 mL MilliQ water at 4 ºC.  Excess water was removed after the resin had settled.  It 
was then rinsed twice with 200 mL 10 mM Tris-HCl. The chromatography column was packed to 
three quarters of its volume with washed resin, which was then equilibrated by washing with 50 
mL 10 mM Tri-HCl 1 M NaCl for about 20 min.  It was then washed with 100 -200 mL 10mM 
Tis-HCl at pH 8.0 to remove residual Na+.  
 
The column was then loaded with 200 mL of filtered and dialysed MHC I monomer solution in a 4 
ºC cold room.  Protein was eluted by washing the column using the Liquid Chromotography 
Controller LCC-500, first with 10 mM Tris-HCl and then with10 mM Tris-HCl 1 M NaCl.  The 
fractions within the peak were collected and examined by SDS-PAGE.  Selected fractions were 
pooled together and then concentrated to a final volume of 0.5 mL using a Millipore Centricon 
tube.   
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2.11.6.2  Gel filtration 
Further purification of protein was achieved by gel filtration.  Briefly, a column was equilibrated 
with 100 -150 mL 10 mM Tris-HCl for 1hr prior to loading.  The sample was loaded onto the 
column and protein was eluted by washing with the same buffer, using the Liquid Chromotography 
Controller LCC-500.  Fractions within the peak were then collected and examined by SDS-PAGE 
and concentrated to a final volume of 0.8 mL.    
 
2.11.7 Biotinylation of D
b
/hβ2m/NP366-374 monomer 
Db/hβ2m/NP366-374 monomers were biotinylated before the tetramer refolding process.  To achieve 
this, 100 µL 10 × Biomix A buffer, 100 µL 10 × Biomix B buffer, 100 µL Biotin and 15 µL BirA 
enzyme were added to 800 µL purified MHC monomer.  The mixture was then held at 28 °C 
overnight.  On the following day, any free biotin was removed by loading on a PD-10 column and 
eluting with 2.5 mL of 10 mM Tris-HCl.  All eluates were checked for protein using Bio-Rad 
protein assay.  Samples containing protein were pooled together and then concentrated to 0.8 mL 
by using a Millipore Centricon 10’s tube and centrifugation at 3,500 rpm at 4 ºC for 30 seconds.   
 
To measure the proportion of monomers that were biotinylated, 50 µL of streptavidin beads were 
washed three times with 1 mL of Wash Buffer by centrifugation at 5,000 × g for 1 - 2 sec and then 
resuspended in 500 µL Wash Buffer.  Fifteen microlitres of biotin-labelled protein were then 
added and the mixture held at 4 ºC overnight.  On the following day, the bead-protein mixture was 
washed three times with 1 mL of Wash Buffer to remove non-biotinylated monomers.  The final 
biotinylated: non-biotinylated monomer ratio was determined by SDS-PAGE gel. 
 
2.11.8 Generation of tetramer D
b
/hβ2m/NP366-374 
For the generation of tetramers, suspensions of Extravidin®-R-PE conjugated beads were added to 
biotinylated monomers in the final ratio of 1:4.  At hourly intervals, 10% of the total volume of 
conjugated beads was added to the monomer preparation in an ice bath.  The tetramers were then 
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stored at 4 ºC after the addition of NaN3 (final concentration 0.02%) and titrated by flow cytometry 
prior to use, using the lymphocytes from influenza virus A/Ann Arbor/6/60 ca-infected C56BL/6 
mice.  
 
2.12  MOUSE EXPERIMENTS 
2.12.1 Anaesthetic 
Mice were anaesthetised by intraperitoneal (i.p) injection with Ketamine/Ilium Xylazine-20 (150 
mg / 50 mg kg-1 body weight). 
 
2.12.2 Immunization procedures 
Groups of 6 mice were inoculated i.n under anaesthesia with 50 µL allantoic virus, diluted in PBS 
to contain 1.45 × 105 PFU.  Control mice were inoculated with normal allantoic fluid prepared in 
PBS at the same dilution used to prepare the virus.  Mice were inoculated twice with the same dose 
at an interval of 3 weeks. Seven or nine days after inoculation, they were anaesthetised before 
being heart bled, and each lung pair was then removed for a series of assays. Sera for HAI tests 
were prepared from blood collected by heart bleed. 
 
2.12.3 Preparation of single cell suspensions from mice lung and spleen 
Single cell suspensions from lung were prepared by a modification of the method of Harling-
McNabb et al (1999).  Pairs of lungs from individual mice were removed and placed in PBS, and 
washed with 3 mL of HBSS containing 60 µg mL-1 penicillin and 100 µg mL-1 streptomycin.  Lung 
tissues were then finely minced with curved scissors and digested with 3 mL Lung Digestion 
Solution at 37°C for 30 min.  To break up the clumps, the digested lung tissues were forced 
through metal sieves using a 5 mL- syringe into a 10 mL- centrifuge tube containing 5 mL of ATC 
Buffer.  
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Spleen tissues were forced through sieves directly into ATC Buffer without the digestion step.  
Mixtures were then allowed to stand for 2-5 min at room temperature to deplete erythrocytes.  
Cells in the supernatant were pelleted by centrifugation at 4 °C 400 g for 5 min and briefly mixed 
with 5 mL of TCM using a vortex mixer.  Cell suspensions were then filtered through 100µm 
Nylon Cell Strainers to remove dead cells and debris.  The resulting single-cell suspensions were 
centrifuged at 400 g for 5 min and the cell pellets resuspended in 0.5 mL of TCM prior to 
counting. 
 
2.12.4 Inactivation of non-specific inhibitors in sera 
Thermostable inhibitors in mouse sera were inactivated by the addition of one part serum to four 
parts RDE solution and incubating at 37°C overnight.  The reaction was stopped by the addition of 
an equal volume of 1.5% sodium citrate and further incubation at 56°C for 30 min in order to 
inactivate thermolabile inhibitors. 
 
2.13 DETERMINATION OF VIRUS MORBIDITY AND LUNG VIRUS TITRES 
For the determination of viral morbidity, mice were weighed immediately before the infection.  On 
day 3 p.i, they were sacrificed and their body and lung were weighted individually.  Morbidity was 
indicated from changes of the body weight pre- and post infection, and changes in the ratio of 
body: lung (w/w) between infected and uninfected mice.  To compare the capacity of different 
influenza strains to replicate in mice, individual lung extracts were prepared by a modification of 
the method of Tannock et al (1984).  Briefly, the right lobe of each lung was removed and 
homogenised in 2 mL of sterile HBSS.  Extracts were stored at –80 ºC until titrated for infectious 
virus by plaque assays in MDCK cells (see Section 2.9.2 for plaque assay). 
 
2.14 HISTOLOGICAL STUDIES ON LUNG TISSUES 
Histopathological changes in the mouse lung were determined by Haematoxylin and Eosin (H&E) 
staining.  Mice were sacrificed by an intraperitoneal injection with Ketamine/Ilium Xylazine-20 
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(375 mg /125 mg kg-1 body weight) at days 3 and 21 after primary infection.  The large left lobe of 
each lung was then removed and fixed by inflation with 4 mL of 10% neutral buffered formalin for 
the H&E staining.  The fixed lung tissues were then processed in Tissue Processor by the standard 
processing schedules.  At the end of this procedure, the tissues were completely infiltrated with 
melted paraffin and were then placed into embedding moulds.  The blocks were allowed to cool 
until ready for sectioning with a microtome.  
 
Three sections from 250 µm levels of bronchial tree were prepared and stained with H&E.  Briefly, 
glass slides with 5- to 8-µm-thick paraffin sections attached were progressively dipped through 
xylene, 100% ethanol, 70% ethanol and tap water for dewaxing and hydration.  The slides were 
first placed in haematoxylin solution and in Scott’s blueing agent.  Finally, they were counter-
stained with Eosin Y solution.  The slides were then dehydrated with alcohol and cleared in the 
resin solvent, xylene.  Cover slips were mounted on the dry slides with DPX resin and slides were 
left to dry at room temperature.   
 
 
2.15  IMMUNE RESPONSE ANALYSIS 
 
2.15.1 Humoral immune responses analysis 
2.15.1.1  Serological analysis –HAI assays   
HAI assays were performed in 96-well V-microtitre plates using 0.5% chicken RBCs, as 
previously described by (CDC 1982).  Haemagglutinin end-points were read by tilting the plates at 
an angle of 45°.  The HI titre was defined as the reciprocal of the highest serum dilution causing 
complete inhibition of haemagglutination.  Geometric mean titres (GMTs) for each vaccine group 
were calculated.  Sera from mice, inoculated with normal allantoic fluid were prepared in each 
experiment for use as controls. 
 
   104 
 
2.15.1.2  Virus-specific ASCs analysis - ELISPOT assay 
Influenza virus-specific ASCs were enumerated by an ELISPOT assay based on that described by 
Sedgwick & Holt (1983).  Briefly, 96-well flat-bottomed polyvinyl chloride microtitre plates were 
coated with 50 µL PBS containing 200 HAU of purified virus per well for in vivo stimulation of 
murine B cells; control titration plates were coated with normal allantoic fluid.  The plates were 
then incubated overnight in a humidified atmosphere at room temperature.  Plates were washed 
three times with PBS-T and blocked with 100 µL of BSA10PBS per well.  After 1 hr of incubation 
in a humidified atmosphere at room temperature, the plates were washed three times with PBS-T 
and then 50 µL of TCM were added to each well.  Aliquots 50 µL of ATC-treated lung or spleen 
cell suspensions were added to triplicate wells, and six serial two-fold dilutions performed.  The 
plates were then placed in a vibration-free incubator at 37°C in 5% CO2 for 6 - 8 hr.  
 
After incubation, the cells were lysed and removed by rinsing the plates twice with Milli-Q water 
and twice with PBS-T.  Goat anti-mouse IgA and IgG2a isotype-specific antibodies, diluted 1:400 
in BSA5PBS-T, was added (50 µL per well) to a triplicate titration series and the plates further 
incubated for 2 hr in a humidified atmosphere at room temperature.  Plates were then washed three 
times with PBS-T and 50 µL per well of alkaline phosphatase-conjugated rabbit anti-goat IgG 
antibody, diluted 1:1000 in BSA5PBS-T, were added and the plates incubated for a further 2 hr in a 
humidified atmosphere at room temperature.  Plates were washed with PBS-T three times and once 
with Milli-Q water.  The assay was then developed by adding to each well 50 µL of BCIP 
substrate solution and held at room temperature for 1 hr.  The plates were washed three times with 
Milli-Q water and spots counted using an inverted microscope.  Each spot represented a single 
influenza virus-specific ASC and results were expressed as the mean number of ASC ± standard 
error of the mean (SEM) or standard deviation (StDev) per 106 cells.  ASCs in lungs or spleens 
from normal allantoic fluid inoculated mice when assayed on normal allantoic fluid-coated plates 
were used to determine background levels. 
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Figure 2.1  Schematic representation of immuno-PCR reaction for IFN-γ  
mAb: monoclonal antibody  
pAb: polyclonal antibody 
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Biotinylated 
reporter-DNA 
Free avidin 
Mouse serum IFNγ (Ag) 
Biotinylated rabbits anti 
mouse IFNγ pAb (2
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 2.15.2 Cell mediated immune (CMI) responses analysis  
2.15.2.1  Serum IFN-γ analysis – Immuno-PCR assay 
Immuno-PCR assays are highly sensitive and have been used for the detection of variety of 
antigens, including cytokines (Anne Mckie 2002).  A DNA label had been used as report marker 
that can be detected by PCR in this assay.  The principle of the assay is shown in Figure 2.1.   
Preparation of biotinylated reporter DNA  
Biotinylated report DNA (227 bp) was prepared from plasmid Bluescript by PCR amplification 
with the biotinylated M13-20 primer and the non-biotinlated M13 reverse primer.  The PCR 
reaction mixture was prepared according the protocol given in the QIAGEN Multiplex PCR Kit.  
The reaction mixture was contained 10 mM Tris-HCl buffer (pH 8.3), 50 mM KCl, 3.0 mM 
MgCl2, 0.2 mM dNTP, 0.2 µM of each primer, 2 units of Taq DNA polymerase, and 5 pg of 
pBluescript.  The reaction was allowed to take place in the following steps: (1) an initial 
denaturation at 95°C for 5 min, (2) 30 cycles of denaturation at 94°C for 30 s, (3) annealing at 
58°C for 1 min, (4) extension at 72°C for 30 s, and finally (5) extension at 72°C for 5 min.  The 
PCR product was purified using QIAquick® PCR purification kit. 
 
Immuno-PCR assay for the detection of IFN-γ 
For coating 96-well ELISA plates (Nunc), 1 µg primary anti-IFNγ monoclonal antibodies in 50 µL 
of carbonate Coating Buffer were added to each test well and the plate incubated at 37°C for 1 hr.  
The plates were washed three times with the Wash Buffer and then 200 µL Blocking Solution was 
added to each well.  The plate was then held at room temperature for 1 hr.  After washing three 
times, 50 µL of each diluted serum samples were added to individual wells and the plate was 
incubated at 37°C for 1 hr.  After washing, 0.025 µg of biotinylated-rabbit anti-mouse IFNγ 
antibody was added to each well and plate incubated at 37 °C for a further hr.  Free avidin was 
added to each well and the plate incubated at 37 °C 30 min to allow it to bind to biotinylated 
secondary antibody.  After washing, 0.1 pg of reporter-DNA was added to each well and the plate 
incubated for 30 min at 37 °C to allow biotinylated reporter-DNA to bind to the complex.   
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Unbound reporter-DNA was removed by washing and the bound reporter-DNA was used as 
template DNA for PCR amplification.  To obtain template DNA, the plate was heated to denature 
the reporter DNA.  PCR was carried out using IF and IR primers, which are nested to M13-20 and 
M13 reverse primers.  Briefly, 50 µL DEPC H2O were added to each well and the plate was sealed 
with Parafilm and heated at 95°C for 5 min.  Then 5 µL of each supernatant was used as template 
DNA in the following PCR reactions. Reactions were performed using a Gene Amp PCR system 
2400 (Applied Biosystems, USA).  Reactions were heated to 95°C for 5 min, followed by 40 
cycles of denaturation at 95°C for 30 s, annealing at 58°C for 1 min and extension at 72°C for 1 
min. A final extension at 72°C for 5 min completed the reaction and samples were stored at 4°C 
until required. 
 
2.15.2.2  Effector T cell analysis 
Phenotype: in vivo peptide-specific CD8
+
 T cell and CD44
high
 T cell 
The PE labelled DbNP366 and D
bPA224 used in these experiments were supplied by Dr. Stephen 
Turner from the Department of Immunology, University of Melbourne.  In addition, DbNP366 
prepared from influenza A/AA ca and H-2Db in Dr. Andrew Brook’s Lab, Department of 
Immunology, and University of Melbourne was tested through these experiments.  CD44 had been 
chosen as an effector and potential memory T cell marker for the T lymphocytes phenotype.  
Lymphocytes isolated from the lungs and spleens of virus-infected mice at the third day post 
primary and secondary intranasal infection were prepared by the method same as described in 
section 2.12.3.  The cells were diluted to a final concentration of 1 × 106 cells 50 µL-1 in FACS 
stain buffer and then transferred to 96-wells U-bottomed tissue culture plate.  
 
For tetramer staining of peptide-specific CD8+ T cells, cells were stained with the tetrameric 
complexes DbNP366 or D
bPA224 at room temperature avoiding exposure to the light.  After 60 min 
incubation time, lymphocytes were washed twice with stain buffer for removing extra tetrameric 
complexes and stained with anti-CD8-FITC for 30 min at room temperature.  Moreover, for 
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identification of CD44high T cell population, cells were stained with anti-CD44-FITC and either 
anti-CD8 or CD4-PE for 30 min at room temperature.  Cells were fixed for the preservation of 
their morphology straight after staining.  Briefly, lymphocytes were washed once with stain buffer 
and twice with fix wash buffer containing gelatine.  Then cells were diluted to a final concentration 
of 1 × 106 cells 200 µL-1 in the fixation buffer with 2% paroformaldehye.  On the following day, 
fixed cells were washed twice with fix wash buffer before they were transferred to the FALCON® 
FACS tube respectively to each sample well.  Cells were analysed by flow cytometer within one 
week. 
 
Functional study: in vitro intracellular IFN-γ staining with stimulation 
This assay used the single cell preparations from lung and spleen that were RBCs lysed and 
cultured for 5 hr in 96-well round-bottom plates at a concentration of 1 ~ 4 × 106 cells per well in 
200 µl of T-cell medium containing 1 µg ml-1 peptide NP366-374 and 10 µg ml
-1 BFA.   The reason 
for using BFA here was to prevent excretion of protein thus leading to intracellular accumulation 
and more intense staining of cytokines. The lymphocytes were then washed and stained with anti-
mouse CD8-PE at room temperature for 30 min. The cells were fixed in ICC fix buffer for 15 min, 
then 10 min in ICC cell permeablisation buffer before staining with a FITC conjugated mAb to 
mouse IFN- γ.  The percentage of CD8+ IFN- γ+ T cells was detected through flow cytometer. 
 
 
2.16  STATISTICS 
Normal distribution of data was determined by the Kolmogorov-Smirnov test (P ≥ 0.05, 
Appendix); Statistical significance was determined by the Student’s t-test (P < 0.05, Appendix).  
Where data did not assume normal distribution, each datum was converted to a natural logarithm.  
The converted data were again checked for normal distribution before being applied to a statistical 
model.  
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Chapter 3:  
 
The relative infectivity of reassortants of the 
cold-adapted influenza A donor strain A/Ann 
Arbor/6/60 in C57BL/6 mice 
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3.1 INTRODUCTION 
 
Earlier studies have indicated that the immunogenicity of ca reassortants was directly related to the 
extent of their replication in the respiratory tract of mice (Tannock et al 1995).  In seronegative 
humans, ca LAIVs have also been found to be highly immunogenic (Treanor et al 1990).  Both 
findings were not unexpected because viral replication can enhance both MHC Class I and II 
antigen presentation pathways (Section 1.2.1.5).  However, immunogenicity is also influenced by 
both the presence of pre-existing Ab and by the intrinsic properties of individual reassortants.  
Detailed studies in mice have shown that: (1) the immunogenicity of both US and Russia ca donor 
strains was 100-1000× less than their wt parental viruses, (2) ca donor strains or reassortants, when 
administered by the i.n route in two low doses, are as immunogenic as a single dose of the 
corresponding parental virulent virus that was used to prepare each reassortant, and (3) the 
immunogenicity of each reassortant is determined by both the genes for cold-adaptation and HA 
glycoproteins (Table 3.1).  
 
In the current study, all ca reassortants had been used in previous studies conducted by the 
Tannock group and their ts and ca phenotypes were confirmed before inclusion in the present 
experiments.  Of the reassortants, CR6 was the first developed for use as a live human vaccine in 
1975.  It was evaluated in vitro and in vivo had all the desired characteristics of an LAIV.  It grew 
to high titres at 25 and 33°C, was attenuated for ferrets and showed no evidence of reversion to 
virulence (Maassab and DeBorde 1985).  Another early reassortant, CR18, possessed the internal 
NS gene from the wt parental virus and was also included in this study (Table 2.1).  Earlier 
experiments on the growth of these viruses in the respiratory tract of outbred mice showed that the 
presence of wt NS gene in CR18 did not provide any growth advantage (Tannock et al 1984).  
Unlike ferrets, all ca reassortants tested grew to higher titres in the lungs of mice compared with 
turbinates (Table 3.1).  These findings are explicable in terms of the different distribution of α-2,3 
glycoprotein receptors in mice and ferrets (Wright et al 2007).   
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Table 3.1  Summary of properties of ca reassortants with similar internal genes in vitro and in vivo (Maassab and DeBorde 1985; Tannock et al 1995) 
 
HAI Ab levels in outbred 
male mice (GMT)
a
 
Histopathology (Ferrets) 6:2 ca 
reassortant 
wt parent 
Dosage required to 
induce maximum Ab 
in seropositive adults 
PD50 with two doses  
(in outbred male mice) 
One dose
b
 Two dose
c
 
Clinical signs 
(Ferrets) 
Turbinates Lung 
CR6 (H3N2) A/QLD/6/72 n.a. 101.17 TCID50
 71 243 Absent  1+ out of 4+ 0 
CR18 (H3N2) A/Scot/840/74 n.a. 10
2.30
 TCID50
 
71 202 n.a. n.a. n.a. 
CR29 (H3N2) A/Alaska/6/77 10
6.5
- 10
7.0 
TCID50 10
2.50
 TCID50
 
40 211 Coryza 1 day 2+  0 
CR35 (H1N1) A/HK/123/77 n.a. 103.00 TCID50
 40 64 Absent 1+ 0 
A/AA/6/60 ca 
(H2N2) 
Master Donor 10 5.3 -10 5.7 TCID50 10
1.13 TCID50
 64 113 n.a. n.a. n.a. 
 
a Titres were determined against the homologous virus. Each figure represents the GMT for the results from six mice.  
b Each dose consisted of 105 TCID50 of virus.  Six weeks after single dose, mice were bled and sera were collected.   
c There was a 3-week-interval period between the two inoculations; mice were bled 3 weeks after the last dose. 
     n.a. not available 
TCID50 50% tissue culture infectious dose 
PD50 50% protective dose; the amount of virus administered i.n as two identical doses 3 weeks apart which completely inhibits multiplication of a standard challenge,                  
consisting of 104.5 TCID50 of a wt parental virus with similar surface Ags, in the lungs of 50% of mice. 
 GMT geometric mean titre 
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In outbred mice, H3N2 reassortants (CR6, CR18 and CR29) were shown to grow to higher titres in 
lungs by day 3 p.i and are to be more immunogenic (Tannock et al 1984).  By contrast, CR35 
(H1N1) is a slower-growing virus that could not be detected by day 3 and is a weaker immunogen.  
A recent study with A/HK/2188-49/06 H3N2 and H1N viruses in MDCK cultures similarly 
indicated that the H3N2 virus formed large plaques and grew to high titres, compared with the 
H1N1 virus.  These differences are associated with differences in levels of phosphorylation by 
extracellular-regulated kinase (ERK; Marjuki et al 2007).  ERK belongs to the MAPK signalling 
pathway which, when induced late in the replication cycle, plays a crucial role in efficient virus 
replication.   
 
In the present study, the relative infectivity of ca reassortants with common internal genes was 
compared in genetically defined inbred mice, in order to provide information on the role of viral 
surface Ags in the absence of a variable MHC background.  Viral infectivity was measured from 
changes in lung pathology, virus yields in lungs and body weight loss.  In addition, inherent 
differences in the replication characteristics of ca reassortants and Ab responses were measured. 
 
 
3.2 RESULTS 
 
3.2.1 Viral replication characteristics 
All viruses were first passaged in embryonated eggs and virus stocks prepared at each passage 
were tested for their infectious titre (expressed as PFU in MDCK monolayers at 34ºC) and HAU 
content.  The replication efficiency of egg-grown viruses was calculated from the PFU: HAU ratio.  
The average PFU: HAU ratio for each virus used is shown in Figure 3.1.  Results indicate that all 
the H3N2 ca viruses have higher ratios than H1N1 ca viruses.  Substitution of the H3 HA gene of 
CR6 for the H1 HA gene of CR35 to produce the new reassortant CR6-35 H1N2 resulted in a 
reduction of the PFU: HAU ratio of almost 50%, compared with CR6.  By contrast, the ratio for 
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the CR6-35* (H3N1) reassortant (possessing the H3 HA gene of CR6 and the N1 gene of CR35) 
was increased by a factor of almost 3, compared with CR35.  However, this phenomenon was not 
observed with wt A/PR8 (H1N1) and it’s reassortant A/HK×31 (H3N2), both of which share the 
same internal genes.  The PFU: HAU ratios of A/PR8 and A/HK×31 are 71.16×103 and 22.80×103 
respectively.  
 
Besides egg-adapted viruses, two recent human epidemic strains and non-egg-adapted isolates, 
A/Fujian/411/02 (H3N2) and A/New Caledonia/20/99 (H1N1) were examined in MDCK cells.  
A/Fujian was found to be highly virulent for embryonated eggs and caused embryo death prior to 
the achievement of a detectable HA titre.  However, A/Fujian could be grown in MDCK cultures 
where they produced low HA titres (2-32 HAU in contrast to 640-1280 HAU for A/PR8) but 
comparatively high PFU titres.  After eight passages in MDCK cells, a PFU: HAU ratio of 
31.25×103 was achieved.  By contrast, the HAU titre of A/New Caledonia/20/99 was 512 after the 
first passage in MDCK culture cells but it’s PFU: HAU ratio was only 6.15.   
 
In addition to variations observed in their replication efficiency, these viruses exhibited different 
plaque characteristics (Figure 3.2).  CR29 forms small plaques of uniform size; other ca viruses 
generate plaques of both medium and large size.  The plaques of wt viruses are generally large, 
whereas those of A/HK×31 are mainly small.  Plaques of human non-egg-adapted isolates 
A/Fujian and A/New Caledonia were large and irregular.  Their plaquing ability in vitro and 
virulence in vivo were confirmed with full-length of PB1-F2, in contrast to the truncated form that 
is present in A/AA ca (Zell et al 2006).        
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Figure 3.1 Viral replication efficiency of ca and wt parental in embryonated eggs, as measured by the average 
PFU: HAU ratio.  The ca reassortants used in previous studies are showed inside the box. 
   
   PFU plaque forming unit 
   HAU haemagglutination unit  
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 Figure 3.2 Differences in plaque shape and size between different influenza viruses.   
Plaques were observed in MDCK cultures after 4 days at 34 ºC p.i.  Non-egg-adapted A/Fujian and 
A/New Caledonia viruses used in this study are human isolates with limited passages (less than 10) in 
MDCK cells.  All the other viruses are egg-adapted.  A/AA ca, CR6 and CR35 were used for the 
following histological studies. 
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3.2.2 The relative infectivity of ca reassortants and a donor strain in C57/BL6 mice 
3.2.2.1  Early pathogenic changes in mice lungs after a single i.n inoculation  
In the following study inbred female C57/BL6 mice were inoculated with ca viruses and their 
corresponding parental wt viruses with H2N2, H3N2 and H1N1 surface antigens.  Early virus-host 
interactions were assessed by determining body weight loss, lung virus titres and histopathology 
within the lungs.  Groups of three 8-week-old female C57/BL6 mice were administered 50 µL 
containing 105 TCID50 of each virus by the i.n route under general anaesthetic.  All mice were 
sacrificed on the day 3 p.i and the lungs harvested.  Body weight losses were determined from 
measurements taken immediately before and 3 days after infection (Figure 3.3).  No infectious 
virus could be detected on day 3-p.i in the lungs of mice infected with A/AA ca, CR6 (QLD) and 
CR35 (HK) (Figure 3.3B), in agreement with a previous study using outbred mice (Tannock et al 
1982 & 1984).   
 
By contrast, mean titres of 6.37 and 72.62 × 103 pfu per lung were observed with the wt parental 
viruses A/AA and A/QLD infected mice, respectively.  However, with A/HK wt virus, no 
infectious viruses could be detected on day 3 (Figure 3.3B).  All groups infected with wt viruses 
experienced more than 5% weight loss within 3 days (Figure 3.3D).  For ca-infected mice, only 
those infected with CR6 exhibited a 3.8% decline and there was no body weight loss observed 
after A/AA ca and CR35 infection.   
 
The lung: body weight ratio was used as an index of lung consolidation in response to infection 
(Figure 3.3C).  Mice infected with A/AA ca and CR6 at day 3 p.i exhibited slight consolidation, 
with lung: body weight ratios of 0.94 and 0.93×10-2, respectively, compared with uninfected 
controls where the ratio was 0.82×10-2.  However, mild consolidation was observed in the lungs of 
CR35-infected mice and the ratio was 1.08×10-2.  By contrast, wt-infected mice exhibited mild 
lung consolidation and their lung: body weight ratios were all greater than 1×10-2.     
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Figure 3.3 Early virus-host interactions indicated by lung virus yield (B), levels of lung consolidation (C) and weight loss (D). 
Graph A showed that the PFU: HAU ratio of each virus used to infect mice.  Each virus group consisted of three 8-
week-old female C57BL/6 mice.  Mice were administered 10
5 
TCID50 viruses i.n under general anaesthetic and 
were sacrificed at day 3 p.i.     
B
C
Uninfected 
mouse 
A
D
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3 days p.i with wt viruses (H&E staining 40×) 
A/AA wt (H2N2) 
 
A/QLD (H3N2)      
  
A/HK (H1N1) 
 
3 days p.i with ca viruses 
A/AA ca (H2N2) 
 
CR6 (H3N2) 
 
CR35 (H1N1) 
 
   
3 weeks p.i with ca viruses (H&E staining 40×) 
   
   
 Uninfected  
 
 
 
 
  
 
Figure 3.4 Lung pathological changes after infection with wt and ca influenza viruses with similar surface antigens.   
 
The lungs of ca-infected mice appeared normal, except for small patches of consolidation in the left lung 
(see arrow) and cardiac lobe of the right lung.  From H&E staining, lungs from both wt- and ca- infected 
mice exhibited similar levels of mild lymphocytic peribronchitis with mild alveolitis at 3days, compared 
with uninfected mice.  However, ca-infected mice regained weight and the inflammation in lung had 
declined markedly by 3-week-p.i.  By contrast, wt-infected mice had to be euthanized within the first 
week p.i due to continuing body weight losses. 
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Figure 3.5 Serum Ab responses to ca influenza viruses, which share the same internal genes but possess different 
surface antigens, 3-week-p.i.  Groups of four 8-week-old female C57BL/6 mice were given 105 TCID50  of 
each virus, and were held for further 3 weeks.  Individual mice were then bled and their serum HI titres 
tested for the calculation of group GMTs. 
 
 
 
 
 
 
 
Table 3.2 Summary of responses at 3-days to infection with ca influenza A viruses with the same internal genes 
but different surface antigen genes.    
 
 
 
 
 
 
A/AA ca (H2N2) CR6 (H3N2) CR35 (H1N1) 
 
Virus recovery from lungs 
(×103 pfu) 
 
0 0 0 
 
Mean Lung: Body weight ratios 
(w/w ×10
-2
) 
 
0.94 0.93 1.08 
 
Average body weight loss  
(- %) 
 
0 3.79 0 
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3.2.2  Histopathological changes in the lungs of infected mice  
Female C57BL/6 mice were administered 105 TCID50 of a particular virus by the i.n. route and 
were sacrificed at either 3 days or 3 weeks p.i.  Their lungs were harvested and then processed for 
H&E staining.  The lungs of mice infected with all ca viruses appeared normal except for small 
patches or foci of consolidation that were mainly seen in the left and cardiac lobes of the right lung 
(Figure 3.4 middle panel).  H&E staining also showed that, at 3 days p.i, the lungs of both wt- an        
ca-infected mice had mild lymphocytic peribronchitis and mild alveolitis (Figure 3.4 upper panel), 
compared with uninfected controls.  However, inflammation caused by ca viruses was much 
reduced after 3 weeks (Figure 3.4 lower panel).  Comparison was not possible at 3 weeks with wt- 
infected mice, which, (under the direction of the RMIT Animal Care and Ethics Committee) were 
euthanized within the first week because of increasing weight loss.  
 
3.2.3 Serum Ab responses 
Three weeks p.i, Ab responses to a single dose of each ca virus were determined and are expressed 
as GMTs for groups of four C57BL/6 mice (Figure 3.5).  All four mice from the CR6-infected 
group had individual titres of 80, and from the CR35-infected group of 10.  One mouse HI titre 
from the A/AA ca-infected group was had a titre of 20 and the other three mice were 10.  
Therefore, the GMT for H3N2 reassortant CR6-infected mice is 80 and for the A/AA ca (H2N2) - 
and CR35 (H1N1)-infected mice 13 and 10, respectively.   
 
 
3.3 DISCUSSION  
 
Viral growth and spread are major determinants of the course of an influenza infection.  Viral load 
is important in the development of immunity and determines the extent of immune stimulation 
(Doherty et al 1997; Hozler et al 2003; Ahmed et al 2007).  In the present study, early virus-host 
interactions were investigated at day-3 after i.n inoculation of C57BL/6 mice with different ca 
   121 
   
reassortants or their parental wt viruses.  Infectivities were determined for (1) ca viruses, in 
comparison with parental wt viruses with the same surface Ags but different internal genes; and (2) 
ca viruses, with common internal genes but different surface Ags.      
 
3.3.2 Early systemic reactions to influenza infection are related to internal viral genes  
An earlier study indicated that the ca/ts/att phenotypes of ca reassortants were responsible for 
reduced infectivity and immunogenicity (Tannock et al 1995).  The current study extended these 
findings and showed that ca viruses possessing surface antigens from three different subtypes that 
exhibited markedly reduced viral replication efficiency both in vitro and in vivo (Figure 3.3 A&B).  
At day-3-p.i, ca-infected mice exhibited no or little body weight loss, while losses for wt-infected 
mice were 5-10% (Figure 3.3 D).  Therefore, at day-3, fewer systemic reactions were induced by 
ca viruses than wt parental viruses with the same surface Ags.  The attenuation of ca viruses for 
mice is considered to be mainly due to mutations in their internal genes, especially PB1 and PB2, 
which are responsible for the induction of cytokines and chemokines (La Gruta et al 2007; Section 
1.2.1.4).  
 
In contrast to the marked differences in body weight between mice inoculated with ca- and wt 
viruses, no substantial differences lung pathology were noted at day 3-p.i (Figure 3.4), indicating 
that the extent of primary local responses induced by either ca or wt viruses was similar during the 
early stages of infection.  These findings were not unexpected, since SPF mice were used that were 
immunologically naïve to influenza A viruses; specific adaptive responses involving the 
recruitment of lymphocytes to the lungs do not usually occur before 1 week (Eichelberger et al 
2006; Section 1.2.2.1).  Consequently, by day 3, lung consolidation in ca-infected mice was only 
marginally less than in mice infected with wt-viruses with the same surface antigens (Figure 3.3C).  
However, by 3-week-p.i, inflammation in ca-infected lungs was much less than at day 3 p.i and 
similar to that of control uninfected mice (Figure 3.4).   
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The results demonstrated, for the first time, that, in the early stages of infection, ca viruses are able 
to induce similar local responses in the lungs to their wt parental viruses in absence of systemic 
symptoms (i.e. body weight loss).  This stimulation of CMI responses following i.n administration 
has been proposed as a major advantage of i.n-administered ca LAIVs over parenterally 
administered inactivated vaccines (Tannock 1991). 
 
3.3.2 Surface HA glycoprotein is a major determinant of the infectivity for ca LAIV 
The relative infectivity of ca viruses with surface from three different subtypes (H3, H2 and H1) 
was investigated in an attempt to elucidate a relationship between their replication efficiency and 
immunogenicity.  The PFU: HAU ratios for H3 reassortants are >1,000 times greater than those of 
H1 reassortants (Figure 3.1).  Importantly, a reassortant possessing the H3 gene (CR6-35*) had a 
PFU: HAU ratio that was >1,500 times higher than CR35 with the same N1 gene (Figure 3.1).  A 
possible explanation is that viral H3 glycoproteins are stronger inducers of cellular ERK than H1, 
and can accumulate more efficiently on the cell surface (Marjuki et al 2007).  The accumulation of 
HA, that is expressed late in the replication cycle is necessary for efficient packaging and budding 
of progeny virions (Marjuki et al 2006).   
 
In previous protection experiments, mice were immunized i.n with ca LAIVs twice before being 
challenged by a standard dose of the wt parental virus (Tannock et al 1984 & 1987).  Only 10 
infectious units of a H3N2 ca reassortant, compared with 1,000 units of a H1N1 ca reassortant was 
required to protect mice against homologous challenge.  Therefore, the H3N2 ca reassortant tested 
was a superior immunogen than the H1N1 ca reassortant by a factor of 100.  Both viral replication 
efficiency and/or the surface protein HA appear to play a significant role in determining the 
immunogenicity of ca LAIVs.  
 
However, not all the H3 viruses replicate more efficiently than H1 viruses.  The parental A/PR8 
(H1N1) exhibited superior replication efficiency (>50,000 times) than the reassortant A/HK×31 
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with H3N2 surface antigens (Figure 3.1).  Other studies suggest that viral internal proteins, 
especially PB1 and PB2, also play a role in the cellular ERK pathway that is related to HA 
accumulation on the cell surface (Marjuki et al 2006 & 2007), indicating a role for the genes of 
both surface- and non-surface-Ags in replication. 
 
3.3.3 Primary Ab responses induced by ca influenza viruses are related to viral 
pathogenicity   
In the study, serum Ab levels were measured 3 weeks after a single i.n inoculation with ca viruses.  
As expected, the H3 subtype ca virus induced a stronger Ab response than the H2 subtype ca virus 
(Figure 3.5) as the H3 replicated more efficiently, as indicated by its PFU: HAU ratio.  The H3 ca 
virus (CR6) was the only ca virus tested in present study that caused weight loss (Table 3.2), 
which is consistent with an earlier study indicated that the H3 ca reassortant is able to induce a 
stronger Ab response than the H1 reassortant 6 weeks after the second vaccination (Table 3.1; 
Tannock et al 1995).  By contrast, A/AA ca (H2N2) also had high in vitro replication efficiency 
but did not induce strong Ab responses or cause body weight loss.  The reasons for these 
differences is unknown but could be related to mutations that specify the ca phenotype.  Overall, 
humoral responses to ca viruses are more closely related to systemic reactions than viral 
replication rates measured in vitro.     
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3.4 SUMMARY  
 
Early virus-host interactions were studied at day-3 after i.n inoculation of C57BL/6 mice with (1) 
ca viruses and their parental wt viruses with the same surface Ags but different internal genes, or 
(2) ca viruses with common internal genes but different surface Ags.  Parameters studied were 
body weight changes, viral growth in the lungs and lung histopathology for consolidation. 
 
Results from lung histopathology studies demonstrated no differences at day-3 p.i between the 
mice infected with ca viruses and their parental wt viruses.  However, as expected, when measured 
by body weight loss, all ca reassortants and the ca donor strain were found to be less pathogenic 
than their wt parental viruses at day-3 p.i.  The H3 ca reassortants CR6, CR18, CR29 and CR6-35* 
exhibited greater replication efficiency (determined by their PFU:HAU ratios) than H1 ca 
reassortants CR35 and CR6-35.  The H3 ca reassortant CR6 caused a 3.79% loss in body weight; 
no losses were observed for H1 ca reassortant CR35 and the ca H2N2 donor strain A/AA ca.   
 
Primary serum responses to ca reassortants and the donor strain were compared at 3-weeks p.i.  
Levels of HI antibody were found to be related to viral pathogenicity in mice.  Higher HI 
responses were induced in groups infected with the H3 ca reassortant CR6 (GMT 80) than the H1 
reassortant CR35 (GMT 10) and the H2 ca donor strain A/AA ca (GMT 13). 
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Chapter 4:  
 
Evaluation of tetramer staining and immuno-PCR 
techniques for the measurement of specific CMI 
responses to ca LAIVs in C57BL/6 mice 
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4.1 INTRODUCTION 
 
The measurement of immune responses is essential for determining the efficacy of human 
influenza vaccines.  Traditional serum Ab tests, such as the HI test, are simple, specific and 
sensitive and are used for measuring responses to individual HA antigens in inactivated TIVs.  
Others, such as the neutralization test, are more complex but provide a greater sensitivity than HI 
assay and are used to measure responses to inactivated H5N1 vaccines (Cassetti et al 2006; 
Eichelberger et al 2008).  
 
For LAIVs administered directly to the respiratory tract, measurement of serum Ab, alone, does 
not provide a complete indication of immunity induced within the respiratory tract (Romanova et 
al 1994; Treanor et al 2000; Belshe 2002).  Optimal protection to respiratory challenge is 
determined by both specific humoral and CMI responses, both of which can be induced by LAIVs 
(Reiss and Schulman 1980; Section 1.2.2.1).  Previous human studies have indicated that vaccine-
induced IFN-γ and local IgA, rather than serum Ab responses, are associated with ca LAIV 
efficacy (Tomoda et al 1995).  Moreover, protection can be induced by ca LAIVs in the absence of 
detectable serum Ab (Belshe et al 2000).   
 
In addition to measuring serum Ab, results from clinical trials in which reductions in infection 
(vaccine efficacy) and illness (vaccine effectiveness) provide a more comprehensive evaluation of 
ca LAIVs.  Clinical studies have shown that vaccine efficacy depends largely on vaccine-induced 
pre-existing neutralizing Ab levels that can lead to sterilizing immunity, whereas vaccine 
effectiveness is more likely to be related to memory CMI responses (Sasaki et al 2007; Wright 
2007).  When an antigenic mismatch occurs between the epidemic strain and the vaccine strain, 
live vaccines are significantly more effective than killed vaccines (Belshe et al 2000; Halloran et al 
2007).  Therefore, the measurement of vaccine-induced CMI responses is required to evaluate the 
performance of ca LAIVs (Eichelberger et al 2008).   
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Several tests on human PBMCs, including ELISPOT assays and tetramer flow cytometry, have 
been developed over 30 years to measure B and T cell responses (Keiholz et al 2002).  However, it 
is not possible to directly measure CMI or IgA responses to infection or vaccination in the lower 
respiratory tract of humans.  The extent to which vaccine-induced T cell and mucosal immunity 
and other factors (e.g. properties of the vaccine virus and the age of the vaccinee) influence 
immunity in humans is largely unknown (Arvin and Greenberg 2006).   
 
Mouse models are convenient due to the availability of immunological reagents and are used in 
many studies of both live and killed influenza vaccines that may provide preliminary evidence of 
the likely situation in humans (van der Lann et al 2008).  As discussed in Section 1.2.1.5, 
fluorescent labelled MHC tetramers have been widely used for the staining of Ag-specific T-cells, 
especially CTLs (Figure 1.8).  This chapter describes attempts to refold a mouse MHC tetramer 
carrying the NP366-374 peptide from the ca donor strain A/AA ca in order to evaluate responses in 
infected C57BL/6 mice.   
 
In addition, the immuno-PCR (I-PCR) was used to measure IFN-γ levels in cell culture 
supernatants after co-culture of mouse lung lymphocytes with the same viruses used for 
vaccination.  The I-PCR assay has been used to detect TNF-α and IL-18 and is a modification of 
an ELISA, in which the enzymes used for detection are replaced with a biotinylated reporter DNA 
(Section 2.15.1.2; Figure 2.1; Sanna et al 1995).  The reporter DNA is bound to the biotinylated 
Ag-Ab complex through a streptavidin linkage.  The I-PCR assay is highly sensitive and has a 
detection limit of 2.5 pg/l, which is 1.6×104 lower than that of the ELISA (Furuya et al 2000). 
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4.2 RESULTS 
 
4.2.1 The formation and titration of a tetramer (D
b
/hβ2m/NP366-374) specific for A/AA  
Tetramers were prepared from four monomers (Figure 1.8), each of which contained a MHC Class 
I heavy chain (Db) specific for C57BL/6 mice, a human light chain (β2m) and a 9-aa peptide 
[NP366-374 (ASNENMDTM)] derived from ca donor strain A/AA ca.  The fluorescent-labelled 
tetramers are the ligands for specific TCRs on the CTLs, allowing them to be characterised by flow 
cytometry (Section 1.2.1.5). 
 
4.2.1.1  Expression vector for recombinant H-2D
b
 protein 
The expression vector Db-KanR was used to transform E. coli BL21 (DE3) by the heat shock 
method, and expression of heavy chain H-2Db was induced by adding IPTG (Section 2.11.2).  
After induction, recombinant protein was expressed largely in the form of inclusion bodies from 
which H-2Db was isolated and purified.  By comparing different dilutions of BSA on the SDS-
PAGE gel, it was estimated that the yield of inclusion bodies after induction was 4~8 mg/mL.  
Recombinant H-2Db protein contains a peptide recognition sequence for the BirA, a biotinylation 
enzyme (O’Callaghan et al 1999).   
 
4.2.1.2              Refolding and biotinylation of monomeric D
b
/hβ2m/NP366-374   
Recombinant eukaryotic proteins expressed from E. coli need to be refolded in order to retain their 
original configuration.  The monomer refolding process was carried out in the presence of the 
peptide (2.11.5) and was the critical step for the preparation of tetramers that bind to TCRs.  After 
refolding, monomers were purified by FPLC to remove contaminants derived from E. coli (Figure 
4.1A).  Electrophoresis in 18% SDS-PAGE gels of unpurified preparations and fractions collected 
within the peak contained both monomers and contaminant proteins derived from E. coli (Figure 
4.1B).   
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Figure 4.1 Purification of Db/hβ2m/NP366-374 monomers specific for influenza A/Ann Arbor/6/60  
 
A Gel filtration chromatogram after FPLC purification showing a  peak of monomer eluted with 
10mM Tris-HCl after absorbance  at 280nm (A280 nm).   
B 18% SDS-PAGE reducing gel analysis of monomer purified by gel filtration. 
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Figure 4.2 Tetramer formation of D
b
/hβ2m/NP366-374 specific for influenza A/Ann Arbor/6/60 
 
18% SDS-PAGE was used to demonstrate pre- and post-biotinylation and tetramer formation.  In the 
absence of biotinylation by BirA, monomers could not bind to SA-bead and were eluted.  By contrast, 
biotinylated monomers that bound to SA-beads were saved from purification steps.  By comparing the 
quantity of tetramer to monomer on SDS-PAGE gel, the final extent of biotinylation was estimated to 
be 20%.  
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4.2.1.3                Formation of D
b
/hβ2m/NP366-374 tetramers 
Refolded and purified monomers were then biotinylated by using the enzyme BirA.  Only after 
biotinylation could the monomers bind to PE-labelled streptavidin beads, each with four sites.  
Tetramers were formed by mixing the biotinylated monomers with streptavidin-PE at a 4:1 molar 
ratio.  By comparing different dilutions of BSA on the SDS-PAGE gel, it was estimated that 
about 20% of Db/hβ2m/NP366-374 monomers formed tetramers with streptavidin-PE (Figure 4.2). 
 
4.2.1.4                  Staining of CTLs with D
b
/hβ2m/NP366-374  tetramers 
The newly formed tetramers were tested using lymphocytes isolated from C57BL/6 mouse lungs 
following i.n infection with A/AA wt.  A/AA wt was used instead of A/AA ca to infect mice in 
the tetramer titration study because: (1) an earlier study demonstrated that peptide NP366-374 
sequences for A/AA ca and A/AA wt were identical (Cox et al 1988).  Therefore, Db/hβ2m/NP366-
374 tetramers are able to recognise NP366-374 - specific CTLs from either virus when used to infect 
C57BL/6 mice; (2) the local CTL immune response and subsequent NP366-374 specific-CTL 
population induced by A/AA wt in lungs was expected to be significantly greater than that 
induced by A/AA ca (Figure 3.3), which would increase the sensitivity of the assay.   
 
Four mice were infected with 105 pfu of A/AA wt and two uninfected mice were used as 
controls.  All mice were held for further 10 days before being sacrificed and their lungs 
harvested.  Lymphocytes from the lungs of infected and uninfected control mice were then 
isolated and pooled separately.  Two parallel assays were carried out on those lymphocytes using 
(1) in vivo tetramer staining and (2) in vitro intracellular IFN-γ staining after stimulation with 
peptide NP366-374.  Because the positive control for the tetramer D
b
/hβ2m/NP366-374 specific for 
A/AA ca was not available, the intracellular cytokine cytometry (ICC) assay for IFN-γ was 
included as a peptide control.   
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IFN-γ ICC is a functional assay since peptide-specific CTLs can be restimulated to secrete IFN-γ 
by co-culture with the relevant peptide.  By staining intracellular IFN-γ following a peptide 
pulse, peptide-specific CTLs can be identified by flow cytometry.  The IFN-γ ICC assay has 
been used widely for the screening of CTL-epitopes (Crowe et al 2006; Wang et al 2007).  
Previous studies have demonstrated that there is a good correlation between the tetramer and 
IFN-γ ICC assays (Doherty 1998; Murali-Krishna et al 1998). 
  
For tetramer titrations, 1 µL of anti-CD8-APC and 3 or 10 µL of tetramer-PE were added to 50 
µL staining buffer containing 106 cells from the lungs of infected or uninfected mice.  The results 
indicate that NP-specific CTLs were not stained by either 3 or 10 µL of tetramer-PE, even 
though the percentage of CD8+ cells increased more than two-fold from 4.21 to 9.72 following 
infection (Figure 4.3 A&B).  After staining with 10 µL tetramer, 0.3% of total lung lymphocytes 
from infected mice were NP+ CD8+ (Figure 4.3A), compared with 0.11% for uninfected mice 
(Figure 4.2B).  Similar results were observed after staining with 3 µL of tetramer where NP+ 
CD8+ cells accounted for 0.1% of total lung lymphocytes from both infected and uninfected 
mice.  
 
During the IFN-γ ICC assay, 50% of the lung lymphocytes isolated from infected or uninfected 
mice were cultured with peptide NP366-374, which was added to cell cultures (1 µg to 10
6 cells per 
mL) in the presence of BFA.  The cultures were then incubated for 4 hr at 37 ºC.  The remaining 
lymphocytes were incubated under the same conditions in the absence of peptide.  After 
incubation, each sample of cells was washed and divided into two tubes.  Cells from one tube 
were stained with anti-CD8-APC and anti-IFN-γ-PE, both at a 1: 50 dilution.  Cells from the 
other tube were used as an isotype control for measuring the non-specific intracellular staining 
background.  The percentage of cells showing background staining in the lung lymphocytes of 
infected and uninfected mice was low, irrespective of whether a peptide pulse was applied (0.08-
0.13%). 
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Figure 4.3 Flow cytometry profiles of A/Ann Arbor/6/60 NP366-374-specific CD8
+
 T cells from lungs stained directly with NP-
tetramer  (Panels A and B; gated on lung lymphocytes) or with INFγ intracellular following the application of an 
NP-peptide pulse in vitro (panels C and D; gated on lung CD8
+
 T cells)  
 
 
To demonstrate the specificity of the NP-tetramer, lung lymphocytes from (A) infected or (B) 
uninfected mice were compared.  Results indicate that the NP-tetramer was unable to identify NP-
specific CTLs, although CD8+ cells of total lung lymphocytes comprised 9.72% for infected 
compared with 4.21% for uninfected mice.   
 
To demonstrate the specificity of the NP-peptide in IFN-γ intracellular staining, lung lymphocytes 
from infected mice were cultured with (C) or without (D) NP-peptide and IFN-γ
+
.  CD8
+
 T cells as a 
percentage of total lung CD8
+
 cells were compared.  Results indicate that NP366-374-peptide was 
able to restimulate NP-specific CTLs and that peptide-specific IFNγ
+
 CD8
+
 T cells increased by a 
factor of 3.5 (2.48 to 8.61%) following the peptide pulse.  
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Figure 4.4  Mouse lung lymphocytes flow cytometry results demonstrating that MHC class I (H-2Db) tetramer containing 
peptide derived from A/PR/8/34 nucleoprotein (NP) 366-374 is also able to stain lung NP366-374-specific-CTLs 7-
days-post secondary i.n vaccination with A/AA/6/60 ca 
 
A  Mice in uninfected control group inoculated with normal allantoic fluid i.n in two doses, 3 weeks apart; 
B Mice in tetramer control group were first inoculated with reassortant A/HK×31 (H3N2) and, 3 weeks 
later, cross-pulsed with the parent virus A/PR/8/34 (H1N1); 
C Mice from A/AA/6/60 ca infected group were vaccinated twice i.n at an interval of 3 weeks. 
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Results from flow cytometry indicate that peptide NP366-374 was able to restimulate a specific-
CTL population in vitro; 8.61% of CD8+ T cells isolated from infected mouse lungs were NP-
specific after the peptide pulse, compared with 2.48% in its absence (Figure 4.3 C&D).  In 
addition, the proportion of CD8+ T cells within the total lung lymphocytes was 22% for infected 
and 4% for uninfected mice.  By contrast, no differences were detected in uninfected mice where 
2.51% were positive following the pulse, compared with 2.34% where it was not applied.   
 
4.2.1.5 MHC class I tetramer H-2D
b
 containing A/PR/8/34 nucleoprotein (NP366-374) 
peptide stains A/AA/6/60-specific CTLs  
 
Tetramers carrying NP366-374 of A/PR/8/34 were used in the following comparative study of lung 
CTL responses to different ca LAIVs.  In a preliminary validation study, three groups of three 
C57BL/6 (H-2Db) mice were inoculated i.n twice at an interval of 3 weeks with A/AA ca, 
A/HK×31 plus A/PR/8/34, or normal allantoic fluid.  The local lung CTL responses were 
investigated a week later after the secondary infection.   
 
In the uninfected control group, mice were inoculated i.n. with normal allantoic fluid.  Mice from 
tetramer control group were first inoculated with 1.45×105 PFU A/HK×31 (H3N2) and then 
cross-primed with 1.45×105 PFU A/PR/8/34 (H1N1) 3 weeks later.  A/HK×31 is a reassortant 
virus with all six internal genes derived from A/PR/8/34.  This cross-priming strategy often used 
to maximize pre-existing specific-CTL populations specific for influenza A internal Ags by 
avoiding anti-HA or NA Abs-mediated suppression by different surface antigens (Doherty et al 
1998).   Finally, mice from the infected test group were vaccinated i.n twice with 1.45×105 PFU 
A/AA/6/60 ca.   
 
The results indicate that the tetramer carrying NP366-374 of A/PR/8/34 is able to stain the CTLs 
primed by A/AA/6/60 ca.  From uninfected group, only 0.3% of total lung lymphocytes were 
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NP-specific-CTLs.  In contrast, a significant expansion of these cells was detected in infected 
mouse groups.  NP366-374-specific-CTLs comprised 4.4% of lung lymphocytes in A/HK×31 plus 
A/PR/8/34-infected mice and 2.1% in A/AA ca-infected mice (Figure 4.4).  
 
4.2.2 Evaluation of the Immuno-PCR assay for the measurement of IFN-γ in cell culture 
supernatants 
The immuno-PCR (I-PCR) technique was used to measure INF-γ levels in the lung lymphocytes 
of vaccinated mice after in vitro restimulation mice with the same virus.   
 
4.2.2.2 Reporter DNA preparation and optimization of I-PCR conditions 
For I-PCR assays, biotinylated DNA was used as a reporter marker that could be detected by 
PCR (Section 2.15.1.2).  This reporter DNA was developed from a Bluescript plasmid by PCR 
amplification with the biotinylated M13-20 primer and the non-biotinylated M13 reverse primer 
(Figure 4.5A).  The optimal I-PCR reporter concentration that did not cause non-specific binding 
and amplification was determined using blocking buffer (1% BSA in PBS) in place of 
recombinant mouse IFN-γ.  Different dilutions of reporter DNA were tested and results are 
shown in Figure 4.5B.  Bands were observed at concentrations of 106, 104 and 103 ng/L DNA, 
indicating that excess reporter DNA was present and non-specific binding led to false-positive 
PCR results.  However, the band was not seen at 1 ng/L, the concentration used subsequently for 
I-PCR assays.  
 
4.2.2.2 Application of I-PCR in the detection of IFN-γ in supernatants from mouse lung 
lymphocytes cultures  
The ca donor virus A/AA ca and reassortants CR6, CR18, CR29, and CR35 that had been 
prepared from A/AA ca were inoculated to groups of 6 C57BL/6 mice.  Each mouse was 
inoculated twice by the i.n. route with 1.45×105 PFU of individual viruses at an interval of 3 
weeks (Section 2.12).  A week after the last inoculation, all mice were euthanased and single cell 
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suspensions of individual lungs were prepared and incubated at 96-well cell culture plate coated 
with a purified preparation of the same virus used for inoculation (Section 2.15.2.1).  Mice from 
an uninfected control group were inoculated with normal allantoic fluid, and lung lymphocyte 
preparations were incubated in a plate coated with normal allantoic fluid.  
 
Following incubation, cell culture supernatants were collected and pooled within the same virus 
group and I-PCR assays were performed to detect IFN-γ in cell culture supernatants.  From the 
intensity of the PCR products on 2% agarose gels, IFN-γ levels in mice vaccinated with A/AA 
ca, CR18, CR29 and CR35 were found to be similar (Figure 4.6).  However, no increase in IFN-γ 
could be detected in CR6-infected mice, where the band intensity was similar to that for 
uninfected control mice (Figure 4.6). 
 
4.3    DISCUSSION 
 
The measurement of specific CMI responses in the respiratory tract remains a challenge in 
determining the efficacy of ca LAIVs for humans.  In most studies, tests on blood and nasal 
wash samples are used to provide surrogate measurements of responses in humans.  In the 
present study in a mouse model the need to include specific measures of CMI, in addition to 
humoral immunity for monitoring responses to LAIVs was clearly indicated from assays 
involving the use of tetramer staining and I-PCR. 
 
4.3.1 Application of the tetramer containing peptide from A/PR/8/34 NP366-374 for the 
identification of influenza A/AA/6/60 ca-specific CTLs by flow cytometry 
As discussed previously in Section 1.2.1.5, fluorescent-labelled MHC tetramers can directly 
measure Ag-specific T cell responses by binding to TCRs.  Viral peptide NP366-374 includes one 
of the immunodominant CTL epitopes in the C57BL/6 mouse for influenza A viruses (Table 
1.3).   
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Figure 4.5 Preparation and titration of biotinylated reporter DNA.  Reporter DNA (227 bp) was prepared from the 
Bluescript plasmid by PCR amplification with the biotinylated M13-20 primer and the non-biotinylated 
M13 reverse primer (A).  The optimal concentration of reporter DNA used in I-PCR was determined 
using 1% BSA in PBS instead of recombinant mouse IFNγ (B). Final PCR products (196 bp) were 
obtained with IF and IR primers nested to M13-20 and M13 primers.  PCR products were 
electrophoresed in 2% agarose gels.    
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Figure 4.6 Measurement of IFN-γ levels by comparing the intensity of the PCR product bands in I-PCR assays.  
Following i.n vaccination, mouse lung lymphocyte suspensions were prepared and co-cultured with 
purified viruses.  After incubation, cell culture supernatants were collected and I-PCR was performed.   
 
 
Uninfected     CR35     CR29      CR18      CR6       A/AA ca    
 
 Supernatants collected from mice lung lymphocyte cultures 
     Size Marker     1              2             3             4              5              6 
 
196 bp 
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 In a previous study, in which mice were challenged with A/HK×31 (H3N2) after priming with 
A/PR/8/34 (H1N1), NP366-374-specific CTLs accounted for 57% of total BAL cells by the 
tetramer technique (Belz et al 1998).  Therefore, the peptide NP366-374 from influenza A/AA/6/60 
was selected to form MHC I tetramers in this study.   
 
For reasons unknown, newly formed NP366-374 tetramers failed to detect NP-specific CTLs from 
lungs, even though the peptide itself was found effective in stimulating the secretion of IFN-γ in 
the same cells under in vitro conditions.  Overall, 8.61% of total lung CD8+ T cells or 1.89% of 
total lung lymphocytes were identified as CD8+ IFN-γ+ T cells - the functional CTLs (Figure 
4.3C).  Similar results were reported in an earlier study, using a cross-priming strategy, where 
7.1% of BAL cells were shown to be the functional CTLs (Belz et al 2001). 
 
Examination of full-length protein sequence alignments from a selection of 130 sequences 
available in GeneBank demonstrated that 80% of NP was conserved (Powell et al 2007).  
Comparison of the peptide NP366-374 from A/PR/8/34 and A/AA/6/60 indicated that the only 
difference found was at the 7th aa where Asp (E) was replaced by Glu (D) (Table 2.3).  As the 7th 
aa is outside the two anchor points (aas 2 and 9), this change should not have affected binding 
between the peptide and MHC I peptide-binding cleft (Parham 1992).  It was, therefore, not 
unexpected that the tetramer containing the peptide from A/PR/8/34 NP366-374 would be able to 
identify influenza A/AA/6/60 ca NP-specific CTLs (Figure 4.4).  After two i.n vaccinations with 
A/AA/6/60 ca and staining with A/PR/8/34 NP366-374 tetramers, 2.1% of total lung lymphocytes 
were identified as NP-specific CTLs (Figure 4.4C).   
 
A good correlation between tetramer staining and IFN-γ ICC assays was demonstrated in this 
study.  Ten days after primary infection with A/AA/6/60 wt, 1.89% of total lung lymphocytes 
were functional NP-specific CTLs that were detected by IFN-γ ICC.  Compared with the 
tetramer assay, 2.1% of these cells were identified as NP-specific CTLs 7 days after secondary 
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i.n vaccination with A/AA/6/60 ca.  Consequently, in the following chapter, IFN-γ ICC assays 
were used for measuring the NP-specific CTLs in BALB/c (H-2d) mice for which the tetramer 
was unavailable. 
 
4.3.2 Detection of IFN-γ in C57BL/6 mice by I-PCR after i.n. administration of a second 
dose of ca LAIVs     
I-PCR is a modified ELISA and a DNA-enhanced immunoassay with broad applications for the 
detection of antigens.  The coupling of biotinylated Abs and biotinylated DNA to a linker 
protein, such as streptavidin, has been widely used (Sano et al 1992).  The major advantage of I-
PCR is the significant increase in assay sensitivity which is achieved using PCR-amplified DNA 
as a signal reporter instead of the traditional enzyme and substrate of an ELISA.  Currently, the 
precise Ag quantitation could be achieved by the test such as real-time PCR (Adler et al 2008).    
 
IFN-γ is produced locally in lungs by T and NK cells in response to the i.n vaccination of mice 
with LAIVs and has critical roles in both the innate and adaptive immune responses to influenza 
infections (Table 1.2).  However, secretion occurs over a very short time in tissues (Morris 
1988), which makes the detection of IFN-γ in vivo very difficult.  In the present study, an I-PCR 
assay for the detection of IFN-γ in vitro was established and IFN-γ induced by different ca 
LAIVs was compared.  Lung lymphocytes were prepared from ca LAIV-primed mice and then 
pulsed with the same viruses used for priming under in vitro conditions.  However, the priming 
viruses used were purified and inactivated and, therefore, IFN-γ secreting T cells were more 
likely to be the HA or NA- than NP-specific.  
 
Increased IFN-γ levels were detected in lung lymphocytes prepared after 7 days from mice 
reinfected with A/AA ca, CR18, CR29 and CR35.  In contrast, no increases could be detected in 
mice reinfected with CR6 (Figure 4.6).  Interestingly, from Chapter 3, serum HI titres induced by 
CR6 (GMT 80) were much higher than those induced by CR35 (10) 3 wee
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(Figure 3.5).  Moreover, CR6 caused on average 3.79% weight loss at day 3 p.i. compared with 
CR35 where no loss could be detected (Table 3.2).  The results suggest that CR6 produces a 
maximum response after one dose, unlike A/AA/6/60 ca and the other reassortants that require 
two doses.   
 
Unlike CR35 which possesses a PFU: HAU ratio of 1.7 × 103, CR6 grows to high titres with a 
PFU: HAU ratio of 2.5 × 103 and could, therefore, be expected to elicit stronger immune 
responses than CR35 (Figure 3.3A).  The replication efficiency of individual ca viruses (see 
Chapter 3) was directly proportional to the primary immune responses induced in mice.  
However, the same pattern was not observed with secondary responses, probably due to the 
presence of pre-existing immunity.  This was evidenced by using I-PCR to measure IFN-γ post 
secondary vaccination with ca LAIVs.  A higher level of IFN-γ level detected in cultured CR35-
infected mouse lung lymphocytes than in CR6-infected mice.   
 
These results indicate that Ab levels generated from primary responses play a role in the 
secondary response to the same Ag, which may have important implications for the use of ca 
LAIVs in humans.  However, unlike mice that are naïve to influenza virus infections, most 
humans have pre-existing immunity from natural infections.  Therefore, during the evaluation or 
selection of candidate ca LAIV, both pre-existing immunity and the viral replication efficiency 
need to be considered.   
 
The I-PCR results presented here had limitations because the test is not amenable to quantitation. 
Therefore, in Chapter 5, the tetramer staining and IFN-γ ICC assays were used in conjunction 
with ASC ELISPOT and serum HI tests to compare immune responses to different ca LAIVs in 
different strains of mice.  Such tests may provide further reliable insights to the correlation 
between the humoral and CMI responses to ca LAIVs. 
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4.4 SUMMARY  
Reliable sensitive assays are required to compare CMI responses to different ca LAIVs in mice 
and in this chapter the use of tetramer staining, ICC and I-PCR were evaluated.  For tetramer-
based flow cytometry assays, the fluorescent-labelled tetramer is the key reagent for estimation 
of in vivo epitope-specific CTL responses.  The NP366-374 peptide of influenza A viruses 
comprises the immunodominant epitope that is highly conserved between subtypes.  For 
A/PR/8/34 (H1N1) and A/AA/6/60 (H2N2), there is only one aa difference within peptide NP366-
374.  Therefore, the peptide NP366-374 was used to prepare tetramers for detecting NP-specific 
CTLs against all influenza A viruses used in this study.   
 
H-2Db monomers were successfully refolded with the NP366-374 peptide, but only 20% were 
found to form tetramers through biotin-streptavidin linkage.  Newly formed NP-tetramers were 
unable to identify NP-specific CTLs isolated from mouse lungs 10 days after infection with 
A/AA/6/60 wt.  In contrast, an IFN-γ ICC assay conducted in parallel demonstrated that peptide 
NP366-374 was sufficient to restimulate NP-specific CTLs to secrete IFN-γ in vitro.  Tetramers 
carrying the A/PR/8/34 peptide NP366-374 also stained NP-specific CTLs prepared from the lungs 
of A/AA/6/60 ca mice after two doses.   
 
Like the IFN-γ ICC assay, I-PCR is a functional assay which requires in vitro Ag restimulation.  
However, unlike IFN-γ ICC in which cells were pulsed by peptide NP366-374, inactivated whole 
viruses were used as the stimulus in I-PCR.  Consequently, IFN-γ detected by I-PCR was more 
likely to be secreted by HA- and NA-specific lymphocytes.  In the present study using the I-PCR 
assay, increased IFN-γ levels were detected in lung lymphocytes prepared after 7 days from mice 
reinfected with A/AA ca, CR18, CR29 and CR35.  By contrast, no increases could be detected in 
mice reinfected with CR6 which induced a higher primary humoral response.  In the following 
chapter, tetramer and IFN-γ ICC assays were used to compare CMI responses elicited by a range 
of ca LAIVs. 
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Chapter 5:  
  
 Analysis of the cellular and humoral responses 
in mice following intranasal administration of ca 
LAIVs 
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5.1 INTRODUCTION 
 
Ca LAIV viruses replicate in the respiratory tract of mice, mostly the LRT, where they induce 
and maintain significant levels of memory ASCs and CTLs and broad-protection across 
influenza A subtypes (Section 1.3.3.3).  The immunogenicity of ca LAIVs is related to the 
infectivity of individual ca viruses for mice (Wareing and Tannock 2001; Wright et al 2007; 
Chapter 3), and is determined by both viral and host factors.  In the following chapter, CMI and 
humoral responses induced by range of ca reassortants prepared from the A/AA ca donor strain 
were compared in different strains of mice, using methodologies developed in earlier chapters. 
 
 
5.2 RESULTS 
 
5.2.1 Relative immune responses to reassortants of A/AA ca in C57BL/6 mice 
 
5.2.1.1  Local and systemic humoral responses to viral surface Ags of ca LAIVs 
This experiment was designed to investigate humoral responses, both local and systemic, against 
the surface Ags of ca LAIVs at different time points.  Groups of six 6-8 week-old female 
C57BL/6 mice were inoculated twice by the i.n. route, at an interval of 3 weeks, with inocula 
containing 1.45 × 105 PFU of the ca donor strain A/AA ca, the H3N2 reassortants CR6, CR18 
and CR29 and an H1N1 reassortant CR35.  Three mice from each group were sacrificed at day 7 
p.i. and the remaining 3 on day 9.  Mouse lungs were harvested and single cell suspensions 
prepared for use in the ELISPOT assay to measure local virus-specific IgA- or IgG2a-Ab 
secreting B cells.  Individual, mouse sera were prepared in parallel and HI tests were performed 
to measure HA-specific-Ab levels (Section 2.15.1).  Higher local ASC responses (both IgA and 
IgG2a) were observed on day 9 than day 7 p.i. for A/AA ca-, CR6-, CR18- and CR29-infected 
mice (Figure 5.1A&B).  Although, the IgG2a ASC response to CR35 was higher on day 9 than 
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on day 7, the IgA ASC response was lower (Figure 5.1A&B).  Furthermore, from day 7 to day 9, 
an increase in anti-HA Abs occurred in groups infected with A/AA ca, CR18 and CR29 but a 
decrease occurred in groups infected with CR6 and CR35 (Figure 5.1C).  Overall, of the five ca 
LAIVs tested at day 7, CR35 induced the highest local B cell responses. 
 
Further statistical analysis using combined data from days 7 and 9 revealed no significant 
differences in humoral responses induced by A/AA ca, CR6, CR18 and CR29 (two sample t-test; 
P > 0.05; Table A.1&A.2; Figure 5.2).  However, the response to CR29 was significantly 
different (Table A.2; Figure 5.2).  CR29 induced a significantly weaker IgA ASC response than 
that induced by CR18 and CR35, and a weaker IgG2a ASC response than CR35.  HI titres 
induced by mice infected with CR29 were significantly lower than in mice infected with A/AA 
ca (Figure 5.2).   
 
In the following experiment, local B cell and serum Ab responses in the tetramer-positive control 
group (Section 4.2.1.5) and the CR35-vaccinated group were compared.  Each group consisted of 
seven C57BL/6 mice.  Mice in the tetramer control group were first primed i.n with 1.45×104 
PFU of A/HK×31(H3N2) and 3 weeks later were challenged i.n with 1.45×104 PFU of A/PR8 
(H1N1).   Mice from the CR35 group received two identical i.n inocula containing of 1.45×104 
PFU 3 weeks apart.  All mice were killed 1 week after the last inoculation, and ELISPOT and HI 
assays were performed.  In the ELISPOT assays, lung lymphocytes from the tetramer control 
group were tested against either A/HK×31 or A/PR8.  Sera from this group were tested against 
A/HK×31.   
 
ELISPOT assays indicated that a higher IgA ASC response was induced in response to CR35 
(189 per 106 lung lymphocytes compared with 53 per 106 for the tetramer control group when 
tested against A/HK×31 or 75 per 106 against A/PR8).  However, no differences were observed 
between the IgG2a ASC responses of the two groups (Figure 5.3B).  By contrast, much higher 
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serum Ab levels were induced by the tetramer control, compared with the CR35 group (GMT 
320 versus 24.37; Figure 5.3C). 
 
5.2.1.2  Local and systemic CMI responses to viral internal Ags of ca LAIVs 
In order to investigate CMI responses to ca LAIVs, groups of four 6-8 week-old female 
C57BL/6 mice were inoculated by the i.n. route.  Mice were infected twice at an interval of 3 
weeks, with inocula containing 1.45 × 105 PFU of ca LAIVs (A/AA ca, CR6, CR18, CR29 and 
CR35) or A/AA wt.  Mice from an uninfected (negative) control group were inoculated with 
normal allantoic fluid; mice from the tetramer (positive) control group were first inoculated with 
1.45×104 PFU of A/HK×31 and, 3 weeks later, were challenged i.n with 1.45×104 PFU of 
A/PR8.  On day 7 p.i., all mice were euthanased and lungs, spleens and sera were collected.  
Single cell-suspensions were prepared from individual organs.  Cell samples from each group 
were pooled for T cell phenotype analysis.  Individual mouse sera were tested for HI Ab and 
group GMTs calculated.     
 
Two-colour flow cytometry was performed at same time on each group in order to compare cell 
populations with markers specific for NP366-374
+ CD8 +, CD8+ CD44 + and CD4+ CD44+, within 
the lungs and spleens.  Since viral peptide NP366-374 contains one of the immunodominant 
epitopes for C57BL/6 mice, especially during secondary infections (Section 1.2.2.1), NP366-374-
specific CTL populations in the lungs have critical roles in the clearance of influenza viruses 
following challenge (Section 1.2.2.3).  Expression of the activation or memory marker, CD44, 
was expected to increase in T cells following exposure to Ags (Unger et al 2003).  The 
expression of CD44 is required to mediate lymphocyte extravasation and migration to virus-
induced inflammatory sites (Flynn et al 1998).   
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Figure 5.1 Local and systemic humoral responses to ca LAIVs in C57BL/6 mice on days 7 and 9 after the 
second inoculation.  Six-eight week-old female C57BL/6 mice were vaccinated twice i.n with 1.45 
×10
5
 PFU of ca LAIVs at an interval of 3 weeks, to groups of 6.  On days 7 or 9 after the second 
inoculation, three mouse lungs and three serum samples from each group were prepared.  ELISPOT 
and HI assays were carried out for the measurement of lung specific IgA (A) or IgG2a (B) ASCs and 
serum Abs(C). 
A
B
C
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Figure 5.2 Overview of local and systemic humoral responses to ca LAIVs in C57BL/6 mice.  The graph was 
generated from combined data for days 7 and 9.   
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Figure 5.3 Comparative studies of local and systemic humoral responses to CR35 and HK×31.  For CR35, 
seven 6-8 week-old female C57BL/6 mice were inoculated i.n twice with an identical dose at an 
interval of 3 weeks.  Another group of 7 mice were first infected with HK×31and then with A/PR8 after 
3 weeks.  This cross-priming system was used as the tetramer control in T cell flow cytometry 
analysis.    
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Figure 5.4 Phenotype of virus-specific T cells in mouse lungs (Experiment I).  Four 6-8 week-old female C57BL/6 mice 
from each group were inoculated twice at an interval of 3 weeks.  Lungs and spleens were harvested and 
pooled 1 week after the 2
nd
 dose.  T cells from lungs and spleens were tested for their phenotype and individual 
sera were prepared for use in HI tests (see also Figure A.1 & 2 for flow cytometry data of lung T cell tetramer 
NP staining and phenotype). 
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        Figure 5.5 Phenotype of virus-specific T cells in mouse lungs (Experiment II) 
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Table 5.1  Lung NP-specific CTL and serum anti-HA responses in Experiments I and II 
 
NP-specific CTL response 
(% of total lung lymphocytes) 
 Serum HI GMT  
PFU:HAU ratio 
(x103 pfu/HAU)a Virus 
Experiment I Experiment II  Experiment I Experiment II  Experiment I Experiment II 
A/AA ca 0.50 2.09  20 80  29.00 6.25 
CR6 3.80 0.34  80 80  N.D.c 3.40 
CR18 0.70 0.76  40 20  N.D. 36.93 
CR29 0.00 0.37  40 20  14.20 12.78 
CR35 0.90 2.92  40 10  0.79 1.67 
A/HK×31->PR8 5.4 4.47  320 (40)b 226 (80)  19.71 (70.31) 27.34 (136.72) 
A/AA wt 0.30 0.40  80 40  105.47 70.31 
Uninfected 0.00 0.30  0 0  N.A.d N.A. 
 
a   PFU: HAU ratios of virus stocks used for preparation of mouse inocula.  A/HK×31 and PR8 were diluted to 1.45 × 104 PFU 
per 50 uL and the remaining viruses were diluted to 1.45 × 105 PFU per 50 uL prior to inoculation;  
b
  Bracketed values are titres against PR8. 
c N.D.: not done;  
d N.A.: not applicable. 
 
Table 5.2  Lung NP- and PA-specific CTL and serum anti-HA responses to ca reassortants with varies surface 
Ags 
 
Virus inoculum Surface Ags NP366-374-specific CTL response 
(% of total lung CD8
+
 T cells) 
PA224-236-specific CTL response 
(% of total lung CD8
+
 T cells) 
Serum HI 
GMT 
CR6 H3N2 1.55 2.10 67.27 
CR6-35 H1N2 1.03 2.06 25.14 
CR35 H1N1 2.22 1.06 29.72 
CR6-35* H3N1 0.62 0.67 47.57 
 
 
Table 5.3  B cell cross-reactions to different HA subtypes in C57BL/6 and BALB/c mice 
 
Specific-IgA ASCs  
/106 lung lymphocytes 
 Specific-IgG2a ASCs 
/106 lung lymphocytes 
 Serum HI GMT Experiment 
setup
a
  C57BL/6 BALB/c  C57BL/6 BALB/c  C57BL/6 BALB/c 
H1-H1 86 142  44 70  60.63 113.14 
H1-H3 76 192  49 71  0 0 
H3-H3 25 46  21 32  40 64.98 
H3-H1 25 49  18 28  0 0 
 
a
 Six 6-8 week-old female C57BL/6 and BALB/c mice were inoculated twice at an interval of 3 weeks 
and lung and serum samples were prepared after 7 days.  Virus inocula were CR35 (an H1 virus) or 
CR6-35* (an H3 virus). ELISPOT plates were coated with either homologous- or heterologous 
viruses.     
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Figure 5.6 Comparison of immune responses in C57BL/6 and BALB/c mice.  Two of 6-8 week-old female 
C57BL/6 or BALB/c mice from each group were inoculated twice at an interval of 3 weeks.  Lungs 
were harvested and pooled 1 week after the 2
nd
 dose for T cells phenotype analysis.  Individual sera 
were prepared for HI tests.  
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Figure 5.7 Comparative studies of local specific-ASC responses in C57BL/6 and BALB/c mice to selected ca 
reassortants.  Six 6-8 week-old female C57BL/6 or BALB/c mice from each group were inoculated 
twice at an interval of 3 weeks. Lungs were harvested 1 week after the 2
nd
 dose and cell suspensions 
were prepared individually for ASCs ELISPOT assays.  Individual sera were prepared at the same 
time for HI tests. 
 
 
   156 
 
The results for phenotyping of virus-specific T cells indicate that, overall, a much stronger T cell 
response was induced in the lungs than in the spleens following inoculation by the i.n route 
(Figure 5.4).  No NP-specific CTL could be detected in the spleens of mice from all, except the 
tetramer control group.  Furthermore, after secondary infection, the CD4:CD8 T cell ratios in the 
lung parenchyma of all infected mice remained at 1:1 (Figure A.3).  Of the ca LAIVs, CR6 
induced the strongest CTL response (Figure A.1).  An increase of CD44 expression on T cells 
was observed in all infected groups but was absent in the uninfected control group (Figure 5.4 & 
A.3).  Except for the CR29 group, the increase of CD44 on T cells occurred more in the lungs 
than in the spleens (Figure 5.4).   
 
In addition to the lung T cell responses, serum HA-specific Ab levels for each group were 
determined by HI assays.  The highest HI GMT (320) was detected in the tetramer control group 
and the lowest (20) in the A/AA ca-infected group.  Other infected groups showed smaller 
increases (80 for the A/AA wt- and CR6-infected groups; 40 for the CR18-, CR29- and CR35-
infected groups; Figure 5.4). 
 
An additional T cell phenotype analysis was undertaken after 12 months with other preparations 
of the same viruses and two additional ca reassortants derived by co-infection with CR6 and 
CR35 (Tannock et al 1995) - CR6-35 (H1N2) and CR6-35* (H3N1).  The viruses used in the 
second experiment were prepared following an additional passage and differences were noted in 
the PFU:HAU ratios of the same viruses used in the first experiment (Table 5.1).  In the second 
experiment, the NP-specific CTL responses to A/AA ca-, CR6- and CR35-infected mice differed 
from those observed in the first experiment (Figure 5.5 & A.2).  Both A/AA ca and CR35 
induced larger NP-specific CTL populations (2.09 and 2.92% of total lung lymphocytes) than 
had been observed previously (0 and 0.9%).  By contrast, a weaker CTL response was induced 
by CR6 (0.34 compared with 3.8% in the first experiment).  However, levels of NP-specific CTL 
responses induced by the other viruses were similar in both two experiments (Table 5.1). 
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To further investigate the role of surface Ags in the local CTL responses to ca reassortants, mice 
were inoculated with two pairs of reciprocal ca reassortants CR6 (H3N2), CR6-35 (H1N2), 
CR35 (H1N1) and CR6-35* (H3N1) (i.e the only difference between the two viruses within each 
pair was the surface Ag HA gene; the remaining 7 genes were the same).  Eight 6-8-week old 
female C57BL/6 mice in each group were administered two identical doses containing of 1.45 × 
105 PFU of each virus, at an interval of 3 weeks by the i.n. route.  At day 7 after the second dose, 
single cell suspensions and sera were prepared for each mouse and flow cytometry and HI assays 
were performed on all samples.   
 
In the flow cytometry assay, lymphocytes samples from individual lungs were detected for 
PA224-236- and NP366-374-specific CTLs.  As mentioned earlier (Table 1.3), peptide PA224-236 of 
influenza A viruses, together with NP366-374, are immunodominant epitopes for C57BL/6 mice.  
The results indicate that there were no significant differences in the CTL responses induced by 
CR6 and CR6-35, when H3N2 or H1N2 viruses were compared (two sample t-test P-values > 
0.05; Table 5.2).  By contrast, higher responses (two sample t-test P < 0.05) was detected in the 
CR35 (H1N1)- than the CR6-35* (H3N1)-infected group (Table 5.2).   
 
5.2.2 Relative immunogenicity of ca reassortants in C57BL/6 and BALB/c mice 
 
MHC Class I or II molecules on the surface of APCs are responsible for the initiation of adaptive 
immune responses (Section 1.2.1.5).  Different mouse strains carry different types of MHC 
molecule i.e H-2d for BALB/c mice; H-2b for C57BL/6 mice.  Furthermore, different types of 
MHC molecules recognise different epitopes derived from the same Ag.  Earlier studies 
demonstrated that no epitopes could be detected for the influenza NA protein of A/HK×31 in 
C57BL/6 mice, but multiple epitopes could be identified for the same protein in BALB/c mice 
(Crowe et al 2006).  Therefore, immune responses to the same Ag in different hosts could be 
expected to differ.  In the following experiments, viral infectivity (measured by changes to 
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lung:body weight ratios following infection) and immune responses (determined by serum HI 
tests and lung T cell phenotyping) to range of influenza viruses were compared in C57BL/6 and 
BALB/c mice.   
 
Results for lung:body weights, indicated that C57BL/6 mice were more susceptible to A/HK×31, 
A/PR8, A/AA wt, A/AA ca and CR6 than BALB/c mice, but no differences were observed for 
the other ca viruses (Figure 5.6).  In general, the levels of serum HI Ab to ca reassortants were 
higher in BALB/c than C57BL/6 mice.  However, lower CD8+ CD44+ and CD4+ CD44+ T cell 
numbers were found in the lungs of BALB/c, compared with C57BL/6 mice, 7 days after 
secondary inoculation (Figure 5.6).    
 
The ASC ELISPOT assay was used to detect local B cell responses to CR6 (H3N2), CR35 
(H1N1), CR6-35 (H1N2) and CR6-35* (H3N1) in both C57BL/6 and BALB/c mice.  Six 6-8 
week-old female mice from each group were inoculated twice at an interval of 3 weeks and 
individual lung and serum samples were then prepared after 7 days.  The results indicate a good 
correlation between local B cell and serum Ab responses (Figure 5.7).  CR6 induced higher local 
B cell and serum Ab responses in C57BL/6 compared with BALB/c mice.  However, for the 
other viruses (CR35, CR6-35 and CR6-35*), higher responses were obtained in BALB/c mice. 
 
5.2.3 Heterosubtypic specific immunity induced by ca LAIVs in mice 
 
Cross-immunity mediated by memory T and B cells to different influenza A subtype viruses has 
long been recognised (see Section 1.2.2.2).  In the present study, B-cell based cross-immune 
responses between the CR35 (H1N1) and CR6-35* (H3N1) infected mice were demonstrated 
(Table 5.3).  Six 6-8 week-old female C57BL/6 or BALB/c mice from each group were 
inoculated twice at an interval of 3 weeks and lung and serum samples of each were then 
prepared.  ELISPOT plates were coated with either homologous or heterologous viruses.  For 
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CR35-infected mice, lung lymphocytes were co-cultured in vitro with either CR35 (an H1 virus) 
or CR6-35* (an H3 virus). Lung lymphocytes, isolated from CR6-35* (H3N1)-infected mice 
were tested against both H3 virus and H1 viruses.  The results indicate extensive local cross-
reactivity in B cell responses to different HA subtypes in both C57BL/6 and BALB/c mice 
(Table 5.3).  By contrast, no cross-HI reactivity could be detected.   
 
5.3 DISCUSSION 
 
Influenza A reassortant viruses in ca LAIVs approved by the FDA have common internal genes 
(NP, M, P, and NS) derived from the donor strain A/AA /6/60 ca and surface Ag genes (HA and 
NA) derived from current epidemic strains.  Previous studies in outbred mice demonstrated that 
such reassortants are less immunogenic than wt parental strains with the same surface Ags 
(Tannock et al 1984).  In mouse challenge/protection studies, viral surface HA Ags were 
identified as major determinants of immunogenicity for all reassortants (Tannock et al 1995).  
However, the immunological basis for these observations has not been investigated.   In the 
present study, the interaction between the two arms of the adaptive immune system in the 
induction of responses to ca reassortants was studied in two inbred mouse strains (C57BL/6 and 
BALB/c).  Specific immune responses were assessed by quantitation of lung virus-specific CTLs 
and ASCs by tetramer staining and ELISPOT assays.  Results obtained were compared in 
parallel with serum antibody responses. 
 
5.3.1 Specific humoral and CMI responses to ca reassortants in C57BL/6 mice 
 
5.3.1.1  Local and systemic humoral responses induced by CR6, CR18, CR29 and CR35 
Earlier challenge/protection studies in outbred mice demonstrated that the ca reassortant CR6 is 
a superior immunogen to CR35 since its 50% protective dose (PD50) after administration of two 
identical vaccinating doses was 101.17 TCID50, compared with 10
3 TCID50  for CR35 (Tannock et 
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al 1995; Table 3.1).   These results indicated that only 10 infectious units of this H3N2 
reassortant were sufficient to induce a protective response in outbred mice whereas, for the 
H1N1 reassortant, 1,000 units were required.  In the same study, a direct relationship was 
observed between serum HA-specific Ab levels induced by ca reassortants and their PD50s CR6 
induced highest HI responses (GMT 243) and CR35 the lowest (64).   
 
These results were partially supported by results from ELISPOT studies in inbred C57BL/6 mice 
in the current study.  GMTs for sera prepared days 7 and 9 after secondary inoculation (Figure 
5.2) indicate that HA-specific Ab levels in the CR6-infected-group (GMT 64) were higher than 
for the CR29- and CR35-infected groups (20 and 36).  However, the lung ELISPOT data 
indicates that CR35 elicited stronger IgA- and IgG2a-ASC responses at day 7 than CR6 (i.e. 2 
days earlier than for the other reassortants; Figure 5.1).  This observation was unexpected, given 
that CR35 grows more slowly than the other ca reassortants (Figure 3.3).   
 
Unexpected lung IgA ASC and serum Ab responses to CR35 and A/HK×31   A/PR8 were also 
observed in comparative studies (Figure 5.3).  Results showed that CR35 induced a strong IgA 
ASC response (189 per 106 lung lymphocytes) but a weak serum Ab response (HI GMT 24.37).  
By contrast, a strong serum Ab response occurred in the tetramer control group (320 when tested 
against A/HK×31), but a relatively weak IgA ASC response in the lungs (53 or 75 per 106 lung 
lymphocytes when tested against A/HK×31 and A/PR8, respectively).  The reason for the weak 
local ASC responses observed in tetramer control group can be explained by the fact that only 
primary B cell responses were being measured.  In the cross-priming protocol, maximum T cell 
responses could be induced since each inoculum had distinct surface Ags (e.g. A/HK×31 H3N2 
and A/PR8 H1N1).  Nevertheless, after secondary inoculation, CR35 induced strong ASC 
responses but a small increase in serum HI Ab (Figure 5.1 & 5.3).  A possible explanation for 
this phenomenon could be that an enhanced mucosal ASC response after second inoculation was 
possible because of low levels of pre-existing immunity from the primary inoculation.  Further 
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evidence came from an earlier experiment using a single dose (Chapter 3; Figure 3.5), in which 
CR35 induced a weak serum Ab response (HI GMT of 10 at week 3 p.i.).  Low specific-Ab 
levels would probably result in a reduced capacity to neutralise virus from the secondary 
inoculation.  Similar results have been observed with the killed subunit influenza vaccines.  From 
clinical trials, vaccinees with initially low antibody levels responded better than those possessing 
higher levels, leading to the conclusion that there was little additional benefit from the second 
dose of vaccine (Feery et al 1976). 
 
Influenza-specific IgA and IgG play important roles in the control of influenza infections in the 
URT and LRT, respectively (Chapter1; Section 1.2.2.1).  In addition, the induction of IgG2a is 
closely related to the secretion of Type I cytokines (e.g IFN-γ, IL-2 and TNF-α) by TH1 cells.  
From the current study, the highest IgG2a ASC response was found in CR18-infected mice 
(Figure 5.2).  This was not unexpected, considering that CR18 is the only ca reassortant studied 
that possessing a wt NS gene whose product is an IFN inhibitor (Garcia-Sastre 2001).  Overall, 
lung ELISPOT results demonstrated that ca LAIVs induced higher superior IgA ASC responses, 
in comparison with IgG2a at days 7 or 9 p.i. (Figure 5.1).  Similar observations had been 
reported in studies using different ca donor strains (Wareing and Tannock 2003).  High local 
mucosal IgA responses are required for the control of influenza, especially in the URT and 
provide full protection against re-infection (Chapter1; Section 1.2.2.1).    
 
In general, serum Ab responses to the same ca reassortant in C57BL/6 mice were lower than in 
outbred mice by a factor of 7.5.  The reasons for this could be related to mouse genotype and/or 
the size of virus inocula used or to the inherent variability that occurs between experiments 
performed at different times.  However, a direct correlation between the local and systemic 
humoral or protective responses was observed for all ca reassortants, except for CR35.   
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5.3.1.2 Local and systemic CMI responses induced by ca reassortants 
Previous studies with different ca donor strains demonstrated that TH1/TH2 cytokine responses 
and an increase in CD4+ or CD8+ T cells occurred primarily in the lungs, the primary site of 
infection. (Wareing et al 2001 & 2005).  In the present studies, T cell immune responses to a 
range of ca reassortants derived from A/AA/6/60 ca following i.n. administration were 
investigated, for the first time, in C57BL/6 mice by tetramer staining and T cell phenotyping 
techniques.  T cell responses in spleens were studied in parallel. 
 
Results from tetramer staining demonstrated that the ca reassortants CR6, CR18, CR29 and 
CR35 induced a detectable NP-specific CTL response in mouse lungs on day 7 after secondary 
infection (Figure 5.4).  However, no CTL responses could be detected in the spleen after 
infection with any of the reassortants.  Similar observations were made in the T cell phenotyping 
study.  Here CD8+ CD44+ and CD4+ CD44+ T cell populations were higher in the lungs than in 
the spleens following i.n. inoculation with CR6, CR18 and CR35.  However, for CR29-infected 
mice, these cell populations were higher in the spleens than in the lungs.   
 
CD8+ CD44+ and CD4+ CD44+ T cell populations in the spleens of CR29-infected mice were 
higher than for mice infected with the other ca reassortants studied, accounting for 6.7 and 7.4% 
of total spleen lymphocytes (Figure 5.4).  Interestingly, CR29 induced the lowest NP-specific 
CTL response in lungs (1.9% of total lung CD8+ T cells) compared with 17.27, 5.07 and 3.55% 
for CR6, CR18 and CR35, respectively.  Furthermore, the lung ASC and serum HI Ab responses 
to CR29 were lower in comparison with the other three ca reassortants (Figure 5.2).  The exact 
reason for the lack of stimulation in lung by CR29 remains unknown, but it is likely to be 
associated with its growth characteristics.  An indication of this, reported in Chapter 3, was the 
capacity of CR29 to produce minute plaques in MDCK cells compared with other viruses (Figure 
3.2). 
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Further variability was observed in lung NP-specific CTL responses to CR6, CR35 and A/AA ca 
during a later experiment (Figure 5.4&5.5).  CR6 induced a high CTL response (3.8% of total 
lung lymphocytes were NP-specific CTLs) in the earlier experiment, but a lower response 
(0.34%) in the later experiment (Table 5.1).  For CR35 and A/AA ca, 0.9 and 0.5% of the same 
cells were induced in the first experiment and 2.92 and 2.09% in the second.  Differences in the 
inocula used for the same virus in both experiments could be a cause of such variability.  
Influenza virus stocks contain variable proportions of infectious particles, non-infectious 
particles and DIPs (Chapter Section 1.1.3).  Non-infectious particles and DIPs could be expected 
to induce lower CTL responses.  Differences in the PFU:HAU ratio were noted in the same virus 
preparations used in the two experiments (Table 5.1).  The variability presented in current studies 
indicates that factors, such as properties of the viruses used, should be taken into consideration 
when comparing results between experiments. 
 
5.3.1.3 Interaction between local and systemic, humoral and CMI responses to ca 
reassortants  
During the course of an influenza infection, the serum Ab response is proportional to the extent 
of viral replication in the LRT (Chapter 1; Section 1.2.2.3).  Therefore, lower serum Ab 
responses could be expected from ca reassortants because of their restricted capacity to replicate 
in the LRT (Figure 5.3).  In the present study, anaesthetised C57BL/6 mice were infected by the 
i.n. route with ca and wt viruses and the serum Ab and lung ASC responses were compared.   
 
No direct correlation between serum Ab and local ASC responses was observed.  Infection with 
the H1N1 reassortant CR35 resulted in a low serum Ab response (HI GMT 36) but a high IgA 
ASC response in the lungs (366/106 lung lymphocytes; Figure 5.2).  For the H3 ca reassortant 
CR6, the serum Ab response was higher (57) but the IgA ASC response (283/106) was lower.  
High serum Ab levels were observed in the A/HK×31   A/PR8-infected group, (GMT 320 
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when tested against A/HK×31), but IgA and IgG2a ASC responses were much lower (53 and 
1/106, respectively; Figure 5.3). 
 
Virus stocks of CR35 that were used in two experiments had PFU:HAU ratios lower than those 
of the other viruses.  Stocks of A/HK×31 had the highest ratio (approximately 10-fold greater 
than for CR35; Figure 3.1).  These results suggest that the stimulation of local ASC and serum 
Ab responses is influenced by the kinetics of viral replication in the lungs.  High-yielding 
viruses, such as CR6 or A/HK×31, generally induce higher serum Ab responses than low-
yielding viruses, such as CR35, although the latter was capable of inducing good local ASC 
responses.   
 
All four ca reassortants elicited detectable NP-specific CTL responses in the lungs.  However, 
NP-specific CTLs could not be detected in the spleens of infected C57BL/6 mice (Figure 5.4), 
which confirms the previous observation that most specific-TEM cells found in the airways and 
lung parenchyma (BALT) are a direct consequence of primary infection (Ely et al 2003).   
 
An inverse relationship appeared to exist between local NP-specific CTL and serum HA-specific 
Ab responses.  For the CR35-infected group, low serum Ab and high lung NP-CTL responses 
were induced by day 7 after secondary infection (Figure 5.5; Table 5.3).  For the CR6-infected 
group, higher serum Ab but lower local NP-CTL responses were detected.  Both CR6 (H3N2) 
and CR35 (H1N1) were derived from same ca donor strain A/AA/6/60 ca and the differences in 
their growth characteristics appears to result from differences in their surface Ags. 
 
A further study with two additional reassortants (CR6-35 H1N2 and CR6-35* H3N1) that were 
derived by co-infection with CR6 and CR35 confirmed the role of surface Ags in the induction 
of CTL responses.  When the HA gene of CR35 was replaced by H3, the PFU:HAU ratio of the 
resulting CR6-35* reassortant increased from 2.28 to 6.83×103 (Chapter 3; Figure 3.1) and an 
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increase in serum HI GMT from 30 to 48, and a decrease in the lung specific-CTL response 
(Table 5.2).  However, increases in the specific-CTL responses also occurred in the presence of 
N2 (i.e. CR6 H3N2 and CR6-35 H1N2).  Taken together, the efficiency of viral replication at the 
site of infection appears to be a key factor in determining the relative contributions of local and 
systemic, humoral and systemic responses in the control influenza.   
 
5.3.2 Immune responses to ca reassortants in C57BL/6 and BALB/c mice 
 
MHCs vary considerably and are present on the APCs of different hosts.  As a consequence, the 
immune responses to the same ca reassortants in different strains of inbred mice could be 
expected to differ.  In an earlier study, virus-specific IgG responses were investigated in 
C57BL/6, BALB/c and CBA/CaH mice following i.n. infection with CR6 (Hocart et al 1989).  
After two i.n. doses, an IgG2a dominant response was detected in the serum, lungs and salivary 
secretions of BALB/c mice.  For C57BL/6 mice, virus-specific IgG1 was dominant in the serum 
but no dominant subclass could be detected in lung and salivary secretions.  In the present study 
mucosal IgA responses in different strains of mouse are described for the first time. 
 
A range of influenza A viruses, including six ca reassortants, was administered twice by the i.n. 
route to both C57BL/6 and BALB/c mice and lung specific-ASC (IgA and IgG2a), T cell and 
serum Ab responses were compared.  In addition the extent of lung consolidation caused by 
different viruses was compared in parallel to determine endpoints.  Results indicate that 
C57BL/6 mice were more susceptible than BALB/c mice to CR6-induced lung consolidation 
(Figure 5.6; top panel).  No consolidation was observed for the remaining five ca viruses in 
either strain of mice.   
 
An inverse relationship between humoral and CMI responses was observed.  In C57BL/6 mice, 
all ca reassortants elicited higher serum Ab but lower T cell responses than in BALB/c mice 
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(Figure 5.6).  These results suggest that (1) BALB/c mice are more likely to develop Type II (B 
cell) responses and (2) C57BL/6 mice are more likely to develop Type I (CTL) responses against 
ca reassortants.  These observations were confirmed in ELISPOT studies, in which higher lung 
IgA- or IgG2a responses were detected in the BALB/c than C57BL/6 mice in response to all 
viruses, except CR6.  From earlier measurements of lung:body weight ratios, C57BL/6 mice 
were shown to be more susceptible to CR6 than BALB/c mice (Figure 5.6), resulting in higher 
local ASC responses (Figure 5.7). 
 
5.3.3 Cross-reactive B- and T- cell responses induced by ca reassortants 
 
Tannock and Paul (1987) demonstrated that significant cross-immune responses to all H3N2 and 
H1N1 wt viruses were present 6-8 weeks after the administration of mice with ca LAIVs.  Other 
more recent studies have indicated that memory CTLs in the MALT are associated with local 
protection against lethal heterosubtypic challenge (Nguyen et al 1999).  Local TEM have a half-
life of about 40 days (Woodland 2002).  Viral internal Ags, especially the highly conserved NP 
and PA protein antigens, have a significant role in the development of heterosubtypic immune 
responses by influenza viruses (Yewdell et al 1985; Bennink et al 1986 & 1987)   
 
In the present studies, the tetramer developed for A/PR8 (H1N1) was also able to detect an NP-
specific CTL population induced by A/AA ca (H2N2) and other reassortants of A/AA ca 
(Figures A.1 & A2).  This finding is consistent with a recent study, in which CR29-primed mice 
survived a lethal challenge of A/PR8 (Powell et al 2007).  In the present study lung ASC 
ELISPOT data revealed that local B cell can also promote such responses against H1 and H3 
viruses (Table 5.3).   However, B cell heterosubtypic immunity is also likely to be mediated by 
common epitopes present in the Ags of different of NA and HA subtypes.  Overall, i.n. 
immunization with ca LAIVs i.n. could provide short-term protection against both shift and drift 
variants of influenza A viruses. 
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5.4 SUMMARY  
 
Results from this chapter indicate that humoral and CMI immune responses were induced by ca 
LAIVs and that these responses were both local and systemic.  These responses were variable 
and were influenced by both viral and host factors.  Type I (CTL) responses were induced by 
low-yielding ca reassortants with reduced growth characteristics, such as CR35 (H1N1).  Viruses 
with enhanced growth characteristics, such as CR6 (H3N2), produced higher Type II (HA-
specific Ab)   responses.  In addition host factors, such as the MHC type, were found to play 
important roles in responses to the same viruses.  Susceptible mouse strains, such as C57BL/6 
showed higher CTL but lower serum Ab responses than more resistant strains, such as BALB/c.  
The efficiency of viral replication at the site of inoculation appears to be a key factor in 
determining the relative contributions of local or systemic and humoral or cellular immune 
responses to ca LAIVs 
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Appendix: Statistics and Flow Cytometry Analysis 
 
 
 
Table A.1. Normality test statistical analysis distribution of C57BL/6 mice lung specific IgA or IgG2a ASC responses to 
various ca LAIVs after  two identical i.n inoculation doses 
 
Group N Mean StDev SE Mean P-Value 
IgA 6 385 366 149 >0.15 
A/AA ca 
IgG2a 6 98 121 NA 0.04 
IgA 6 283 320 131 >0.15 
CR6 
IgG2a 6 78 99 41 >0.15 
IgA 6 329 142 58 >0.15 
CR18 
IgG2a 6 195 196 80 >0.15 
IgA 6 103 130 53 >0.15 
CR29 
IgG2a 6 14 28 12 >0.15 
IgA 6 336 139 57 >0.15 
CR35 
IgG2a 6 64 41 17 >0.15 
 
 
 
 
Table A.2. Two-sample t-test statistical analysis of differences between two groups of C57BL/6 mice for lung specific IgA, 
IgG2a ASC and serum Ab responses to ca LAIVs after two identical i.n doses 
 
 P-value of two-sample t-test for IgA data: 
  CR6 CR18 CR29 CR35 
A/AA ca 0.622 0.74 0.13 0.77 
CR6  0.76 0.25 0.73 
CR18   0.018 0.94 
CR29    0.015 
 
 P-value of two-sample t-test for IgG2a data: 
  CR6 CR18 CR29 CR35 
A/AA ca 0.76 0.33 0.16 0.54 
CR6  0.23 0.17 0.76 
CR18   0.075 0.17 
CR29    0.037 
 
 P-value of two-sample t-test for HI titre data: 
  CR6 CR18 CR29 CR35 
A/AA ca 0.91 0.82 0.027 0.56 
CR6  0.91 0.050 0.65 
CR18   0.071 0.73 
CR29    0.12 
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Figure A.1  Flow cytometry analysis for lung influenza NP366-374-specific T cell responses to different influenza viruses (gated on lymphocytes, Experiment I).  Four 6-8 week-old female 
C57BL/6 mice from each group were inoculated twice at an interval of 3 weeks.  One week after the 2
nd
 dose, lung single cell suspensions were prepared and pooled for each 
group.  Tetramer staining and flow cytometry assays were performed to measure NP-specific CTLs.   
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Figure A.2  Lung influenza NP366-374-specific T cell responses to different influenza viruses (gated on lymphocytes; Experiment II)   
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Figure A.3 Overlay plots of mice lung lymphocytes showing different cell populations that stained 
with CD44-FITC, CD8-PE or CD4-PE at day 7 after secondary inoculation with different 
viruses.  Cell samples were collected from the same mouse study as Figure A.1.   
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